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ABSTRACT
Fibroblast Growth Factor 2 (FGF2) plays an important role in modulating cell 
proliferation and differentiation in the developing central nervous system. It has been 
shown that FGF2 affects the transcription of several genes. In this study, a previously 
uncharacterised gene downstream of FGF2, named ‘coiled coil protein 1* (ccpl), was 
identified and characterised. The expression at the tissue levels, particularly, in the 
brain, and cellular localization of ccpl was investigated. In addition, functional 
analysis was carried out by overexpression and RNAi approaches.
Ccpl was identified by previous microarray analysis of primary cortical neuron 
culture derived from mouse embryonic brains stimulated by FGF2. Microarray data 
showed that ccpl was up-regulated by 2.3-fold upon FGF2 stimulation. The study in 
this thesis showed that FGF2 up-regulated ccpl both at the transcript and protein 
levels. Ccpl cDNA is 1697 nucleotides long and the protein size is predicted to be 
180 amino acids. Bioinformatic analysis revealed ccpl homologues in various 
species, including human, rat, zebrafish, and drosophila. The gene is located in mouse 
chromosome 1,1B and its human homolog in chromosome 2q21.2.
Next, in order to gain insight into the physiological role of ccpl in mouse 
forebrains, its expression pattern was further analysed using in situ RNA 
hybridisation. Ccpl was highly expressed early in the brain development in a ventro­
lateral area of the cortex and in the specific layer of the dorsal cortex. The pattern of 
ccpl expression reflects some of the aspects of the tangential and radial migration 
that occurs at the early stages of brain development.
A number of conserved domains are contained within the amino acid sequence 
of ccpl, including two coiled coil regions, a leucine zipper and two nuclear exporting 
signals (NES). These domains are related to specific protein functions and they may 
provide information in determining a role of ccpl in the cell and in animal 
development. Analysis of enhanced green fluorescent protein (EGFP)-tagged ccpl 
expressed in cells demonstrated that ccpl was localised to the cytoplasm in a punctate 
pattern.
Finally, ccpl function was investigated using a retroviral overexpression system 
and RNAi in vitro. Ccpl overexpression induced cell proliferation in the absence and 
presence of serum. Silencing of ccpl expression by RNAi decreased cell 
proliferation, which provided further evidence for the role of ccpl in this process. 
Incorporation of the S phase marker, 5-Bromo 2-Deoxyuridine (BrdU), has indicated 
that ccpl enhances Gi-S transition. To address the signalling mechanism by which 
ccpl induces proliferation, involvement of ‘Mitogen-Activated Protein Kinase’ 
(MAPK) pathway was investigated. The addition of the ‘MAPK or ERK Kinase’ 
(MEK) inhibitor, U0126, blocked cell proliferation in cells overexpressing ccpl in 
the presence of serum. The data suggested that MAPK pathway may be at least 
partially responsible for the ccpl-induced cell proliferation.
The data presented in this thesis form the bases for functional study of ccpl in 
vivo in the future, and provides novel insights into the mechanism of cell proliferation 
by growth factors.
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CHAPTER 1 
INTRODUCTION
1.1 Identification and characterization of ccpl
Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) are proteins that have 
important roles in development, angiogenesis and tumorigenesis (75). FGFs regulate 
proliferation, differentiation and migration of cells and are expressed in many tissues 
and different cell types (75). A major role for FGFs has been demonstrated in 
embryonic brain development (89,106, 119, 157, 158). FGFs have been shown to 
directly affect the transcription of several genes, such as proto-oncogenes, homeobox 
genes, and growth factors and their receptors (74). In order to understand the 
molecular basis of FGFs function during the brain development, I hypothesised that a 
particular set of genes may be downstream of FGF2. The aim of this thesis is to 
identify and characterise a novel gene downstream of FGF2 that I named coiled coil 
protein 1 (ccpl).
1.1.1 Preliminary microarray experiments and identification of ccpl
To identify the genes downstream of FGF2 in cortical cells during embryonic
development, a microarray was performed using cortical neuron culture (CNC).
Microarray experiments were previously carried out in the laboratory before this PhD
project had commenced. CNC were treated with FGF2 in the presence of heparin for
4 h, and the expression of the genes was compared to those in the absence of FGF2.
A microscopic glass chip containing 15,247 unique cDNA clones in the National
Institute of Aging (NLA) mouse 15K clone set (http://lgsun.grc.nia.nih.gov) was used
2
(276). The study showed more than 500 genes with altered expression levels after 
FGF2 stimulation by more than 1.5 fold (283). 324 genes were shown to be up- 
regulated and 225 were down-regulated. The genes were categorized with known 
function based on the information on the NIA gene ID list. In contrast, more than half 
of the identified genes did not show any homology to genes with annotation or known 
function. In this project, 39 genes were initially selected from the list based on the 
intensity of the induction, novelty of the genes, as well as their characteristics in 
correlation with FGF functions. Based on the interest on an uncharacterised gene, I 
decided to focus on only one gene, which I named coiled coil protein 1 or ccpl (see 
Chapter 3.1 for screening details).
1.2 The brain development
1.2.1 Development of the Central Nervous System (CNS)
The CNS is one of the most complex organs. In vertebrates, the CNS derives from the 
neural plate, an epithelial region that originates from the ectoderm (1). At the end of 
the gastrulation, the neural plate start to fold in itself in a process called neurulation 
and it forms the neural tube, a structure that is designated to give rise to the brain and 
the spinal cord. The rostral (front) part of the neural tubes develops into the brain and 
the rest of the neural tube develops into the spinal cord. The neural tube is originally 
constituted by three different regions, the forebrain (or prosencephalon), the midbrain 
(or mesencephalon) and the hindbrain (or rhomboencephalon). The forebrain 
differentiates into secondary vesicles, consisting of the optic vesicles, the 
telencephalic vesicles (or telencephalon) and the diencephalon. The telencephalon 
will form the cerebral cortex, the basal telencephalon and the olfactory bulb, while 
the diencephalon will form the thalamus and the hypothalamus. The telencephalon is 
composed of dorsal (pallium) and ventral (subpallium) domains. The pallium is 
subdivided in the cerebral cortex and the hippocampus, while the subpallium is 
subdivided into the basal ganglia that consist in proliferative regions named medial 
ganglionic eminence (MGE), lateral ganglionic eminence (LGE), and caudal 
ganglionic eminence (CGE) (2). The LGE give rise to the striatum, while the MGE to 
the globus pallidus and the CGE to the amygdaloid of the limbic region. The 
midbrain differentiates into the tectum and, finally, the hindbrain differentiates in the 
cerebellum, the pons and the medulla oblongata (1).
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1.2.2 Development of the cortex
The mammalian telencephalon is the seat of all higher brain functions, including the 
sensory and motor processing (1). It originates from a sheet of germinal cells that 
differentiate into neurons and glial cells at precise timing of the development. The 
typical laminar structure arises through a series of histogenetic processes involving 
neuronogenesis followed by neuronal migration. The process of cell death is also 
known to contribute the regulation on cortical cell number (3, 4). Cell migration is 
one of the important processes during the development of the CNS (1). Two types of 
neuronal migration identified so far are the radial and the tangential migration (5). 
Studies have demonstrated that some cortical neurons arise in the proliferative zone 
of the dorsal telencephalon (6, 7), while other neurons arise in the ventral 
telencephalon (8-10).
1.23 Radial migration
In Ihe neocortex, the major component of radially migrating cells is a class of 
projection neurons that express the excitatory neurotransmitter, glutamate (5). The 
fomation of the neocortex occurs in mice between embryonic day 11 and 18 (E ll 
andE18) and it is composed of six layers of neurons that have distinct morphological 
and functional identities (11, 12). It has been shown that cortical progenitors in the 
venricular zone (VZ) undergo 11 cell cycles between E l l  and E17 during 
neuogenesis and the timing of cell cycle exit is closely correlated to their destination 
in tie cortical layers (13). The development of the layers involves the migration of
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Figure 1.11\eo cortical-layer formation
The neocortical-layer formation occurs mainly by migration along 
radial glia. At El 1, the preplate (PP) is established by a postmitotic 
wave of neurons that has migrated from the ventricular zone (VZ) 
to the pial surface (PS). By E l3, a second postmitotic neuronal 
wave has migrated through the intermediate zone (IZ) and split the 
PP into the marginal zone (MZ) and subplate (SP), creating the 
cortical plate (CP). During E l4—El 8, subsequent waves o f neurons 
expand the CP in an inside-out fashion, as each wave o f neurons 
passes its predecessors to settle underneath the MZ. Fgf2 knockout 
mice show neuronal defects in the cerebral cortex. Mutant mice 
show a general decrease in neuronal cell number and a group of 
neuronal precursors fail to migrate from the place of origin to their 
target layers II and III. IZ, intermediate zone; MZ, marginal zone; 
PS, pial surface; VZ, ventricular zone. (Adapted from Gupta et al, 
2002).
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neurons at a distance from their birth-place to final destination (14, 15) (Fig 1.1). 
Around E ll, the neocortex consists of a layer of progenitor cells. The first group of 
post-mitotic neurons leaves the VZ towards the pial surface of the brain forming the 
preplate (PP). At E13, a second group of neurons that forms the cortical plate (CP), 
splits the PP into the superficial marginal zone (MZ) and a deeper subplate (SP) (16). 
Experiments using [3H]-Thymidine-incorporation (17) have shown that layers II-VI 
of the cerebral cortex are produced during E14-E18 in an 'inside-out' manner, in 
which neurons that are generated early form the deepest layers, whereas later-bom 
cells migrate past the existing layers and form the superficial layers. Consequently, 
the MZ and SP contain the earliest-generated neurons of the cerebral cortex. The SP 
is separated from the VZ by the intermediate zone (IZ), a layer that will eventually 
contain the afferent and efferent axons of the cortex (white matter). As the CP 
emerges, the subventricular zone (SVZ), another layer of proliferating cells, is formed 
between the VZ and IZ. At adult stages, the SP degenerates (1).
In the radial migration, neural progenitors migrate using the radial glia as 
scaffold, which have an elongated shape with processes attached between the VZ and 
the pial surface (3, 18). It has been reported that, when the radial glia cells stop 
functioning as support for new migrating neurons, they differentiate into astrocytes 
(19, 20). In addition, it has been shown that some neurons, especially at early stages, 
migrate by extending and then retiring their processes from the VZ to the pial surface 
independently from the radial glia, following a process called somal translocation (16, 
21). Neurons following the somal translocation migrate through the IZ but they are 
not associated with radial glial processes. It has been hypothesised that neurons
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destined to migrate radially follow (a) the somal translocation during the early stages 
of corticogenesis, when the cerebral wall is thin and (b) the glia-guided migration 
during the later stages of cortical formation, when the cerebral wall is thicker (16, 
22).
1.2.4 Proteins expressed by cells known to migrate radially.
In this study, several layer markers were used to investigate migration of ccpl- 
positive cells in the brain. To study the radial migration, two genes expressed by 
projection neurons, reelin and T-brain-1 (Tbrl) were used as layer markers. These 
genes are important for radial migration during development (12). Mutations in their 
sequences have been identified to be responsible for abnormal cortical layer 
formation (12).
Reelin
Reelin is a protein secreted by the Cajal-Retzius (CR) cells, a group of cells located in 
the MZ (23). Reeler mice are naturally occurring mutants that present an autosomal 
recessive mutation of the reelin gene (24). These mice show abnormalities in the 
cortical layer formation (24). Reelin mediates its response by binding to its receptor, 
Very Low Density Lipoprotein Receptor (VLDLR) and ApoE Receptor 2 (ApoER2). 
Consequent phosphorylation of the downstream molecule Disabledl (DAB1) is 
observed (25, 26). Reelin mutation in humans causes lissencephaly with cerebellar 
hypoplasia (LCH). Patients affected by lissencephaly present abnormal layering of 
the cortex, which is caused by migration defect (27, 28).
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T-brain-1 (Tbrl)
Tbrl is a transcription factor and a member of the T-box gene family (29). It is 
expressed by early-born cortical neurons designated to form the cortical layer VI (29). 
Since Tbrl is expressed only by post-mitotic neurons, it is likely to have a role in 
neuronal differentiation (29). Tbr-1 mutant mice showed severe disruption of the 
laminar organization, a deficiency in CR cells, and hypoplasia of the olfactory bulb 
(30). Furthermore, Tbrl mutant mice show abnormal organization of the cortical 
layers and disrupted axonal connection (31).
1.2.5 Tangential migration
A sub-set of cells that originate in the basal ganglia migrate tangentially to the 
developing cortex (32) (Fig 1.2). These cells constitute the class of intemeurons and 
express the inhibitor neurotransmitter GABA (33). Intemeurons arise in the 
subpallium, in particular in the two major regions of the basal ganglia, the LGE and 
the MGE (32, 34). From these regions, post-mitotic intemeurons, avoiding the striatal 
region, migrate towards the dorsal cortex superficially to the MZ and IZ and deeply to 
the SVZ (8, 10, 35). Intemeurons start to migrate from the MGE to reach the IZ 
around E12 (10). Later, a second group of cells leave the LGE (around E14) to reach 
the SVZ and the olfactory bulb (34, 36). Once the intemeurons reach the cortex, they 
can also migrate radially and locate in defined layers, similar to the projection 
neurons (37, 38). Intemeurons may move both toward and away from the VZ (35, 
39). Migrating intemeurons may be guided and orientated by a series of chemo- 
repulsive and chemo-attractive factors, whose identity and mechanism of action is
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Figure 1.2 Detailed overview o f  the known and hypothesized 
routes o f  tangential cell migration.
The embryonic telencephalon is shown in coronal (a, b) and 
sagittal (c). Well characterized routes o f migration are shown as a 
solid arrow; less well characterized routes are shown by a dashed 
arrow. Key to migratory routes: (1) MGE to neocortex and 
hippocampus (2) MGE to LGE (3) cortical-striatal boundary to 
ventrolateral telencephalon (lateral cortical stream) (4) LGE to 
neocortex and hippocampus (5) CGE to dorsal telencephalon (6) 
LGE to olfactory bulb (rostral migratory stream) (7) Retrobulbar 
region to marginal zone75, 76. HIP, hippocampus.
still unclear (5). One known chemo-repulsive molecule is Slitl/2, a molecule secreted 
in the VZ of the basal ganglia that repels the intemeurons from the subpallium 
towards the cortex (40). Netrinl and the family of Semaphorin inhibit neural 
migration from the MGE to the cortex, creating a path between exclusion zones for 
migrating cells (41, 42).
1.2.6 Proteins expressed by cells known to migrate tangentially.
Several genes have been identified as being exclusively expressed by tangentially 
migrating intemeurons. These genes are used as tools to better understand and 
characterise intemeurons and their migration processes from the basal ganglia to the 
cortex. In this study, three genes, the Distal-less homeobox gene 2 (Dlx2), calbindin, 
and Glutamic Acid Decarboxilase 65 and 67 (GAD 65/67), were used to investigate 
whether ccpl expressing cells follow the tangential migration.
Distal-less homeobox gene (Dlx)
The Dlx-homeobox gene family is a group of transcription factors. Four members 
(Dlx 1, 2, 5 and 6) are specifically expressed by intemeurons and their precursors (8, 
43). Dlxl/2 is expressed at Ell-12 in the progenitor cells of the LGE and MGE (34, 
43). Dlxl/2 is later found in the dorsal region of the cortex. Dlxl and Dlx2 show 
similar expression patterns in the forebrain (43). Dlx2-knockout mice do not show 
any significant brain phenotype (44), suggesting a redundant effect by the Dlx family 
members. In mice lacking both Dlx2 and Dlxl, late bom neurons do not differentiate 
and intemeurons fail to migrate from the basal ganglia to the cortex (8). This effect 
results in the accumulation of tangentially migrating neurons in the VZ of the basal
9
ganglia and a decrease of the GABAergic neurons in the dorsal cortex, hippocampus 
and olfactory bulb (30, 34, 45).
Calbindin
Calbindin is a member of the calmodulin superfamily of calcium binding proteins 
(CBP) (46). The main function of calbindin in rat dorsal root ganglion neurons is to 
buffer calcium levels and to protect cells from degeneration and excito-toxicity (47). 
Calbindin is a well-known marker for mature GABAergic neurons (48). At E12.5, the 
calbindin positive-cells localise to the mantle of the MGE and the developing cortex 
(49).
Glutamic Acid Decarboxylase 65 and 67 (GAD 65/67)
GAD is an enzyme that synthesizes the inhibitory neurotransmitter, GABA, from L- 
glutamate, and therefore it is a marker for GABAergic intemeurons (50-52). In the 
adult brain, GAD exists in two major isoforms, GAD65 and GAD67, named 
according to their molecular masses (50). GAD65 is a membrane protein whereas 
GAD67 is soluble and distributed in the cytoplasm (53). GAD65 is the predominant 
GABA synthetic enzyme in rat and mouse brains (54), whereas GAD67 is the major 
form in the human brain (55). In vitro, GABA is known to inhibit DNA synthesis and 
to affect migration and neurite outgrowth (56-58). Knockout mice for GAD65 have 
been generated (59). Brain abnormality was not observed in the GAD65 knockout 
mice, probably due to compensation from GAD67 (59). Mutant mice lacking both 
GAD65 and GAD67 die immediately after birth due cleft palate, however, the 
embryonic brain did not present any abnormalities (60).
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1.2.7 Types and functions of brain cells
The developing forebrain consists of different type of cells that are usually classified 
into two categories, neurons and glia. Function of neurons is to receive, conduct, and 
transmit impulses in the nervous system. Glial cells are subdivided into radial glia, 
astrocytes and oligodendrocytes. Glial cells are more abundant than neurons: they 
constitute 90% of the brain's substance. Of these cells, the astrocytes are the most 
numerous (1). Radial glia cells function as scaffolding during the radial migration of 
neurons. As discussed earlier, neurons have been shown to attach to radial glial fibres 
and to slide along these fibres (3). Radial glial also function as neural progenitors 
(19). Astrocytes are star-shaped cells that provide physical and nutritional support for 
neurons. Astrocytes have been considered the as brain glue', providing an inert 
scaffold necessary for neuronal distribution and interactions. They also regulate the 
chemical content of extra-cellular space (1). It has been shown that astrocytes express 
voltage-gated channels suggesting an involvement in intercellular communication 
(61). Finally, oligodendrocytes provide the insulation to neurons in the CNS by 
producing myelin sheaths (62). These cells wrap around axons concentrating the 
propagation of the action potentials along the axon at regular, discontinuous sites, 
called nodes of Ranvier. The myelin functions as an intemodal insulator and 
facilitates the current flow increasing the action potential conduction speed (1).
A common multipotent progenitor cell gives rise to (a) the astrocytes, (b) the 
radial glia, and (c) the progenitors for oligodendrocytes and neurons (63) (Fig 1.3). 
Astrocyte differentiation in the telencephalon involves factors including 
BMP2/Smads, LIF/STAT and FGF2 (64). In radial glia differentiation, Pax6 plays an
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Figure 1.3 Model o f  neuronal fate
The developing forebrain is formed by different type o f cells that 
are usually classified in two categories, neurons and glia. Radial 
glia cells function as scaffolding during radial migration o f the 
neurons and also function as neural progenitors. Neural stem cells 
are multipotent and can generate all neural cell types; that is, 
neurons, astrocytes and oligodendrocytes. Generally, neural stem 
cells first generate neurons, and later produce glia.
essential role (65). Oligodendrocyte differentiation occurs in the ventral 
telencephalon and involves the signalling molecule Shh and the bHLH transcription 
factors Oligl and 01ig2 (66-68). Neurons arise during the embryonic stages, while 
the most of the glia is produced after birth (69). Several factors have been recently 
implicated in the differentiation process of the neural progenitors in the 
telencephalon. Some of these factors include Notch, its downstream effectors, Hes, 
and the homeodomain factor, Emx2 (70-73).
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1.3 Fibroblast growth factors and their receptors
1.3.1 Gene family of FGFs and FGFRs
Fibroblast Growth Factors (FGFs) are a family of at least 22 polypeptides (74). They 
constitute a group of factors that act during tissue development and regeneration (75). 
Roles of FGFs include organ development, angiogenesis, wound healing and 
tumorigenesis (75). FGF actions are mediated by activation of receptors on the cell 
surface (75). Three classes of cell surface receptor have been identified for FGFs: (1) 
high-affinity receptors (termed FGFR1-4), (2) low-affinity receptors (heparan 
sulphate-containing proteoglycans), and (3) cysteine-rich FGFRs (CFRs) (76). Both 
FGFs and FGFRs have been found in many species, including vertebrates, fruit flies, 
worms and sea urchin (77-81). FGFRs are single-pass transmembrane proteins. The 
extracellular domain consists of a signal peptide, an immunoglobulin (Ig)-like motifs 
(Ig loops) and an acid box. Most forms of FGFR have two or three Ig-like domains. 
The intracellular region includes a conserved kinase domain, which is split by the 
kinase insert region, and a caiboxy tail domain (82).
Different FGF family members activate the receptors to different extents, 
depending on their ability to bind each receptor type (83). One FGF-molecule 
simultaneously binds two adjacent receptors and the binding occurs in cooperation 
with heparan sulphate proteoglycan (HSPG), which is either soluble or cell surface- 
bound (84, 85). Binding of the extracellular FGF ligand to FGFR leads to 
dimerization of the receptor and initiates the intermolecular autophosphorylation of
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tyrosines (86). Dimers are formed between FGFRs of the same type 
(homodimerization) and between different FGFRs (heterodimerization) (87). FGFRs 
transmit extracellular signals to various cytoplasmatic signal transduction pathways 
through tyrosine phosphorylation. Signalling pathways known to be involved in the 
FGFRs activation include phosphatidylinositol 3' kinase (PB-kinase), MAPK, Statl 
and Stat3 and PLC-y (88).
1.3.2 Expression of FGFRs and FGF.
The expression pattern of the FGF family is variable, from almost ubiquitous, such as 
FGF2, to very restricted (75). Expression of FGFs in the developing CNS is listed in 
Table 1.1 (89).
FGFRs expression is regulated at the level of transcription, translation and post­
translation (90, 91). FGFR1 is widely expressed in the mesenchyme of limb buds and 
in the developing spinal cord (92, 93). FGFR2 is expressed in diverse epithelial 
tissues, such as the skin (93). FGFR3 is mainly expressed in the growth plate 
chondrocytes of developing bone (93). Finally, FGFR4 is highly expressed in several 
tissues of endodermal and mesodermal origin (94, 95), such as skeletal muscles (92) 
and adult liver (96). All the four receptors are present in the developing brain at 
different stages and in specific regional patterns (89, 93, 97-101).
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Table 1.2 Expression of FGFs in the developing central nervous system (89)
FGF Timing Location
FGF1 E ll onwards Telencephalon, diencephalon, mesencephalon, 
metencephalon, spinal cord
FGF2 < E9 onwards Telencephalon, diencephalon, mesencephalon, 
spinal cord
FGF3 E8-E11 Otocyst, hindbrain
FGF4 - -
FGF5 - -
FGF6 - -
FGF7 E14.5-E15.5 Lateral ventricle
FGF8 E8.5-E12.5 Telencephalon, diencephalon, midline, 
midbrain-hindbrain boundary
FGF9 E10-E14 Spinal cord motor neurons
FGF10 Otocyst
FGF15 E8-E14 Telencephalon, diencephalon, mesencephalon, 
metencephalon, spinal cord
FGF16 — —
FGF17 E9-E16 Telencephalon, midline, midbrain-hindbrain 
boundary
FGF18 E10-E15.5 Telencephalon, midbrain-hindbrain boundary
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1.3.3 Functions of FGFs and FGFRs
The functions of the FGF family are diverse. FGFs play a key role in the regulation of 
many critical processes, such as cell differentiation, migration and mitogenesis (74, 
88). Functions of the FGF and FGFR family members are summarised in Table 1.2. 
Several members of the FGF family have been disrupted or mutated in mice, which 
have shown a broad range of phenotypes, from early embryonic to adult defects. In 
contrast, some of the knockout mice did not show any obvious phenotype, probably 
due the FGF functional redundancy. The major phenotypes observed in FGF and 
FGFR knockout mice are summarised in Table 1.3.
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Table 1.3 Functions of the FGF and FGFR family members
Gene Function References
FGF1
FGF2
FGF4
FGF5
FGF6
FGF7
FGF8
FGF9
FGF10
FGF17
FGF18
FGFR1
Modulates early cell migration, proliferation and (89,102-104) 
initial differentiation in neuronal cells in vitro;
induces morphogenesis in primary murine
fibroblasts and stimulates fibroblast migration; 
inhibits cell attachment to multiple ligands and 
cytoskeletal organization; regulates angiogenesis.
Modulates proliferation in the developing nervous (75, 89,103,105-109)
system; stimulates the differentiation of the
neuroepithelial cells into mature neurons and glia
and the early migration and proliferation of
ganglion cells; has a neurotrophic and mitogenetic
activity in fibroblast and pre-endothelial cells
during embryogenesis; regulates blood pressure.
Induces differentiation, proliferation and migration (110-112)
of murine aortic endothelial and in mesenchymal 
cells; regulates limb development during
embryogenesis.
Functions as an inhibitor of hair follicle growth. (113)
Regulates muscle regeneration. (114)
Functions as a paracrine mediator of epithelial cell (115-117)
growth.
Regulates patterning of forebrain and midbrain (118-120)
during embryogenesis; regulates the anterior-
posterior axis formation; regulates nephrogenesis.
Induces glial cell proliferation and motoneuron (121-123)
survival; regulates chondrocyte proliferation, 
differentiation and apoptosis.
Regulates caudal neuronal tube and limb (118,124,125)
development.
Regulates midbrain-hindbrain patterning. (126)
Regulates midbrain-hindbrain patterning. (127)
Regulates cell proliferation and migration during (97,128,129)
the axial organization of early post-implantation 
embryos; stimulates mesodermal and 
neuroectodermal development.
FGFR2 Regulates proliferation, differentiation and (97,130-132)
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apoptosis in cells; stimulates the differentiation 
and the maintenance of the inner cell mass.
FGFR3
FGFR4
Negatively modulates endochondral bone growth, 
inhibiting chondrocyte proliferation and 
differentiation; controls the development of the 
cortex, by regulating proliferation and apoptosis of 
cortical progenitors. Promotes the differentiation 
of oligodendrocytes and myelination at early 
postnatal stages.
Promotes muscle progenitor differentiation.______
(133)(134-137)
(138)
Table 1.4 The major phenotypes observed in Fgf and Fgfr knockout mice
FGF knockout mice
Gene Survival Phenotype References
Fgfl Viable Morphologically
normal
(139)
Fgf2 Viable Mild cardiovascular, 
skeletal, neural
(106,139,140)
Fgf3 Viable Mild inner ear, 
skeletal
(124)
Fgf4 Lethal at E5.5 Inner cell mass 
proliferation
(1 1 2 )
Fg£5 Viable Long hair (113)
Fgf6 Viable Subtle, muscle 
regeneration
(141)
Fgf7 Viable Hair follicle growth (115,116)
Fgf8 Lethal at E8.5 Gastrulation defects, 
CNS development, 
limb development
(142,143)
Fgf9 Lethal Lung mesenchyme, 
XY sex reversal
(144)
FgflO Lethal at PO Development of 
multiple organs
(125)
FGF17 Viable Cerebellar
development
(127)
Fgfr knockout mice
Gene Survival Phenotype References
Fgfrl Lethal at E9.5 Growth retardation, 
defect of 
mesodermal 
patterning
(128,145)
Fgfr2 Lethal at E10.5 Mutant embryos 
died a few hours 
after implantation
(132)
Fgfr3 Viable Bone over growth 
inner ear defect
(133,146)
Fgfr4 Viable Morphologically
normal
(147)
Fgfr3/Fgfr4 Viable Neonatal growth 
retardation, lung 
abnormalities.
(147)
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1.3.4 Function of FGF2 during brain development
FGF2 plays an important role during the development of the CNS (148, 149). In 
vitro, FGF2 has a mitogenic activity in specific neural cell types (150). FGF2 was 
shown to promote differentiation and long-term survival of neurons in culture in a 
concentration-dependent manner (108, 151-155). FGF2 is also an inhibitor of 
oligodendrocyte proliferation and differentiation during remyelination (156). It has 
been shown that microinjection of FGF2 into the cerebral ventricles at the beginning 
of neurogenesis produces permanent increases in cortical volume and number of 
neurons, an effect that is maintained until the adult stages (155). Furthermore, in vitro 
experiments showed that FGF2 treatment increases the number of both glutamate- 
and GABA-containing neurons (155), two major neurotransmitters expressed by 
projection neurons and intemeurons, respectively, of the cortex. Fgf2 knockout mice 
show neuronal defects in the cerebral cortex, hippocampal commissure and spinal 
cord (106,139). Mutant mice show a general decrease in neuronal cell number (155). 
FGF2 has a function before the onset of cortical neurogenesis, since Fgf2 knockout 
mice show a 60% reduction of proliferating cells within the dorsal pseudostratified 
ventricular epithelium (PVE) at early stages as E10.5 (157). Furthermore, a group of 
neuronal precursors fail to migrate from the place of origin to their target layers II and 
in (106). The development of the basal telencephalon and the number of neurons 
within the basal ganglia do not present abnormalities in the absence of FGF2 (157). 
The FGF family is composed of at least 22 polypeptides (74), which could all 
potentially interact with the same FGFRs (75). Therefore, the fact that Fgf2 knockout
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mice present such a dramatic brain phenotype suggests that FGF2 by itself may play a 
major role in regulating corticogenesis (155).
Similar to Fg£2 null mouse, Fgfl-Fgf2 double knockout mice showed abnormal 
organization of neurons of the frontal motor cortex (139).
1.3.5 FGFs and FGFRs in the brain
Several FGFs and FGFRs are expressed within the developing CNS. They have 
multiple roles during the embryonic development, including cell proliferation and 
apoptosis as well as regulating areal patterning (89). Some FGFs, such as FGF1 and 
FGF2 are more involved in regulating cell proliferation, while others, such as FGF8, 
regulate mainly areal specification (106,119,157,158).
The FGFRs are expressed in partly overlapping areas of the embryonic 
neuroepithelium, however, with distinct patterns and intensities (97, 159). The 
expression pattern of each receptor becomes more distinct in the adult stages, which 
may indicate their role in specific populations of cortical cells (160). For example, in 
the developing choroids plexus, FGFR1 and FGFR4 are expressed only at early 
stages, suggesting a role in the early stages of the development (101). On the 
contrary, FGFR2 is present throughout development of the choroids plexus (101). 
Interestingly, FGFR3 has been observed only in the cell nuclei in the choroids plexus, 
probably playing a role in the intracrine signalling (101).
FGFR1 null mice are lethal prior to the formation of the mature CNS (161). To 
investigate the role of FGFR1 signalling in the telencephalon, FGFR1 conditional 
knockout mice have been crossed with Foxgl-Cre mice (162). Foxgl-Cre allows Cre-
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lox recombination specific to the telencephalon. The Foxg:Fgfrlflox/flox mice show 
abnormal formation of the olfactory bulb suggesting a key role for FGFR1 in 
patterning and morphogenesis of the telencephalon (162).
FGFR2 null mice display failure of early post-implantation development (132). 
FGFR2 conditional knockout mouse has been generated using Cre-mediated RNAi 
strategy but the brain phenotype has not been investigated to date in these mice (163).
No obvious brain phenotype was originally reported in the FGFR3 null mice 
(133). However, FGFR3 has been recently been implicated in glia differentiation. It 
has been shown that FGFR3 represses glial fibrillary acid protein (GFAP) expression 
in grey matter astrocytes in the adult spinal cord (137) and promotes the 
differentiation of oligodendrocytes and myelination at early postnatal stages (164). 
Recently, it has also been shown that FGFR3 controls the development of the cortex, 
by regulating proliferation and apoptosis of cortical progenitors (135).
1.3.6 Pathologies related to FGFR mutations
FGFRs have been implicated in multiple pathological processes, including skeletal 
disorders and tumorigenesis (165, 166). The skeletal disorders can be classified into 
two groups, the dwarfing chondroplasia syndromes and the craniosynostosis 
syndromes. The dwarfing chondroplasia syndromes include Achondroplasia (ACH), 
Hypochondroplasia (HCH), Thanatophoric dysplasia types I and II (TDII and TDII), 
and Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans 
(SADDAN) (167-171). The phenotypes of HCH, ACH and TD display progressively 
increasing clinical severity (169, 172-174). Point mutations in FGFR3 have been
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associated with these diseases (175). These conditions result from mutations that 
render the FGFR3 constitutively active (175). Patients affected by these conditions 
are characterised by a disproportionate shortening of the proximal segment of limbs, a 
relatively large skull and increased spinal curvature (169,170).
The majority of craniosynostosis syndromes are associated with mutations in 
FGFR2. These disorders are characterized by premature fusion of the sutures of the 
skull, causing an abnormal head shape (169). The craniosynostosis syndromes 
include Apert syndrome (AS), Beare-Stevenson cutis gyrata, Crouzon syndrome 
(CS), Jackson-Weiss syndrome (JWS), and a non-syndromic craniosynostosis (NSC) 
(168-171,176). The FGFR1 is also involved in autosomal dominant craniosynostosis 
syndromes such as the Pfeiffer syndrome (PS), characterized by craniofacial 
abnormalities (177).
Malformation of the cerebral cortex is also a condition associated with TDII (178). 
The malformation is characterized by enlargement of the temporal lobe and 
hippocampal dysplasia (178,179).
Loss of function mutations in FGFR1 are associated with the autosomal dominant 
form of Kallmann syndrome (KAL) (180). KAL is a rare genetic condition in which 
the gonadotrophin releasing hormone (GnRH)-synthesizing neurons fails to migrate 
from the olfactory epithelium, causing hypogonadotropic hypogonadism (181).
Finally, the mutations found in severe skeletal dysplasia have been also identified 
in certain types of cancer, including multiple myeloma, cervix carcinoma and bladder 
carcinoma (165). Table 1.4 summarizes the known types of cancers associated with 
altered expression of FGFRs (182).
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Table 1.5 Genetic alterations of FGFRs in human cancers
Gene Alteration Reference
FGFR1 8P11 myeloproliferative syndrome (EMS), breast 
cancer, prostate cancer, astrocytoma, pancreatic 
adenocarcinoma
(183-187)
FGFR2 Prostate cancer, astrocytoma, gastric cancer (186-188)
FGFR3 Transitional cell carcinoma of bladder, thyroid 
carcinoma, cervical carcinoma, colorectal cancer, 
peripheral T cell lymphoma, multiple myeloma
(189-195)
FGFR4 Pancreatic adenocarcinoma, head and neck squamous 
cell carcinoma
(185,196)
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1.4 Growth factor regulation of cell proliferation
1.4.1 Cell proliferation and cell cycle
Cell proliferation is the basic biologic process that results in an increase in the 
number of cells. The rate of cell number depends on (a) the time the cells take to 
complete a cell cycle of division, (b) the fraction of cells within the population 
undergoing cell division (growth fraction), and (c) the rate of cell loss from the 
population due to terminal differentiation or cell death (197).
Cells divide by progressing through a sequence of phases that constitute the 
mitotic cycle (or the cell cycle). The cell division cycle is composed of two functional 
phases, S (for Synthesis) and M (for Mitosis), and two preparatory gap phases, Gi 
and G2. During the S phase the DNA is synthesized, whereas during the M phase the 
parent cells divide into two daughter cells. Gi and G2 phases are necessary for 
checkpoints and for the synthesis of cellular constituents. The cells that do not 
proliferate usually enter a phase called Go. The length of time that a typical human 
cell takes to complete the S phase lasts between 12 and 24 h, whereas the length of M 
phase is about 1 h and the G2 phase lasts for about 2-3 h. The length of Gi phase is 
variable and can last from about 6 h to several days or longer.
The cell cycle is rigorously regulated. The M phase cannot start unless the S 
phase has been completed, and vice versa (198). At the end of the cell cycle, the 
daughter cells, in the Gi phase, either start another cycle or arrest in a quiescent Go 
phase, depending, on external conditions. If these conditions are not adequate, the cell 
arrest in Go before it reinitiates cell cycle. Neuronal and skeletal muscle cells are in
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terminally differentiated Go and the expression of cell cycle regulators is permanently 
off. Liver cells, in contrast, are in Go phase but they can re-enter the cell cycle after 
tissue damage.
1.4.2 Growth factors signalling and proliferation through MAPK pathway
Proliferation of mammalian cells is strictly regulated by extracellular signals, such as 
mitogens present and the supply of nutrients. They largely exert their effects on cells 
during Gi phase of the cell cycle (199). Binding of a growth factor to its receptor can 
trigger activation of the tyrosine-kinases (200). The signal is then transduced from the 
cytoplasm to the nucleus by a heterogeneous group of molecules known as second 
messengers. Binding of the extracellular FGF ligand to FGFR leads to dimerization 
of the receptor and initiates the intermolecular autophosphorylation of tyrosines (86). 
The phosphotyrosines either stimulate the intrinsic catalytic activity of the receptors 
or serve as high-affinity recruitment sites for the binding of downstream signalling 
proteins (201).
One of the major pathways modulated by growth factor signalling and known to 
promote cell proliferation is the MAPK pathway (202) (Fig 1.4). Binding of FGF to 
its receptor triggers cell cycle progression through different pathways, including the 
MAPK signalling (88). The MAPK family is composed of protein kinases that are 
highly conserved in evolution and play central roles in signal transduction in the cell. 
The MAP kinases are protein-serine/threonine kinases activated in response to a 
variety of growth factors and are known to regulate cell growth, death and 
differentiation (203).
26
0  f g f
® 0 0 '
R0PI3 K
STAT
GDP
GENE REGULATION
^D N A
Figure 1.4 Dimerization, autophosphorylation and signalling o f  
FGF/FGFR
Schematic diagram showing several FGF signalling pathways and how they 
interact to form a signalling network. Binding of the extracellular FGF 
ligand to FGFR leads to dimerization o f the receptor and initiates the 
intermolecular autophosphorylation o f tyrosines. The ERK/MAPK cascade 
is one o f the best known for its key role in mediating the transduction o f 
signals from FGFRs. Other pathways involve PI3-kinase, Statl/3 and 
PLCy.
Autophosphorylation of receptor protein tyrosine kinases results in their 
association with adaptors, which contain modular protein-protein interaction 
domains, such as She and ‘Growth factor Receptor Binding 2 protein’ (GRB2). This 
mediates protein-protein binding, such as between the SH2 domains of the modular 
proteins and the FGFR (204). Association of GRB2 with activated receptors localises 
‘son-of-sevenless protein’ (SOS) to the plasma membrane and it stimulates guanine 
nucleotide exchange, resulting in activation of RAS, a GTP-binding protein (205). 
Activation of RAS leads to activation of the ‘rabbit fibrosarcoma protein’ (RAF) 
serine-threonine kinase (206). Three isoforms of RAF have been identified so far, A- 
RAF, B-RAF, and RAF-1. RAF-1 is widely distributed in the body and expressed in 
most cultured cells, whereas the other isoforms are more restricted in the expression. 
For example, B-RAF is expressed specifically in neuronal tissues (207). When 
activated, RAF phosphorylates and activates the protein MEK. MEK selectively 
activate ERK1/2 by phosphorylation of both threonine and tyrosine residues (208, 
209). ERK1 and ERK2, proteins of 44 and 42 kDa respectively, share 83% amino 
acid identity and are expressed in various type of tissues (207). Once activated, ERK 
translocates to the nucleus, where it phosphorylates various targets, including other 
protein kinases and transcription factors. For example, ERK phosphorylates and 
regulates transcription factors such as Myc, a protein that promotes cell cycle entry 
by regulating the expression of cyclin D (210).
The family-named ‘immediate-early genes’ expression is also induced by 
growth factor stimulation (197). These genes are induced through the regulation of a 
sequence, which is recognized by a complex of transcription factors including the
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serum response factor (SRF) and ELK-1 (212). ERK is known to phosphorylate and 
activate ELK-1, providing a direct link between MAP kinase family and immediate- 
early gene induction (212).
1.4.3 Negative feedback of MAPK
MAPK signalling events are precisely regulated to ensure a physiologically 
appropriate biological effect. One of the mechanism by which MAPK signalling is 
regulated involves a negative-feedback loop through Sprouty (SPRY) (213) (Fig 1.5). 
SPRY expression is induced by MAPK signalling upon growth factor stimulation, 
such as FGFs (214, 215). SPRY proteins undergo phosphorylation in response to 
growth-factor stimulation (216-218). Its phosphorylation site functions as a binding 
site for the SH2 domain of the adaptor molecule GRB2 (217). FGFs induce 
interaction of SPRY with GRB2, preventing GRB2 from binding to either ‘FGF- 
receptor substrate-2’ (FRS2) or ‘ SH2-domain-containing protein tyrosine 
phosphatase-2’ (SHP2) (217). The SH2-dependent recruitment of complexes of 
GRB2 and SOS to FRS2 and SHP2 is a fundamental step in the MAPK signalling to 
lead RAS activation. Therefore, the sequestration of GRB2 by SPRY blocks the 
signalling events downstream of RAS (217).
Other inhibitors of MAPK signalling have been identified, including 
PYST1/MKP3, Sprouty-related 1/2 (Spred-1/2), and the ‘Similar expression to FGF 
gene’ (SeQ (219-221).
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Figure 1.5 The MAPK cascade and its negative-feedback.
(A) The members o f the MAP kinase family are ERK1/2, MEK and 
RAF, which are coupled to growth factor receptors by a GTP-binding, 
RAS. Once activated, ERK translocates to the nucleus, where it 
phosphorylates various targets (B) FGF stimulation leads to GRB2- 
SOS complex formation, which is recruited to the phosphorylated 
tyrosine residues on FRS2 or SHP2. This recruitment event results in 
the activation o f RAS. When Sprouty (SPRY) is activated, it generates 
a binding site for GRB2-SOS complex preventing RAS activation.
1.5 Characteristic domains identified within ccpl 
sequence and cellular compartments where ccpl may
localise
Proteins contain several functional domains that may be related to specific protein 
functions, such as DNA binding, enzyme activity, and other important cellular 
processes. The protein motif search tools have predicted specific domains within the 
ccpl amino acid sequence (Chapter 3.1). In this section, the domains that have been 
identified in ccpl amino acid sequence are introduced, including the coiled coil 
region, the leucine zipper and the nuclear exporting signal (NES). Furthermore, when 
transiently expressed, ccpl localised in vesicle-like structures identified as lysosomes 
(Chapter 3.3). Here, an overview of the main endosomal/lysosomal pathway is 
presented.
1.5.1 The coiled coil domain
Coiled coil domains are known to form a stable superhelix structures when two or 
three a-helices bound around each other (222). These structures allow 
oligomerisation and binding to other proteins possessing coiled coil domains. Two- 
stranded, three-stranded, and four-stranded versions of coiled coils are known to be 
possible (223). In the coiled coil domain, the amino acids are positioned to form a 
heptad repeat pattern in which the first and fourth amino acids are hydrophobic and
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the fifth and the seventh are charged or polar (222, 224). The interactions between 
amino acids at these heptad positions are essential for the formation of the coiled coil 
structure. The specificity of these interactions and the amount of packing space 
required for the residues at each position vary depending on the oligomerization state 
of the coiled coil (223).
A large number of coiled coil proteins with diverse functions have been identified. 
They are roughly categorised into four functional groups, (a) cytoskeletal proteins, 
such as keratin and vimentin, (b) motor proteins, such as myosin, kinesins, and 
dyneins, (c) proteins important for vesicular transport, such as synaptobrevin, 
syntaxin and SNAP-25, and (d) transcription factors, such as fos and jua 
Cytoskeletal proteins
The cytoskeleton of eukaryotic cells contains three filament moieties: microtubules, 
actin-containing microfilaments and intermediate filaments (IFs) (225). One of the 
most common families of IFs is that of the keratins and vimentin. Keratin filaments 
are elongated molecules that contain a coiled coil domain (197). The protein a- 
keratin was the first protein in which the coiled coil structural motif was identified 
(226). The coiled coil structure defines the elongated shape of IF molecules, which 
form heterodimers and, subsequently, interact with other IFs to form tetrameric 
subunits (227). The interconnected network of IFs gives mechanical stability to the 
cell and is involved in processes such as cell division and cell motility (228).
Motor proteins
In eukaryotic cells, different organelles often move in the cytoplasm using 
macromolecular complexes located on microtubules and actin filaments (229, 230).
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Specific motor proteins, such as myosin, kinesins, and dyneins, mediate these 
movements (231). Myosin is known to move along actin and kinesins along 
microtubules (232). In the nervous tissue, both kinesin and dyneins show a function 
in anterograde and retrograde axonal transport respectively (232, 233). The motor 
protein dynein and its binding partner dynactin are essential for nuclear migration in 
fungus (234). The Lisl gene is known to be involved in function as nuclear 
translocation and mitosis together with the cytoplasmatic proteins dynein and tubulin 
(235, 236). Recently, more proteins that interact with motor proteins have been 
identified by yeast two-hybrid and biochemical analyses (237). One of these proteins 
is NUDEL, a coiled coil protein fundamental for neurofilament assembly and neuron 
cytoskeleton integrity in vitro (238). NUDEL is known to interact with dynactin and 
Lisl (239-241), indicating that NUDEL is required for active transport along 
microtubules.
Proteins important for vesicular transport
During the endocytic traffic, the cargo vesicles recognise the target membrane 
through specific surface markers. The SNAP receptor (SNAREs) family is a class of 
protein that control this recognition process (242). SNARE proteins are known to 
form complexes through their coiled coil regions (243). In neurons, most vesicles and 
protein complexes are generated in the cell body and are then transported along axons 
(244). The SNARE family has been well characterised in neurons, where it mediates 
synapse connections (245). Well studied SNARE family members in the neuronal 
cells include SNAP-25 and Synaptobrevin (242). Another protein is Syntabulin,
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which connects syntaxin-containing vesicles to microtubules, ensuring their 
anterograde transport (246).
Transcription factors
Transcription of DNA is a cellular process that involves specific interactions between 
DNA and DNA-binding proteins. Many transcription factors contain coiled coil 
regions that are fundamental for specific recognition between molecules (247). An 
example of transcription factors containing coiled coil regions are the GCN4 proteins 
(223, 248, 249). Fos and jun proteins (which are part of the AP-ltranscription factos) 
are associate preferentially to form a heterodimer that binds to DNA, and thereby 
modulates transcription of a wide variety of genes in response to mitogenic stimuli. It 
is reported that incorrect coiled coil pairing may result in oncogenic activity. In this 
functional category, coiled coil pairing must therefore be very specific in order to 
avoid unfavourable modulation of transcription.
1.5.2 The leucine zipper
The leucine zipper is a periodic repetition of leucine residues at every seventh 
position that facilitates dimerisation between two peptides as well as the binding of 
the DNA chain (250). The leucine zipper can fold as a parallel, two-stranded coiled 
coil (251, 252). A leucine zipper consists of two a-helices, one from each 
monomer. Transcription factors containing a leucine-zipper bind DNA as dimers. The 
a-helices of two proteins are held together by hydrophobic interactions between 
leucine residues, which are located on one side of each helix. Examples of leucine 
zipper containing proteins are the B-ZIP class of transcription factors (253). The B-
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ZIP family includes the activator protein-1 (AP-1), the cyclic AMP response element 
binding protein (CREB) and CCAAT/enhancer binding proteins (C/EBP) (254-256).
1.5.3 The Nuclear Exporting Signal (NES)
A NES is a short sequence that determines the nuclear transport from the nucleus to 
the cytoplasm through the nuclear pore complexes (NPC) (257). In contrast to small 
proteins (< 40 kDa) that can freely diffuse through the pore, larger proteins require a 
NES. These protein signals are recognised by specific soluble receptors, karipherins, 
which are able to interact with the NPC (258). When the cargo and the karipherins 
form a complex, they translocate through the NPC with an active transport using the 
energy provided by RAN, a GTPase of the RAS family (259).
There are several type of NES, but the most common NES is the leucine-rich 
NES domain (260). It is composed of a leucine-rich region. The accepted consensus 
is LX2-3LX2-3LXL, although many of the known leucine-rich NES deviate from this 
generally accepted consensus (261). Only 36% of the sequences known so far contain 
a NES domain that fit the consensus (257). The leucine-rich NES was first identified 
within the protein kinase inhibitor (PKI) and the HTV Rev protein (262) (263).
The receptor ‘Chromosome Region Maintenance V  (CRM1) has been identified 
as the export receptor for proteins containing leucine-rich NES (264, 265). CRM1 
was originally identified as a protein responsible for maintaining the chromosome 
structure of the Scizosaccharomycespombe (266). Later, CRM1 was associated to the 
nuclear exporting process (264, 265). Recognition of the NES domain by CRM1 is
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inhibited by the fungicide leptomicin B (LMB) and ratjiadone (RAT) (264, 267). 
LMB binds to a single sulfydryl group of CRM1 inhibiting its activity (268).
At least 75 proteins containing a leucine-rich NES have been identified so far 
(257), including MEK (269), the tumor suppressor protein p53 (270), Smadl (271) 
and Cdc25A (272). Activation of MAP Kinases leads to their nuclear translocation 
and phosphorylation of DNA-binding proteins that are mainly transcriptional 
regulators (273). MEK contains a NES and it is mainly localised to the cytoplasm 
(274). Nuclear localisation of ERK is transient, since, after its activation, it is 
immediately re-localised to the cytoplasm to prepare for the next stimulation. Since 
ERK does not contain a NES, its relocation to the cytoplasm is likely to be mediated 
by a protein anchor, which has been hypothesised to be MEK (275).
1.5.4 The endosomes lysosomes pathway
When transiently expressed, ccpl fusion protein localised in a vesicle-like structure 
similar to endosomes or lysosomes. During the course of this study, the ccpl-positive 
structures were identified as lysosomes (Chapter 3.3).
Cells are known to elaborate internal membrane system that allows them to 
internalised macromolecules by a process called endocytosis (197). After 
endocytosis, most membrane proteins return to the cell surface to be recycled up to 
several hundred times, whereas other membrane components are delivered to late 
endosomes or to lysosomes in order to be degraded (197). There are different types of 
endocytosis that can transport molecules to several destinations within the endosomal 
system. A well-known endocytic process is the one of the internalization of receptors
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and their ligands by clathrin-coated pits (334). However, non-clathrin mechanisms 
are also known, although their mechanism is still not fully understood. Endosomes 
are commonly classified in early endosomes or sorting endosomes, late endosomes 
and recycling endosomes. After entering the cytoplasm, the endocytotic vesicles 
loose its clathrin coat and fuse each other or with pre-existing endosomes (334). They 
appear tubular-vesicular structures and have a lumenal pH of 6.0. Early endosomes 
uptake material for only about 5-10 minutes and then translocate along microtubules, 
stop fusing with newly endocytosed vesicles and become more acidic (197). At this 
step, early endosomes acquire add hydrolases and take on the properties of late 
endosomes. These changes in sorting endosomes are called as maturation (334). The 
fusion of coated-pit-derived primary endocytic vesicles with sorting endosomes is 
regulated in part by early endosome antigen 1 (EEA1) and Rab5 (334). EEA1 is a 
phosphoinositide-binding protein containing zinc finger like domains in the amino 
and carboxyl terminal (295). Rab proteins are a family of small GTPase regulatory 
proteins (334). Late endosomes are formed as the pH continues to drop to 5-6 and 
they acquire the surface marker Rab7. Late endosomes are not able to digest all the 
material, therefore they form a dynamic network together with lysosomal structures, 
the end point of endocytosis and site of protein degradation (197). Lysosomes are 
membrane-bound vacuoles, which play a critical role in cellular metabolism that act 
as sites for digestion of foreign materials and for specialized autolytic cellular 
processes (197). Membrane-associated glycoproteins have an important role in 
normal lysosomal function and they can be used as marker for a late endosome or a
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lysosome, for example the heavily glycosylated lysosomal associated membrane 
proteins (LAMPs) (299,300).
Receptors such as LDL-receptor (LDLR) and transferrin receptor (TfR), are 
continuously internalized, delivered to early endosomes and finally recycled back to 
the plasma membrane via recycling endosomes (296). The Tfr is included in the class 
of ligand transport receptors that are internalized and clustered in coated pits (293). 
The Tfr binds the semm transport protein transferrin (Tf) and mediates the uptake of 
iron into the cell (293).
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CHAPTER 2 
MATERIALS and METHODS
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2.1 Materials
2.1.1 Chemicals and tissue culture media
The chemicals and tissue culture media used in this study were all purchased from 
Sigma or Invitrogen, unless indicated in the text.
2.1.2 Plasmid Vectors
A list of plasmid vectors used during this study is presented in table 2.1, detailing 
specific applications and characteristics.
2.1.3 Ccpl cDNA
The original ccpl cDNA was obtained from the National Institute on Aging (NIA) 
mouse 15 K cDNA clone set (source: Max-Planck, Martinsried, Germany). The 
original cDNA was cloned in Notl/Sall site of the ampicillin-resistant pSportl vector 
(Life Technologies) (276).
2.1.4 Cells
Human embryonic kidney HEK293, human neuroblastoma SK-N-SH cells, human 
ostesarcoma U20S cells and primary MEF were obtained from colleagues at the 
Beatson Institute. Immortalized rat oligodendrocytes progenitors, OPC/c-myc/bcl-2 
cell line or BC30, were a gift from Dr. Sue Barnett (277).
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2.1.5 Mice
CD1 mice were obtained from Charles River, UK. All procedures using mice were 
performed in accordance with the Project Licence (PPL 60/3060) and Personal 
Licence (60/9362) under the Home Office Animal (Scientific Procedures) Act 1986.
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2.2 Methods
2.2.1 Cell culture
2.2.1.1 Brain dissection
Female pregnant mice were sacrificed at different stages of gestation by neck 
dislocation. Embryos were collected from the uterus and immediately sacrificed by 
decapitation. Mice heads were kept in warm PBS containing 100 U/ml of penicillin- 
streptomycin (Pen-strep) until dissection was performed. The forebrain was dissected 
out from mouse embryos. The tissue was incubated in trypsin solution (0.25% 
trypsin/1 mM EDTA) for 15 min and dissociated by polished Pasteur pipettes.
2.2.1.2 Primary cortical neuron culture (CNQ
The cells were allowed to attach in Minimum Essential Media (MEM, Gibco)-HS 
(MEM, 0.6% glucose, 2 mM glutamine and 10% horse serum). After 4 h, the medium 
was replaced with N2-MEM (MEM, 1.25 mM pyruvic acid, 0.6% glucose, 2 mM 
glutamine, 0.1% egg albumin, 20 nM progesterone, 100 pM putrescine, 30 nM 
selenium dioxide, 0.1 mg/ml transferrin) and cultured ON at 37°C in 5% CO2. The 
cells were grown in 10 cm dishes or in glass cover-slips inserted into 24-well tissue- 
culture plates. All the dishes and cover-slips were coated overnight (ON) with 1 
mg/ml poly-L-Lysine (SIGMA).
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2.2.1.3 Immortalised oligodendrocytes progenitor culture BC30
BC30 were maintained in Dulbecco’s MEM (D-MEM, Gibco) supplemented with 
60% SATO mix, 40% BI04 cells supernatants, 43 mM Insulin, 65.5 mM transferrin, 
and 2 mM glutamine. SATO mix consists of 2.8% bovine serum albumin (Miles SCI, 
Pentex), 0.45 M putrescine, 180 pM T4, 227 pM T3, 0.9 mM progesterone (Sigma), 
and 1 mM sodium selenite. Cells were maintained at 37°C in 5% CO2.
2.2.1.4 Other cells
Human neuroblastoma SK-N-SH, human HEK 293, mouse Phoenix packaging cells 
and primary mouse fibroblast MEF cells were maintained in D-MEM, 10% foetal 
bovine serum (FBS) and 2 mM glutamine. Cells were maintained at 37°C in 5% CO2.
2.2.1.5 Cell treatment
Cells were starved in media without serum for 4 to 24 h and treated with different 
concentrations of recombinant h-FGF2 (1-10 ng/ml) and heparin (1-0.001 pg/ml) 
depending on the experiment. Cells were observed daily and used from 1 to 6 days in 
vitro (DIV).
2.2.1.6 Cell transfection
Cells were plated at 90% confluence in 6-well or 24-well tissue-culture plates. 
Transfections were performed using Lipofectamine 2000 reagent according to the 
manufacturer’s instructions (Invitrogen) using the appropriate plasmid. 2 or 0.5 
pg/dish of DNA was used when 6 or 24-well tissue-culture plates were used, 
respectively. Non-transfected cells and empty vectors were used as negative controls.
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Cells were used for the experiments after 24 h and processed depending on the 
protocol. See table 2.1 for expression vectors used in the transfections.
2.2.2 Preparation of DNA and RNA
2.2.2.1 Small scale preparation of plasmid DNA
Preparation of DNA from small quantities of bacterial culture was performed using 
the QIAprep Spin Miniprep Kit (Qiagen) as per manufacturers’ instructions. 
Bacterial cultures were prepared as explained in section 2.2.4.1. Briefly, 5 ml of 
overnight culture was pelleted at 2500 rpm for 10 minutes and the supernatant 
discarded. The pellet was subjected to alkaline lysis followed by neutralisation then 
centrifugation at 13000 rpm to remove cell debris. Supernatant was transferred to a 
spin filter containing a silica-gel membrane to which DNA was specifically adsorbed 
in the presence of high salt. Following a wash step to remove salts, DNA was eluted 
in 50 pi of distilled water. DNA was examined by electrophoresis in 1% (w/v) 
agarose gel that contained TAE buffer with 0.5 pg/ml ethidium bromide (EtBr). The 
100 bp and 1 kb (New England Biolabs) markers were used.
2.2.22 Large scale preparation of plasmid DNA
Maxi-preparation of plasmid DNA was performed using the Qiagen Plasmid 
Maxiprep kit as per manufacturers’ instructions. Briefly, 50 pi glycerol stock or 500 
pi fresh overnight culture was added into 5 ml LB media containing an appropriate 
antibiotic and incubated ON in an orbital shaker at 37°C. The following day cultures 
were expanded in 500 ml of LB media with appropriate antibiotic and incubated 
overnight in an orbital shaker at 37°C. The bacteria were harvested by centrifugation
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at 4000 rpm for 10 min and alkaline cell lysis performed. Crude cell lysate was 
cleared by centrifugation and then loaded onto an anion exchange column, which 
selectively binds plasmid DNA under appropriate low-salt and pH conditions. 
Following wash steps in medium salt buffer plasmid DNA was eluted in high salt 
buffer then precipitated by adding 0.7X volume of isopropanol and centrifugation at 
4000 rpm for 30 min at 4°C. The DNA pellet was washed with 5 ml of 70% ethanol 
then centrifuged again at 4000 rpm for 15 min. Finally, the pellet was air-dried at 
37°C for 10 to 15 min and re-dissolved in a suitable volume of water.
2.2.2.3 Total RNA extraction from cell culture
Total RNA was isolated from cells using RNAzol (Biogenesis). The cells were 
harvested in 1.6 ml RNAzol/10 cm dish. RNA was extracted using 200 pi of 
chloroform/ml lysate. The lysate was centrifuged at 12,000 g for 15 min at 4°C. This 
separates the mixture into 3 phases: a lower red, phenol-chloroform phase (containing 
protein), an interphase (containing DNA) and a colourless upper aqueous phase 
(containing RNA). The aqueous phase was transferred to a fresh tube and precipitated 
with 1:1 volume of isopropanol. After centrifugation, the RNA pellet was washed 
with 1 ml of 75% ethanol/ml lysate. The sample was allowed to stand for 10 min at 
room temperature (RT) and then centrifuged at 12,000 g for 10 min at 4°C. The 
supernatant was removed and the RNA pellet was washed once by adding 1 ml of 
75% (v/v) ethanol prepared with diethyl pyrocarbonate (DEPC) water. The sample 
was vortexed and then centrifuged at 7,500 g for 5 min at 4°C. The RNA pellet was 
briefly air-dried and re-suspended in an appropriate volume of DEPC water. RNA
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was examined by electrophoresis in 1% (w/v) agarose gel that contained TAE buffer 
with 0.5 pg/ml EtBr and the remaining RNA was aliquoted and stored at -80°C.
2.2.2A Total RNA extraction from tissue
Tissue dissected from embryonic body was homogenised using an EZ-Gen 
Homogenizer (Omni International) in 1 ml of RNAzol. From this step, the same 
protocol described in the previous section was followed.
2.2.2.5 Polv A-RNA extraction from cell culture
Poly A-RNA was isolated from cells using Micro-FastTrack 2.0 kit (Invitrogen) 
according to the manufacturer's instructions.
2.2.2.6 Quantification of nucleic acids
Nucleic acid concentrations were estimated by spectrophotometry at A260/A280 
(Eppendorf BioPhotometer), where an optical density (OD) of 1 at 260 nm 
corresponds to 50 pg/ml of double-stranded DNA and 40 pg/ml of single-stranded 
DNA and RNA. Readings were zeroed with the solution in which the samples had 
been diluted. The ratio of A260/A280 provided an estimate of nucleic acid purity. 
Values between 1.8 and 2.0 indicated pure preparations.
2.2.3 Gene manipulation
2.2.3.1 Reverse transcriptase reaction (RT)
RNA extracted from cells or tissue was reverse-transcribed using Superscript II 
(Invitrogen). 2 pg of total RNA was added into a reaction containing 500 ng of 
Random examers to a final volume of 12 pi water. The reaction was heated to 70°C
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for 10 min, and then placed on ice to denature the secondary structure of the RNA. To 
each reaction the following mix was added: IX first strand buffer, 0.1 M DTT, 25 
mM MgCl2 and 10 mM of dNTPs (Invitrogen). After 5 min incubation at 25°C, 200 
Units (U) of Superscript II Reverse Transcriptase (Invitrogen) was added and the 
reaction incubated at 25°C for 10 min and 42°C for 50 min. Final reaction volume 
was 20 pi. The reaction was terminated by 15 min incubation at 70°C, and the 
RNA/DNA duplex degraded by the addition of 2 U of RNase-H (Invitrogen) for 20 
min at 37°C.
2.2.3.2 Polymerase Chain reaction (PCR)
Standard PCR protocols were used for amplification of cDNAs. 2 pi of template 
cDNA were used per reaction. Each reaction contained IX PCR buffer (minus 
M gCy, 1.5 mM MgCl2, 0.2 mM each dNTP, 0.2 pM forward and reverse primers 
and 1.25 U Taq DNA polymerase (Biotaq, Bioline), in a final volume of 25 pi. 
Cycling was performed in thin-walled dome-topped 0.2 ml PCR tubes in an PTC-200 
Peltier thermal cycler. Initial denaturation was at 94°C for 2 min, followed by 25-30 
cycles of 94°C, 30 sec; 58°C, 30 sec; 72°C, 1 min, and final extension at 72°C for 5 
min. PCR product was examined by electrophoresis in 1.5% (w/v) agarose gel that 
contained TAE buffer with 0.5 pg/ml EtBr. Primers used were obtained from TAGN, 
Newcastle Ltd, as a purified pellet. Some primers were designed in order to 
incorporate specific restriction enzymes at the 5’ and 3’ of ccpl CDS (Table 2.2, 2.3 
for primers details). Prior to use, the primers were diluted using water to appropriate 
concentrations and, once diluted, stored at -20°C.
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2.2.3.3 Automated DNA sequencing
Automated sequencing was performed at the Beatson Laboratories. The templates 
(0.5-1 pg) and primers (3.2 pmol) were supplied. A single-stranded reaction was used 
with a PCR mix containing fluorescently labelled di-deoxynucleotides. Samples were 
run on an agarose gel and the nucleotides detected on a Beckman CEQ 2000 
sequencer. Analysis was carried out by Beckman CEQ 8000, and the sequence data 
viewed and further analysed using SeqMan n. See Table 2.2-2.3 for the list of 
primers used.
2.2.4 Cloning techniques
2.2.4.1 Ligation and transformation
Following agarose gel purification, cDNAs were ligated into the appropriate vectors. 
Each 10 pi mixture contained 6.5 pi sterile water, 1 pi ligation buffer (10X), 50 ng 
linearised vector, 100 ng DNA insert and 4 U of T4 DNA ligase (Invitrogen). These 
reactions were carried out overnight at 15°C. Transformation was performed using 2 
pi of ligation product. Plasmid DNA was added to a thawed vial of DH5a competent 
E. coli cells and, after gently mixing with a pipette tip, was incubated on ice for 30 
min. Cells were then heat-shocked through incubation at 42°C for 45 sec and 
immediately cooled on ice for 2 min. 250 pi of SOC medium (Invitrogen) was added 
to the competent cells before incubating at 37°C for 1 h with agitation. Selection of 
transformed cells was then achieved by plating 100-200 pi of culture on LB/agar (15 
g/L bacto-agar in LB broth) that contained antibiotic selection (30 pg/ ml kanamicyn 
or 50 pg/ml ampicillin). Transformed colonies were identified by incubating plates
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ON at 37°C. Individual colonies were then selected and grown ON at 37°C (with 
continuous shaking) in 5 ml LB containing the appropriate antibiotic. Plasmid DNA 
extraction was carried out using Qiagen plasmid mini or maxi kits, following the 
manufacturer’s instructions.
2.2.4.2 Identification of recombinant positive clones
After DNA quantification, digestion of isolated plasmid DNA was carried out in a 10 
pi volume containing 6 pi sterile water, 1 X of buffer, 200 ng of DNA and the 
appropriate restriction enzyme. DNA digestion took place at 37°C ON. 1 pi of the 
digestion product was analysed by agarose-gel electrophoresis. See Table 2.6 for the 
list of enzymes used and their applications.
2.2.4.3 TA cloning
Following RT-PCR, the cDNA was ligated into pCRII vector (TA cloning kit, 
Invitrogen). The same procedure described in the above section was followed, except 
that INVa F’ competent E. coli cells (Invitrogen) were used instead of DH5a E. coli 
cells.
2.2.4.4 Expression vectors construction
A list of plasmid vectors used during this study is presented in Table 2.1, detailing 
specific applications and characteristics. See Table 2.6 for the list of enzymes used 
and their applications.
47
2.2A.5 pdEGFP-N-ccpl. pEGFP-C-ccpl. pDsRed-N-ccpl and pDsRed-C-ccpl 
vectors construction
pdEGFP-N, pEGFP-C, pDsRed-N and pDsRed-C vectors (Clontech) were used to 
express ccpl in the cells. EGFP, or enhanced green fluorescent protein, is a red- 
shifted variant of GFP showing brighter luminescence in mammalian systems (278). 
Red is the Discosoma sp. red fluorescent protein. Ccpl CDS was generated by RT- 
PCR as explained in the section 2.2.3.2 (Table 2.2-2.3 for primers details). The PCR 
fragments were first cloned in pCRII vector and sequenced using the primers SP6 and 
T7. After confirmation of the fragment identities, they were digested with EcoRI and 
Sail restriction enzymes and cloned in the expression vectors. The vectors pdEGFP- 
N, pEGFP-C and pDsRed-C were from Clontech. The vectors pDsRed-N was 
engineered in the laboratory. Specific primers were designed in order to amplify the 
Red-CDS (F-pRed and R-pRed) flanked by the BamHI and Notl restriction enzymes 
and missing the STOP codon. As a template, the pDsRed-C vector was used. The 
PCR fragment was sequenced using the primers Sp6 and T7 and cloned in the pCRU 
vector. At the same time, the pdEGFP-N vector was digested with BamHI and Notl 
restriction enzymes in order to eliminate the GFP tag and ligated with the Red-CDS 
fragment. Ccpl CDS was cloned in the pDsRed-N vector using the EcoRI and Sail 
restriction enzymes.
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2.2.5. Northern Blotting
2.2.5.1 Preparation of probes for Northern Blotting
The DNA probe was prepared by digesting the plasmid in a 10 pi volume containing 
6 pi sterile water, 1 X of buffer, 200 -  500 ng of DNA and the appropriate restriction 
enzymes (Table 2.6). DNA digestion took place at 37°C ON. DNA was examined by 
electrophoresis in 1% (w/v) agarose gel that contained TAE buffer with 0.5 pg/ml 
EtBr. The 100 bp and/or 1 kb (NewEngland Biolabs) markers were used. DNA was 
visualised by UV illumination at 302 nm or 365 nm. DNA fragments were excised 
from the gel using a scalpel blade and the DNA extracted using the Qiagen Gel 
Extraction kit according to the manufacturers’ instructions. The DNA was eluted in 
30 pi of water.
2.2.5.2 Northern electrophoresis and blotting
All equipment and surfaces used for gel preparation were cleaned with RNaseZap™ 
(Ambion) and rinsed with DEPC water. The NorthemMax Kit (Ambion) was mainly 
used following the manufacturer instructions. When buffer produced in laboratory 
were used the following protocol was used. A 1% agarose-formaldehyde/lX 3-N- 
morpholino-propanesulfonic acid (MOPS) gel and IX MOPS was used as running 
buffer diluted from a 10X stock. The total RNA (10 pg) or Poly A-RNA (2pg) and 2 
pg of RNA marker (Invitrogen) were mixed with 5 pi RNA loading buffer, IX 
MOPS and 20% formaldehyde and incubated at 65°C for 15 min, then on ice for 1 
min. After loading the samples, the gel was run at a constant 50 V for 3 h. The gel 
was washed twice for 15 min using 20X SSC to remove formaldehyde. The part of
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the gel containing the marker and the positive control were stained in IX running 
buffer containing 0.5 pg/pl EtBr ON. The DNA was visualised by UV illumination at 
302 nm or 365 nm. RNA was transferred from the agarose gel to a positively charged 
nylon membrane (Hybond-N+; Amersham). The following materials were assembled 
as follows: Three pieces of Whatmann 3 MM paper soaked in 2X sodium 
chloride/sodium citrate (SSC) were placed on top of a 5 cm stack of paper towels, the 
membrane and the gel (upright). 3 pieces of wet Whatmann paper were stacked on 
top and the transfer was left ON. The RNA was cross-linked using a UV Stratalinker 
2400 (Stratagene) for 1200 pjoules x 100.
2.2.5.3 Northern hybridisation
20 ng of the probe DNA, denatured at 100°C for 5 min was labelled with [a 32P]- 
dCTP using Rediprime II (Amersham) and purified with Probe Quant™ G50 Micro 
Columns (Amersham). Following pre-hybridisation in 6x SSC, 5x Denhardt’s, 0.5% 
SDS at 65 °C for 1 h, hybridisation was performed with the labelled probe at the final 
concentration of 500,000 cpm/ml at 65 °C ON. The membrane was washed twice in 
2x SSC, 0.1% SDS, at RT for 10 min, once in lx  SSC, 0.1% SDS, at 60°C for 10 
min, and finally in O.lx SSC, 0.1% SDS, at 60°C for 10 min. Hybridisation was 
visualised and quantified by Molecular Imager FX (Biorad).
2.2.5.4 Stripping Northern blots
Blots were stripped with boiling 0.1% (w/v) SDS until the solution was cold and for a 
few minutes in 2X SSC. The membranes were stored at -20°C.
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2.2.6 Multiple Tissue Northern blot
Multiple Tissue Northern blotting was performed using mouse adult poly A-RNA 
derived form adult mouse tissues and from adult human brain, according to the 
manufacturer's instructions (Clontech). Hybridisation was performed at 42°C. (1-actin 
hybridisation was performed for normalization of the loading.
2.2.7 Western blotting
2.5 x 106 cells/well were plated in 6-well plates. Cells were lysed in 100 pl/6-yell o>f 
Laemmli sample buffer (BIO-RAD) and one fifth of lysate was analysed on If)-12% 
SDS-PAGE followed by immobilisation on nitrocellulose membranes (Hybond ECI>, 
Amersham).
2.2.7.1 Protein quantification
Proteins from whole cell extracts were quantified using BCA/Q1SO4 protein assays 
(Pierce). Standards were made up with 8, 100, 200, 400, 1000 and 2000 pg/fril off 
Bovine Semm Albumin (BSA) made up to 200 pi with water. For each sample, seriall 
dilutions of cell extract were added up to 200 pi with water. For each sample 200 pll 
of protein assay buffer (50 parts of buffer A and 1 part of buffer B) were added This? 
was incubated for 30 min at 37°C. The optical density of the standards was measured  ^
at 562 nm and a standard curve created. The OD of samples was then measutd to> 
give the protein per ml of cell extract.
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22.1.2 Blotting and transfer
20 pi aliquots of the lysated extracts were denatured at 90°C for 10 minutes on a 
heating block. Proteins were separated on 7.5-12% SDS-PAGE followed by 
immobilisation on nitrocellulose membranes (Hybond ECL, Amersham) using semi­
dry or dry blotting apparatus. 6 pieces (1 in the dry transfer) of 3 MM Whatman 
blotting papers were soaked in transfer buffer and placed onto the conductive plate of 
a semi-dry or dry blotting apparatus. The Millipore filter with the gel facing upwards 
was placed on top of the blotting paper followed by a further 6 pieces (1 in the dry 
transfer) of 3 MM Whatman blotting papers soaked in transfer buffer. Transfer was 
performed at 100 V constant for 1 h. After transfer the blotting the filter was blocked 
for at least 1 h at RT in TBS-T containing 10% non-fat dried milk (Marvel).
2.2.13 Probing and Detection
Primary antibodies were diluted with 10 % Marvel in TBS-T, added to the blots and 
incubated on a rocker for 2 h at RT or ON at 4°C. After probing with the primary 
antibody, filters were washed 2 times for approximately 10 min each with TBS-T. 
Horse Radish Peroxidase (HRP) conjugated secondary antibody appropriate to the 
species of the primary antibody (Table 2.4) was diluted in 10% Marvel in TBS-T and 
incubated with the blots for 1 hour at RT on a shaker. Following probing with the 
secondary antibody, filters were washed 2X for approximately 10 minutes each with 
TBS-T.
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22.1 A  Western signal detection
Chemilluminescence detection using the ECL™ Western blotting analysis system 
(Amersham Pharmacia) or SuperSignal West Femto Maximum Sensitivity Substrate 
(Perbio) was performed by adding equal volumes of reagent 1 and reagent 2 to the 
membrane, incubating at RT for 1-5 min and then exposing the blot to ECL film 
(Amersham Pharmacia) for different lengths of time before developing using an X- 
OMAT 3000RA film processor. After developing membranes were washed in PBS-T 
and stored in Saran wrap at 4°C.
22.1.5 Stripping Membranes to re-probe
Before re-probing, membranes were stripped of bound primary and secondary 
antibodies by submerging in 2% SDS, 64.5 mM Tris-HCl and 100 mM p-mercapto- 
thanol for 1 hour at 50°C. Membranes were then rinsed in TBS-T and re-blocked in 
10% Marvel in TBS-T.
2.2.8 Heterologous expression and purification of recombinant proteins
2.2.8.1 Expression vector construction
pET28b-His expression vector (Novagen) introduced an N-terminal polyhistidine tag 
to facilitate subsequent protein purification through nickel-beads. The vector was 
prepared as described in the section 2.2.4.1. See Table 2.6 for enzymes used in this 
protocol.
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2.2.8.2 Transformation of BL21 (DE3)pLvsS E. coli cells
For the purpose of protein expression, pET28b-His vector containing the insert was 
propagated in BL21(DE3)pLysS (Novagen) cells. DE3 designation means that the 
strain of bacteria carries the gene for T7 RNA polymerase, which is inducible by 
IPTG, whereas the pLysS produces T7 lysozyme to reduce basal level expression of 
the gene of interest in the event of ccpl being toxic. Plasmid DNA (50-200 ng in 1 
pi) was added to a thawed 50 pi aliquot of BL21(DE3)pLysS competent E. coli cells, 
gently mixed with a pipette tip and incubated on ice for 10 min. Cells were then heat- 
shocked through incubation at 42°C for 45-50 sec and immediately cooled on ice for 
2 min. 250 pi SOC medium (Invitrogen) were added, and the cells incubated at 37°C 
for 1 h in a shaker. Selection of transformed cells was then performed by plating 
these cultures on LB/agar (15 g/L bacto-agar in LB broth) that contained 15 pg/ml 
kanamicyn at 37°C. Individual colonies were then selected and grown overnight in 5 
ml LB containing 15 pg/ml kanamycin, continuously shaking at 37°C.
2.2.8.3 Heterologous expression of recombinant proteins
BL21(DE3)pLysS transformed colonies were grown to exponential phase (OD600 0.4- 
0.6) whilst shaking at 37°C in 100 ml LB medium containing 15 pg/ml kanamycin. 
Expression through the T7 promoter of the pET28b-His vector was induced ON both 
at 25°C and 37°C, through the addition of 1-0.1 mM isopropyl p-D-thiogalactoside 
(IPTG). Samples were collected after 1,2, 4, 6 and 24 h. Bacteria were then harvested 
by centrifugation at 6000 g for 20 min at 4°C and the cell pellets stored at -70°C until 
required.
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2.2.8A Purification of the recombinant protein
3 g of bacterial pellet were lysated in 15 ml of BugBuster reagent (Novagen) and 25 
U of Benzonase Nuclease (Novagen). The His Bind Kits (Novagen) was used to 
purify the protein from the insoluble fraction following the manufacturer’s 
instruction. 6 M Urea was used as denaturant. The final protein concentration was 
determined using the ABC kit from Perbio, following the manufacturer’s instructions.
2.2.8.5 Gel electrophoresis
4 ml of the protein lysated at the concentration of 1 mg/ml and 500 pi of Laemmli 
Sample Buffer (BIO-RAD) were loaded in a 10 % SDS-PAGE gel and run at 120 V 
for 2.5 h. The band corresponding to the right molecular size was cut from the gel 
and, after fractionating, inserted in a dialysis bag (Medicell International Ltd, MW 
12-14 KDa).
2.2.8.6 Electro-elution of the protein
The dialysis bag was previously prepared by heating in 2% Sodium bicarbonate and 
ImM EDTA at 80°C for 30 min. The bag was washed several times in distilled water. 
At this step the gel fragments and 6 ml of elution buffer (0.2 M Tris-Acetate, 1% 
SDS, 100 mM dithiothreitol, DTT) were inserted into the bag already closed at the 
extremities. The protein was electro-eluted at 120 V for 3 h in running buffer (50 mM 
Tris-Acetate, 0.1% SDS). At the end, the protein solution was recovered and 
centrifuged for 1 h using a centricon tube (Amicon, MW 3 KDa), in order to desalt 
and concentrate the solution.
55
The protein concentration was determined by eye-comparison running the solution in 
a 10% SDS-PAGE gel next to protein samples whose concentration was known.
2.2.9 Antibody generation
5 ml of protein solution (antigen) at the concentration of 0.6 mg/ml was given to the 
Antibody Facilities of the Beatson Laboratories in order to generate monoclonal and 
polyclonal antibodies against ccpl/His recombinant protein.
2.2.9.1 Hvbridoma production (Beatson antibody facility)
An outbred strain of mice CD-I (Harrlan-UK) was immunised at 4 week intervals 
subcutaneously with 25 pg ccpl/His recombinant protein. The protein was emulsified 
with equal quantities of Freunds adjuvant. Complete adjuvant was used for the first 
immunisation and then incomplete for subsequent immunisations. Test bleeds were 
taken after the 2nd’ 3rd and 4th immunisation and tested by ELISA assay on plates 
coated with the immunising protein. The best responding mouse was selected and 
splenocytes were prepared. The splenocytes were fused with SP2/0-Agl4 mouse 
myeloma cells using polyethylene glycol (Roche) following the method of Lane & 
Harlow (Antibodies a laboratory Manual CSH Press 1988). Hybridomas were grown 
for 10 days then assayed by ELISA. ELISA positive hybridomas were further 
screened by Western blot analysis and positive hybridomas were single cell cloned by 
limiting dilution.
2.2.9.2 Polyclonal antibody production
New Zealand White rabbits were immunised with 50 pg ccpl/His recombinant 
protein at 4 week intervals. The protein was emulsified with equal quantities of
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Freunds adjuvant. Complete adjuvant was used for the first immunisation and then 
incomplete for subsequent immunisations. Test bleeds were taken after the 2nd and 3rd 
immunisation and tested by ELISA assay on plates coated with the immunising 
protein. The rabbits were exsanguanated after the 4th immunisation.
2.2.10 Cellular localisation
2.2.10.1 Cell immunostaining
500,000 cells/well were plated on cover-slips inserted in 24-well tissue-culture dishes 
and transfected with the expression vectors listed in the Table 2.1, following the 
protocol detailed in the section 2.2.4.1. After 24 h, cells were fixed with 3.7% 
formaldehyde in PBS and permeabilised in 0.5% Triton X-100 for 20 min each. 
Blocking solution (0.2% gelatine and 0.1% Triton X-100 in PBS) was applied for a 
further 20 min. Incubation with the primary antibody was performed ON at 4°C and 
the secondary antibody for 1 h at RT (Table 2.5 for the list of antibodies used in this 
study). Filamentous actin structures were visualised after incubation for 1 h at RT 
with Texas Red-cojugated phalloidin (1:250, Molecular probes). Endoplasmatic 
reticulum was visualised using specific stain solution (1 mg/ml, Chemicon). 
Autophagy vesicles were visualised with Monodansyl-cadaverin (MDC, Sigma) as 
described in (279). Briefly, the cells were incubated with 1 nM MDC in PBS at 37°C 
for 10 min. After incubation in antibodies, the cells were washed with PBS and 
mounted on slides using DAPI (4, 6 diamino-2-phenylindole, Vectashield). The slides 
were analysed by fluorescence microscopy using Zeis Axioplan 2 and the computer 
program ISIS. Leica confocal SP2 was used and, based on the scanning 14 serial
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sections of 0.6 pm, three-dimensional image of the cell were build up. Exitation and 
emission were: for DAPI (blu) 359 nm and 461 nm; for Texas Red (red) 596 nm and 
615 nm; for FITC (green) 494 nm and 520 nm.
2.2.10.2 Chloraquine treatment
500,000 cells/well in 24-well tissue culture dishes with cover-slips were transfected 
for 24 h in the presence of 25, 100 and 500 pM of chloraquine (Sigma). Cells were 
immunostained as above.
2.2.11 Generation of stable cell lines over-expressing ccpl
2.2.11.1 Retrovirus system and vector pLPC/ccpl construction
The retrovirus expression vector pLPC was obtained from Dr S. Lowe. The vector is 
a derivative of pBabePuro (280) and has been modified by Dr S. Lowe: the SV40 
promoter driving puro was deleted to put puro under the control of the LTR (this 
region contains all signals necessary for gene expression, including the enhancer, 
promoter, transcription initiation, transcription terminator and polyadenylation 
signal). The CMV promoter and multi-cloning site was inserted downstream of puro. 
pLPC and ccpl CDS were ligated together following the protocol detailed in the 
section 2.2.5.1. See Table 2.6 for enzymes used in this study. The vector pLPC/EGFP 
was obtained from L. Bell, Beatson Institute.
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2.2.11.2 Retrovirus vector pLPC-ccpl/ GFP-N (GFP-C) construction
pLPC vector was cut with Hindin (Xhol) restriction enzyme at 37°C for 3 h. The 
linearised vector was blunted using 0.2 mM dNTPs, IX buffer, 5U of T4 Polimerase 
(Epicentre) at 12 °C or 15 min and 65°C for a further 15 min. After the blunting 
reaction, the vector was purified using the Qiagen PCR purification kit and cut ON 
with the enzyme BamHI (EcoRI) at 37°C. The vector was dephosphorilated using 
Shrimp Alkaline Phosphates (Promega) at 37°C for 10 min and 65°C for 15 min. The 
vector was purified using the Qiagen PCR purification kit. In parallel, pd2EGFP-N 
(pEGF-C)/Ccpl was cut with Agel (Notl) restriction enzyme for 3 h at 37°C, blunted 
as above and purified with Qiagen PCR purification kit. The linearised vector was cut 
with BamHI (EcoRI) restriction enzyme and the ccpl/EGFP fragment was isolated by 
agarose gel purification. The pLPC linearised and the ccpl/EGFP fragments were 
ligated together as explained in section 2.2.4.1. In order to eliminate the plasmid that 
was not blunted, the ligation product was cut with HindlH (Xhol) restriction enzyme. 
The product was transformed in DH5a E.coli and, after bacterial culture and 
miniprep, the presence of the insert was tested by restriction enzyme digestion, using 
StuI and BamHI (EcoRI and Nhe) enzymes.
2.2.11.3 Retrovirus generation and recipient cells infection
As packaging cell line (specially-engineered cell lines that express the viral genes and 
produce vector virus), phoenix cells were chosen. The cells were obtained from Dr K. 
Ryan. The choice of packaging cells depends on the desired host range, or tropism, of 
the virus. For infection, retroviruses require a highly specific cell to interact with a 
protein on the surface of the viral particle. Tropism can be categorized by the range of
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host cells that can be infected: Ecotropic (ecos = home), containing the EcoR 
receptor, in which virus replicate only in cells from the natural host or closely related 
species; xenotropic (xenos = foreign) virus replicate efficiently only in cells of 
foreign origin, not the host; amphotropic (amphos = both) virus replicate in cells of 
both the natural host and foreign origin. Phoenix is a second-generation retrovirus 
producer line for the generation of helper free ecotropic and amphotropic 
retroviruses. The lines are based on the 293T cell line. Ecotropic phoenix lines 
(capable to infect only cells containing Eco receptor, including mouse, rat and rabbit 
cells) were created by placing into 293T cells constructs capable of producing gag- 
pol, and envelope protein for ecotropic viruses. Retroviral expression vector provided 
the packaging signal psi and a target gene. 2,000,000 cells/well phoenix packaging 
cells were plated in a 10 cm dish and transfected with 5 pg of vectors pLPC/EGFP, 
pLPC-ccpl/EGFP-C and pLPC-ccpl/EGFP-N using Lipofectamine 2000 as 
explained in section 2.2.I.5. Cells were incubated ON in 20% FBS media in order to 
allow virus production. Primary MEF cells were plated at the density of 2,500,000 
cells/well in a 10 cm dish and infected with the Phoenix-supernatant filtered and 
containing 10 mg/ml of polibrene. The infection was repeated three times at intervals 
of 12 h each. After the last infection, cells were cultured for 1 week in media 
containing 25 mg/ml of puromycin in order to select the cells that have been infected. 
As a control non-infected MEF were selected with the same antibiotic. The same 
experiment was carried out using SK-N-SH. Since SK-N-SH cells are human cells, 
the cells were transfected with the pWZLneo-EcoR expression vector.
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2.2.11.4 Stable cell lines selection
The surviving cells were plated in a 15 cm-tissue culture dishes and single colonies 
were grown for one week. The singles clones were picked using cloning rings and 
grown individually in 10 cm dishes.
2.2.12 RNA interference (RNAi)
RNAi approach was used as tool to suppress gene expression based on a phenomenon 
in which the introduction of double-stranded RNA (dsRNA) causes degradation of 
the complementary mRNA (281). Upon introduction the cells with small interfering 
RNAs (siRNAs) by normal transfection, a RNA-induced silencing complex (RISCs) 
is assembled. The siRNA strands guide the RISCs to complementary RNA 
molecules, where they cleave and destroy the cognate RNA. SK-N-SH were plated at 
90% confluence in 6-well. Transfection was performed using Lipofectamine 2000 
reagent in Optimem media (Gibco) according to the manufacturer's instructions 
(Invitrogen). 50 nM/well of pre-designed and annealed siRNA (Ambion) was used, 
RNAi 1, sense 5 ’-aguugaagccuuugacuuctt-3 ’, anti sense 5 ’ -gaagucaaaggcuucaacutc- 
3’. As negative controls, silencer siRNA were used, respectively. Non-transfected 
cells were also used as negative controls. After 24 h, cells were harvested and RNA 
was extracted and used for RT-PCR as described in the sections 2.2.2.3 and 2.2.3.1. 
The primers used were F-338 and R-1096.
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2.2.13 Functional assays
2.2.13.1 Proliferation assay
Proliferation KIT I from Roche was used for the proliferation assay and the 
manufacturer protocol was followed. Briefly, cells were grown on cover-slips coated 
at a density of 500,000 cells/well in a 24-well tissue-culture dish. 5-bromo-2- 
deoxyuridine (BrdU) labelling medium (10 pM BrdU) was added for 60 min. The 
cover-slips were washed 3 times with PBS, fixed with ethanol fixative (50 mM 
glycine, 70% of 100% ethanol) for 20 min at -20°C and again washed 3 times with 
PBS. Anti BrdU (1:10 in incubation buffer: 66 mM Tris, 0.66 mM MgC12, 1 mM 2- 
mercaptoethanol) was added and incubated for 30 min at 37°C. The cover-slips were 
washed 3 times with PBS and incubated with the anti mouse Ig-fluorescein (1:10 in 
incubation buffer) for 30 min at 37°C. After washing in buffer, the cover-slips were 
mounted using Vectashield containing DAPI and analysed by fluorescence 
microscopy using Zeis Axioplan 2 and the computer program ISIS.
2.2.13.2 Apoptosis assay
TUNEL enzyme and TUNEL labelling mix from Roche were used for apoptosis 
assay and the manufacturer protocol was followed. Briefly, cells were grown on 
cover-slips coated at the density of 500,000 cells/well in a 24-well tissue-culture dish. 
The culture medium was aspirated and the cover-slips washed 3 times with PBS. 
Cells were fixed with 4% paraformaldeyde for 1 h at RT. After washing in PBS, the 
cover-slips were incubated with permeabilization solution (0.1% TritonX-100 in 
0.1% sodium citrate) 2 min at 4°C. The cover-slips were washed 3 times with PBS
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and covered with the IX labelling mix and deoxynucleotidyl transferase enzyme (5 
lil) and incubated 1 h at 37°C. After washing in PBS, the cover-slips were mounted 
with Vectashield containing DAPI and analysed by fluorescence microscopy using 
Zeis Axioplan 2 and the computer program ISIS.
2.2.13.3 Wound assay
Cells were plated at the density of lxlO5 cells/well in a 6-well tissue culture plate. For 
treatment, the cells were serum-starved for 24 h. A wound was made on the 
monolayer using a P200 pipette tip and pictures were taken at 4, 6, 8, 24 h. The cells 
were fixed and stained with 50% methanol, 10% acetic acid, 0.25% Comassie blue 
for 10-15 min.
2.2.13.4 Statistics
Student's T-test was performed to test the significance of difference in numerical data 
as appropriate. The t-test assessed whether the means of two groups were statistically 
different from each other. The data in the text represents “mean ± standard error 
(SEM)”. SEM also represents the error bars in the graphs. In the BrdU and TUNEL 
assays, 6 pictures for each samples were taken, analysed and % mean of the values 
obatained was calculated. Each ccpl-entity was compared to each control entity.
2.2.14 Histology
After dissection, the tissue was fixed in 4% paraformaldehyde ON at 4°C, processed, 
and embedded in paraffin. Sections (8 pm) were cut using a microtome and mounted 
on siliconated glass slides by the Techonology Service at the Beatson Laboratories. 
The sections were de-waxed in histoclear (Fisher) and re- and dehydrated in graded
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ethanol. For the Haematoxylin and Eosin staining (H&E) sections were stained with 
haematoxylin for 4 min and rinsed with water. Slides were immersed briefly in 1% 
cloridric acid in 70% ethanol followed by Scott’s Tap Water (Surgipath) for 1 min, 
then washed in water and counter-stained with eosin for 30 sec.
2.2.15 In situ Hybridization
2.2.15.1 Transcription of Riboprobes
The DIG RNA labelling Kit (SP6/T7) from Roche was used. Ccpl-DNA to be 
transcribed consisted of part of the CDS and the 3’ UTR. Ccpl was originally cloned 
into the vector pSPORTl containing promoters for SP6 and T7 RNA polymerases 
adjacent to the polylinker. 15 pg of DNA template were linearised using Sail (SP6 
riprobe generation) and Notl (T7 riprobe generation) restriction enzymes in a total 
volume of 100 pi at 37°C for 2 h. The samples were extracted in phenol/chloroform 
twice and precipitated in 100% ethanol at -80°C for 30 min. The samples were 
centrifuged at 13 rpm for 30 min and the pellets washed with 70% ethanol. The 
pellets were re-suspended in 11 pi of DEPC water. RNA polymerase was used to 
produce "run-off' transcripts. Digoxigenin (DIG)-UTP was used as a substrate and 
incorporated into the ccpl transcript every 20-25th nucleotide. The riprobes were 
transcribed using 1 pi of cut DNA, IX DIG RNA labelling mix, IX transcription 
buffer, 1 U of RNase inhibitor and 1 U T7 or SP6 RNA polymerase. Samples were 
incubated at 37°C for 2 h and RNase free DNasel was added to the rest and incubated 
at 37°C for 15 min. 0.3 M Sodium acetate and 300 pi of 100% ethanol in DEPC 
water were added to each sample and stored ON at -20°C. The transcripts were then
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centrifuged at 13 rpm for 30 min and the supernatant removed. The pellet was washed 
with 70% ethanol and centrifuged for 10 min. The pellet was air dried for 10 min and 
re-suspended in 100 pi of water.
2.2.15.2 Dot Blot Method
In order to check that the probes are correctly labelled, a dot blot experiment was 
performed. 1 pi of each sample was dotted onto a Hybond-N* (Amersham) membrane 
and cross-linked for 12 sec using the UV-crosslinker. The membrane was washed 1% 
blocking reagent (Boeringer Mannheim) in DIG1 (20 mM Tris base, 80 mM Tris 
HC1, 150 mM N aC y, for 30 min. Anti-DIG-AP conjugate (1:5000, Roche) was 
applied to the membrane for 45 min. The bound antibody conjugate was visualised by 
colour detection using 5 mg/ml of 5-Bromo 4-cholro-3 indolyl phosphate (BCIP) and 
7.5 mg/ml of Nitro blue tetrazolium (NBT) from Sigma. Phosphatase activity was 
detected by a colour reaction. Ccpl-probes signals were were used at the dilution of 
1:50 in hybridization buffer.
2.2.15.3 Hybridization
In situ hybridization was performed using standard procedures. Sections were washed 
in 0.2 M cloridric acid and then washed in 0.3% triton X100 on a shaker for 15 
minutes each. The sections were covered with 100 pg/ml Proteinase K solution for 30 
minutes in a moist chamber at 37°C and then fixed in 2% paraformaldehyde solution 
for 5 minutes at RT. After 2h of incubation in pre-hybridization solution (2X SSC, 
20% formaldehyde in water) the slides were incubated in hybridization buffer (0.1 
mM Tris, pH 7.5, 12.5X Denhardt’s solution, 2X SSC, 0.5 % SDS, 50% formamide,
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10% dextran sulphate, 0.25 mg/ml of salmon sperm DNA) containing the probes 
diluted 1:50. Hybridazation was carried out ON at 37°C. Anti-Digoxigenin-alkaline 
phosphatase conjugate (1:2000, Anti-DIG-AP, Roche) was applied in DIG1 buffer 
(20 mM Tris base, 80 mM Tris HC1,150 mM NaCy, 25% normal swine/horse serum 
for 1 h at RT. The antibody conjugate was detected using 5 mg/ml of BCIP and 7.5 
mg/ml NBT.
2.2.16 Immunohistochemistry
The sections were deparaffinized in Histoclear (Fisher) and dehydrated in graded 
ethanol. The sections were boiled twice for 5 min in 0.01 M Citric Acid (pH 6). 
Endogenous peroxidases were inhibited by a wash in cold 0.3% hydrogen peroxide in 
methanol for 20 min. Sections were blocked for 1 h at RT in 10% normal horse 
serum, 0.5% bovine albumin, and 0.3% Triton X-100. The primary antibody was 
applied ON at 4°C and the secondary for 1 h at RT. The immunoreactivity was 
visualised by Vectastain IgG ABC kit or Impress Kit (Vector Laboratories) and DAB 
(Dako) in the presence of Nickel. See Table 2.5 for antibodies used.
2.2.17 Microarray analysis
CNC were treated with 50 ng/ml FGF2 in the presence of 10 pg/ml heparin for 4 
hours, and the expression of genes were compared to those in the absence of FGF2. 
Seventeen features representing housekeeping genes in the array (GAPDH, HPRT 
and S16, S9, and S8 ribosomal proteins) gave average value of Ratio of Medians 
(ROM), 1.20 ± 0.28, which was confirmed to be acceptable. Total RNA was
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extracted from cells in the growing phase by using RNA Clean (Hybaid) according to 
the manufacturer’s instruction and further purified with RNeasy mini kit (Qiagen). 
Direct labelling of 20 pg of total RNA primed with 01igo(dT) was performed in the 
presence of Cy-5 and Cy-3-dUTP (Amersham Pharmacia Biotech) using Superscript 
II (Invitrogen). The Cy5- and Cy3-labelled cDNA samples were then mixed and 
purified with GFX DNA purification kit (Amersham Pharmacia Biotech). The 
samples were added with 1.2 pg of salmon sperm DNA and 5 pg of Poly-A and dried 
in SpeedVac at 60°C. The high-density glass microarray chips were prepared at the 
EMBL core facility by spotting the PCR products prepared from the NIA 15k cDNA 
mouse clone set (Tanaka et al., 2000; Cortes-Canteli et al., 2004). Array slides were 
pre-hybridized in 6x SSC, 0.5% SDS, 1% BSA at 42°C for 1 h and incubated in a 
boiled water for 2 min shortly prior to hybridisation. The cDNA samples were 
resuspended in 15 pi of hybridisation buffer (50% formamide, 6x SSC, 0.5% SDS 
and 5x Denhardt’s) and denatured by incubating at 95°C for 2 min. Hybridisation was 
at 42°C for 16 h. The slides were washed for 10 min each with 2x SSC, then with 
0.5x SSC, 0.1% SDS, followed by O.lx SSC, 0.1% SDS, at RT. Scanning was 
performed with GenePix 4000B (Axon). The data acquisition and initial data analysis 
was performed with GenePix Pro 3.0 and the data tables were analysed further in 
Excel in order to obtain the gene list. Quality control was performed, firstly by eye, to 
confirm scanner alignment and absence of significant bubbles and scratches. Scatter 
plots were further used to eliminate the unacceptable hybridisation data. The multiple 
spike-in controls RNA template were added to the sample upon direct labelling, and 
the successful labelling and hybridisation was confirmed in each hybridisations.
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GenePix Pro grogram calculates the Normalisation Factor of each hybridisation, 
based on the premise that the arithmetic mean of the ratios from every feature on the 
given array should be equal to 1. Normalisation was therefore performed by 
multiplying the Factor to ROM in each gene. The program also identifies features that 
did not give good alignment to the expected spotted area as “flagged” spots, 
indicative of the impaired-quality hybridisation of the specific genes. To generate the 
list, we have removed all flagged genes from the list. Finally, the genes that passed all 
these criteria were sorted by ROM and those that showed more than ±1.5 fold 
changes were selected from each data table. Only those genes that appeared in all 3 
experiments were selected in the final list and average ROM value was calculated. 
Gene functions were categorised based on the information given in the NIA mouse 
15k cDNA clone gene ID list at the first instance and modified when necessary. The 
original microarray data has been deposited to GEO database (Accession No. 
GSE2066).
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Table 2.1 Features of plasmid vectors and their uses
Vector (Source) Selection Description
pSPORT (Stratagene) ampicillin resistance Vector containing the NIA 15K 
clone set
pCR®II (Invitrogen) ampicillin resistance Used as a holding vector for 
sequencing after initial 
propagation.
pCDNA4/Myc-Hys, C kanamycin resistance Protein expression in mammalian
(Invitrogen) cells
pd2EGFP-Nl (Clontech) kanamycin resistance Protein expression in mammalian 
cells
pEGF-Cl (Clontech) kanamycin resistance Protein expression in mammalian 
cells
pDsRED-Nl (constructed kanamycin resistance Protein expression in mammalian
in the laboratory) cells
pDsRED-Cl (Clontech) kanamycin resistance Protein expression in mammalian 
cells
pLPC (gift from Dr Ryan) puromycin resistance Retroviral expression vector. It is 
a derivative of pBabePuro
pWZLneo-EcoR (gift from neomycin resistance EcoR protein expression in
Dr Ryan) mammalian cells
pET28b (Novagen) ampicillin resistance, N- Protein expression in Escherichia
terminal His-tag, T7-tag coli. Transcription of DNA 
inserts driven by the isopropyl P- 
D-thiogalactoside (IPTG)- 
inducible T7 promoter
69
Table 2.2 Primers and PCR conditions
Primers Annealing Cycles Applications 
T
Usage
F-338
R-1096
58°C
58°C
F-338-EcoRI 58°C
R-850-NotI * 58°C
F-338- EcoRI + 58°C
1AA
R-850-SalI 58°C
R-850-SalI + 2 58°C
AA*
R-850-SalI + 1 58^0
AA*
F-pRed 55°C
R-pRed 55°C
F-GAPDH 64°C
R-GAPDH 64°C
30 aoning in pCRII
30 Qoning in pCRII
30 Qoning in pQDNA4/Myc-
His
30 Qoning in pQDNA4/Myc-
His
30 Qoning in pdEGFP-N,
pEGFP-C and pDsRed-C
30
30
30
25
25
30
30
Qoning in pEGFP-C and 
pDsRed-C
Qoning in pdEGFP-N
Qoning in pET28b
Qoning in pdEGFP-N 
Qoning in pdEGFP-N 
Loading control 
Loading control
Ccpl 5’ UTR, CDS and part of the 3’ 
UTR amplification
Ccpl 5’ UTR, CDS and part of the 3’ 
UTR amplification
Ccpl CDS amplification; EcoRI
incorporation at the 5’ end of the CDS 
Ccpl CDS amplification; Notl
incorporation at the 3’ end of the CDS; 
stop codon missing
Ccpl CDS amplification; EcoRI
incorporation at the 5’ end of the CDS; 1
AA was added to the sequence to obtain
the exact reading frame
Ccpl CDS amplification; Sail
incorporation at the 3’ end of the CDS 
Ccpl CDS amplification; Sail
incorporation at the 3’ end of the CDS; 2
AA were added to the sequence to obtain
the exact reading frame
Ccpl CDS amplification; Sail
incorporation at the 3’ end of the CDS; 1
AA was added to create the exact reading
frame
pRed sequence amplification 
pRed sequence amplification 
GAPDH amplification 
GAPDH amplification
Stop codon omitted
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Table 2.3 Primers sequences
Ccpl-primers Sequence
F-338 5 ’-ATTGGCTGTCATGCACATGGC- 3’
R-1096 5 ’-CACACGTCACTGTCATGCCCTGA-3 ’
F-338-EcoRI 5 ’-5 ’TTGAATTCACCATGGCGGTCCAGGCTCrGCGAGAGGAGT T -3’
R-850-NotI * 5’-GGGCGGCCG€GGCAG CCCAGG -3’
F-338- EcoRI + 1AA 5’-T TGAAT TCAATGGCGGTCCAGGCTCTGCGAGAGGAGT T -3’
R-850-SalI 5 ’ -GTCGACTCAGGCAGGCCCAGG -3’
R-850-SaU + 2 AA* 5’-CCCGTCGACTTGGCAGGCCCAGG -3’
R-850-SalI + 1 AA* 5 ’-CCCGTCG CTGGCAGGCCCAGG -3’
Other primers Sequence
F-pRed 5’- TTGGATCCA ATGGCCTCCTCCGAGGACGTCATC -3’
R-pRed 5’- GGGCGGCCGCTTCACAGGAACAGGTGGTG -3’
T7 Primer 5 ’ - AATACGACTCACTATAG-3 ’
SP6 Primer 5' -ATTTAGGTGACACTATAG 3'
F-pLPC 5 ’CTATATAAGCAGAGCTCTCTGGCTAAC-3 ’
R-pLPC 5 ’ -CTAGATGCATGCTCGAGCGGCCGCCAG-3 ’
R-BGH 5 ’-CCrCGACTGTGCCITCrA -3’
F-GAPDH 5 ’-ACCACAGTCCATGCCATCAC-3 ’
R-GAPDH 5 ’ -TCCACCACCCTGTTGCTGTA-3 ’
* Stop codon omitted
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Table 2.4 Details of antibodies and conditions used in the Western blotting
Primary
antibody
IgG class Source Dilution
Anti-ccpl 79a Rabbit Beatson antibody facility 1:500
Anti-ccpl Mouse monoclonal Beatson antibody facility undiluted
Anti-myc 9E10 Mouse monoclonal IgGl Beatson antibody facility 1:1000
Anti-GFP Rabbit polyclonal Abeam 1:4000
Anti-actin Mouse monoclonal IgGl Sigma 1:2000
Anti-ERK Rabbit polyclonal Cell Signalling 1:1000
Anti-phospho- Rabbit polyclonal Cell Signalling 1:1000
ERK
Anti-lamin A/C Goat polyclonal Santa Cruz 1:1000
Secondary
antibody
IgG class Source Dilution
Conjugated Mouse IgG Transduction Lab 1:5000
horseradish
peroxidase
Conjugated Rabbit Transduction Lab 1:20000
horseradish
peroxidase
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Table 2.5 Details of antibodies and conditions used in the immunohistochemistry
1° antibody IgG class Source Dilution
Anti-ccpl 79a Rabbit polyclonal Beatson antibody 
facility
1:100
Anti-myc 9E10 Mouse monoclonal IgGl Beatson antibody 
facility
1:100
Anti-c-myc Rabbit polyclonal Santa Cruz 1:100
Anti-P-tubulin Mouse monoclonal IgGl Sigma 1:100
Anti- Transferrin receptor Mouse monoclonal IgGl Zimed laboratories 1:100
Anti-GFP Rabbit polyclonal Abeam 1:4000
Anti-Lamp2 Mouse monoclonal IgGl BD Bioscience 1:100
Anti-EEAl Mouse monoclonal IgGl BD Bioscience 1:100
Anti-Vinculin Mouse monoclonal IgGl Chemicon 1:100
Anti-DIx 2 Rabbit polyclonal Chemicon 1:200
Anti-glutamate decarboxilase Rabbit polyclonal Chemicon 1:200
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Anti Reelin Mouse monoclonal IgGl Chemicon 1:500
Anti-FGFR3 Rabbit polyclonal SantaCruz 1:200
Anti- calbindin Rabbit polyclonal Chemicon 1:1000
Anti-A2B5 Hibridoma gift from Dr Sue 
Barnett
1:10
Anti-Map2 Mouse monoclonal IgGl Sigma 1:500
Anti-Tujl Mouse monoclonal IgG2a Covance 1:500
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Secondary antibody Class Source Dilution
FITIC-conjugated Mouse IGgl Cambridge 1:100
Bioscience
TRITC -conjugated Mouse IGgl Cambridge 1:100
Bioscience
FITIC-conjugated Anti Rabbit Cambridge 1:100
Bioscience
Texas red Mouse IgGl Molecular Probes 1:400
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Table 2.6 Restriction enzymes
Enzyme Source Plasmid cut Application
Notl BioLabs pSPORTl/ccpl Northern blots-probes
Sail Invitrogen preparation
EcoRI Invitrogen pCRH/ccpl Check fragment insertion
Notl BioLabs
Notl
Sail
BioLabs
Invitrogen
pCRII/ccpl Check fragment insertion
EcoRI Invitrogen pCDNA4/Myc-Hys/ccpl Expression vector
Notl BioLabs preparation and checking of 
fragment insertion
BamHI Invitrogen pd2EGFP-N 1/ccpl Elimination of GFP
Notl BioLabs
EcoRI Invitrogen pET28b/ccpl Expression vector
Sail Invitrogen preparation and checking of 
fragment insertion
EcoRI Invitrogen pLPC/ccpl Retrovirus vector preparation
Xhol Invitrogen and checking of fragment 
insertion
Sail Invitrogen pSPORTl/ccpl Sp6  riprobe production for in 
situ hybridisation
Notl BioLabs pSPORTl/ccpl T7 riprobe production for in 
situ hybridisation
75
Table 2.7 Buffers
Buffers Composition
Agarose gel buffer (TAE) 40 mM Tris-base, 1 mM acetic acid, 1 mM 
EDTA, pH 8.5
Luria-Bertani Medium (LB) 10 g/1 bacto-tryptone, 5 g/1 bacto-yeast extract, 
10 g/1 NaCl
10X MOPS 0.2 M MOPS, 50 mM Sodium acetate, 10 mM 
EDTA
SDS/PAGE running buffer 25 mM Tris-base, 192 mM glycine, and 0.1% 
(w/v) SDS, pH 8.3
SDS/PAGE sample buffer 0.5 M Tris-base, 10% or 25% (v/v) glycerol, 
10% (w/v) SDS, 0.05% 2 p-mercaptoethanol, 
0.05% (w/v) bromophenol blue, pH 6.8
TBS 200 mM Tris, pH 7.6,137 mM NaCl
TBS-T 200 mM Tris, 137 mM NaCl, 0.1% Tween 20
Western blot transfer buffer 25 mM Tris, 192 mM glycine, 20% (v/v) 
methanol
Electro-elution miming buffer 50 mM Tris-Acetate, 0.1% SDS
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Figure 2.1 Plasmid map o f  pCR II-ccpl
Ccpl CDS and part o f the 3’ UTR were amplified the using RT-PCR. 
Several fragments were generated: (A) A 853 bp PCR product generated 
using primers F243 and R1096. (B) A 512 bp PCR product generated 
using primers F338-EcoRI and R850-Not. (C) 512 bp PCR product 
generated using primers F338-EcoRI and R850-Notl. (D) A 512 bp PCR 
product generated using primers F338-EcoRI and R850-Sall. (E) A 512 
bp PCR product generated using primers F338-EcoRI and R850-Sall + 2 
AA.
A SP6
EcoRI 
5’ ATG  f....
338
Notl 3’
■O'
850
A Myc-His 
r r T  .i wmm *~1T7
pcDNA4/Myc-His,C
pcDNA4-ccp1/Myc(His)
B
SP6
EcoRI 
5- ATG
4  O
338
Sail
TGA 3*
-------
850
T7
^ T 7
pET28b-ccp1/His
Figure 2.2 Plasmid map o f  pcDNA4-ccpl/Myc(His) and o f  pET28b- 
ccpl/His vectors
(A) Ccpl CDS was digested with EcoRI and N otl restriction enzymes 
and ligated into the complementarily digested pcDNA4/Myc-His, C 
expression vector. (B) Ccpl CDS was digested with EcoRI and Sail 
restriction enzymes and ligated into the complementarily digested 
pET28b expression vector.
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Figure 2.3 Plasmid map o f  pEGFP-ccpl/EGFP-C, and pDsRed- 
ccpl/Red-C and pd2EGFP-ccpl/EGFP-N vectors
(A-C) Ccpl-CDS was ligated into pEGFP-C, pDsRed-C and pd2EGFP-N 
expression vectors. The vectors contained a (A) EGFP at the N-terminus, 
a Red tag (B) at the N-terminus and a (C) EGFP tag at the C-terminus.
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Figure 2.4 Plasmid map o f  pDsRed-ccpl/Red-N vector
(A) The EGFP-sequence was cut out from the vector pd2EGF-N and 
substituted with DsRed fragment. (B) The final vector contained ccpl- 
CDS tagged with DsRed at the N-terminus.
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Figure 2.5 Plasmid map o f  pLPC-ccp 1/EGFP-N and pLPLC- 
ccpl/EGFP-C vector
The retroviral vector pLPC was ligated together with the fragments 
ccpl/EGFP-N (A) and ccpl/EGFP-C (B).
CHAPTER 3 
RESULTS
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3.1 Identification and characterization of c c p l  gene
FGF2 is expressed in the telencephalic neuroepithelium and is known to modulate 
cell proliferation and differentiation and long-term survival of neurons in culture 
(106, 282). FGFs have been shown to directly affect the transcription of several genes 
(74). To identify the genes downstream of FGF2 in cortical cells during embryonic 
development, a microarray was previously performed using cortical neuron culture 
(CNC). A microscopic glass chip containing 15,247 unique cDNA clones in the 
National Institute of Aging (NIA) mouse 15K clone set (http://lgsun.grc.nia.nih. govl 
was used (276). The study showed more than 500 genes with altered expression 
levels after FGF2 stimulation by more than 1.5 fold (283). 324 genes were shown to 
be up-regulated and 225 were down-regulated. Genes were categorized with known 
function based on the information on the NIA gene ID list. In contrast, more than half 
of the identified genes did not show any homology to genes with annotation or known 
function. At the beginning of this thesis, 39 genes were selected from the list based 
on the intensity of the induction, novelty of the genes, as well as their characteristics 
in correlation with FGF functions. In order to determine the identity of the 
corresponding bacterial clones, first the original plasmids were sequenced and 
compared with the 3’ and 5’ sequences provided by the NIA website. The genes were 
blasted against NCBI databases and identified the name, if known and provided 
details, including accession number, predicted protein size, coding sequences size and 
base composition. First, 14 genes were chosen and analyzed by northern blotting in 
order to study the expression level upon FGF2 stimulation. The ccpl cDNA probe
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was prepared from the NIA mouse 15k cDNA clone set (pSportl-H3104E08) that 
contained a part of the coding sequence and 3’ un-translated region (UTR). To test 
the expression of the genes in the embryonic brain and the specificity of the probe, 
first northern blotting was performed using total RNA extracted from brain tissue 
from E14.5 mice (CD1 background). Only the genes that gave good quality results in 
the northern blotting were selected for the further analysis. The list included Protein 
phosphatase 1, TRIM8, gene 29a (Riken, XM_129811), gene 31 (NOID, AK034517), 
gene 35 (Riken, XM_133378) and formin binding protein 3. Next, northern blotting 
was performed using RNA extracted from CNC treated with or without FGF2 for 4 h 
in the presence of heparin at 1 DIV. GAPDH hybridisation was performed to 
normalize the level of expression. 4 genes were selected for further investigation: 
TRIM8, gene 29a, gene 31 and formin binding protein 3 (Fig. 3.1.1). In situ 
hybridisation was also performed on the selected genes using CD1 mice coronal 
section obtained from whole E12.5 body and E14.5 cortex (Fig. 3.1.1, B, E, H, K). 
The genes showed specific staining in the embryonic body and in the dorsal cortex. 
Gene 29a was highly expressed in the ventricular zone of the cortex (Fig. 3.1.1, F), 
whereas TRIM8 and formin binding protein 3 (Fig. 3.1.1, C, L) were more restricted 
in the cortical plate. Gene 31 expression was diffuse in the cortex thickness (Fig. 
3.1.1,1).
Based on the quality of the data and my interest in an uncharacterized Riken clone 
gene 29a, was chosen as subject of this study. The gene is a previously 
uncharacterised Riken clone encoding a putative 180 amino acid (AA) protein was 
identified and characterised. The amino acid sequence predicted two coiled coil
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Figure 3.1.1 Selection o f  the genes o f  interest.
In order to select the gene of interest, a number downstream genes of FGF2 
were analysed by northern blotting: TRIM 8 (A, B, C); novel gene 29 
(ccpl) (D, E, F); novel gene 31 (G, H, I); formin binding 3 (J, K, L). First, 
the genes were analysed by northern blotting using 2 pg o f RNA extracted 
from E l4.5 CNC treated with 50 ng/ml FGF2 and 10 pg/ml heparin (+) or 
heparin alone (-). Normalization with GAPDH is reported below each 
northern-sample (A, D, G, J). Secondly, the genes were analysed using non 
radioactive in situ hybridization in El 2.5 sagittal sections o f the body (B, E, 
H, K) and in El 4.5 coronal section o f the cortex (C, F, I, L).
domains, therefore the gene was named ‘coiled coil protein V  (ccpl). The ccpl gene 
was characterised at the molecular level as follows. Firstly, ccpl gene structure was 
characterised using information available from the databases. Secondly, Northern 
blotting was performed to analyse regulation of ccpl expression upon FGF2 
stimulation in cell lines and in primary cortical neurons. Thirdly, expression vector of 
the ccpl gene was constructed and its expression was examined. Finally, monoclonal 
and polyclonal antibodies were raised against the bacterially expressed ccpl protein 
and characterised for the detection of both expressed and the endogenous ccpl 
proteins using Western blot.
3.1.1 Characterization of the novel gene, coiled coil protein 1 (ccpl)
Using a blast search against the NCBI database, a novel gene, Riken clone 
2310061109 (NIA clone ID; H3104E08, GeneBank accession #; XM_129811) was 
characterised. Based on the NCBI GeneBank information, the gene is 1697 bp long 
and encodes a putative protein composed of 180 AA (Fig. 3.1.2 and 3.1.3). Various 
protein motif search tools available at the Expasy Proteomics Server 
(http://www.expasy.org), including SMART (Simple Modular Architecture Research 
Tool) and the Protein Information Resource (PIR), have predicted specific domains 
within the sequence (Fig. 3.1.2). Two coiled coil domains (CC1 and CC2) at amino 
acid positions 3-38 and 154-175 were present in the sequence. A coiled coil domain 
is known to form a stable superhelix structure when two or three a-helices bind 
around each other (222). This structure renders opportunities for oligomerisation as
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Figure 3.1.3 Schematic view o f  the ccpl gene structure and protein 
product
Ccpl genomic sequence is composed o f 5 exons and 4 introns. Ccpl is 
transcribed into a mRNA of 1.7 kb size. The gene product is predicted to be 
180 AA. There are two coiled-coil regions in the protein at 3-38 AA and 
154-175 AA, with a leucine zipper motif and two NES domains present 
within the first CC region (LZ/CC1 and CC2). Domain flanked by the two 
coiled coil regions contained putative phosphorylation sites for protein 
kinase C and casein kinase II (P), as well as an N-myristoylation site (Myr).
well as the binding of other proteins with a coiled coil domain. Based on this 
particular feature, the gene was named ‘coiled coil protein 1 (ccpl) ’.
A leucine zipper structure was also predicted at the N-terminus of the protein 
within the CC1 domain (CC1/LZ) based on the presence of 4 leucine-repeats with 6 
amino acid residue intervals. The leucine zipper is a periodic repetition of leucine 
residues at every seventh position that facilitates dimerisation between two peptides 
as well as the binding of the DNA chain (250).
Two putative NES domains were also found in the N-terminus of ccpl. NES is a 
short sequence that determines the nuclear transport of the host protein through the 
nuclear complex from the nucleus to the cytoplasm (257). NES is composed of a 
leucine rich region with the accepted consensus, LX2-3LX2-3LXL (261). Many of the 
known nucleoplasmatic shuttle proteins are involved in signal transduction and cell 
cycle regulation (284).
Other motifs were also detected in the ccpl sequence, including putative 
phosphorylation sites by protein kinase C (position 80, 100, and 134) and casein 
kinase II (position 19, 61, and 90). Both of these enzymes are serine/threonine 
kinases and the putative patterns are [ST]-X-[RK] and [ST]-X2-[DE], respectively. A 
potential N-myristoylation site (position 145) was also present. N-terminal 
myristoylation is a lipid anchor modification of eukaryotic and viral proteins 
targeting them to membrane locations (285). The pattern for a putative myristoylation 
site is G-{EDRKHPFYW}-X2-[STAGCN]-{P}.
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3.1.2 Ccpl genomic structure and its chromosomal location
To assess ccpl genomic structure, alignment between cDNA sequence and the mouse 
genomic database was performed (see Table 3.1 for GeneBank accession numbers). 
Comparison of the cDNA and the genomic sequence allowed identification of the 
boundaries between exons and introns (ag-gt sequences) (Table 3.2). The gene is 
composed of 5 exons and was spaced with relatively short introns sized between 66 to 
991 bases. Ccpl was localised in mouse chromosome 1,1B. In addition, human 
homologue of ccpl was located in human chromosome 2q21.2.
3.1.3 Ccpl protein sequence is conserved between species.
To determine whether ccpl sequence was conserved between species, a blast search 
of the protein sequence was performed in NCBI database. It revealed several putative 
homologues of ccpl across species (Fig 3.1.4). Alignment of the mouse primary 
sequence revealed a high similarity with the rat (97.2% similarity and 83.3% identity) 
and the human sequence (83.3% similarity and 78.9% identity). The sequence was 
well-conserved throughout the entire protein, however some divergence was found in 
the two coiled coil domains, as well as the localised regions in the middle portion 
(position 46-61 and 121-129).
The NES sequences were similar between mouse and human. The mouse ccpl 
sequence contained the NES consensus LX3LX2KXL and LX2LX2LXA, while the 
human ccpl contained LX3LX2LXL and LX2LX2LXA (position 6-17 and 18-26, both 
in mouse and human sequences). Similarity was also present in zebrafish (37.2% 
homology and 30.6% identity) and drosophila (31.9% homology and 19.5% identity)
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Table 3.1 The Accession Numbers o f the ccpl sequences
Type Species Accession Number
cDNA Mouse XM 129811 (NCBI)
Genomic Mouse NT 039170 (NCBI)
Protein Human NP_115733 (NCBI)
Protein Mouse XP 129811 (NCBI)
Protein Rat XP_343552 (NCBI)
Protein Drosophila N P649550 (NCBI)
Protein Zebrafish EN SD ARP00000042663 
(Ensembl)
Table 3.2 Nucleotide sequences at the exon-intron boundaries o f ccpl.
Alignment between the genomic and cDNA sequences (NT 039170 and XM 129811) 
was performed to identify boundaries o f the exons of the ccpl gene in the mouse. 
Sequences of the exons and introns of mouse ccpl gene are in upper and lower case, 
respectively. The GT/AG sequence was conserved in all exon-intron boundaries 
(bolded).
Exon 3’ splice donor 5’ splice donor Exon Intron Domain
size size
(bp) (bp)
1 GGTGGAGGAGg tgggccacg 444 66 5’ UTR
CDS
2 tctccccc agGGTTGGCTCT TGCGTGCCAGgtgagcgccc 105 112 CDS
3 tttttcccagCGAGGCCCAG AGCGAAGCATgtaagtctcc 80 991 CDS
4 111 c 11 tcagCTCTGCGCAG TTCCGGGATGgtgagtttta 125 112 CDS
5 ctctcaccagGCCTACAGCT 1096 CDS
3’ UTR
Mouse- 
Human- 
Rat-
Zebrafish- 
Drosophila-
MAVQALREELDSKCLQLLSDLEELEAKRAALNARVEEGWLSLAKARYAMGAK 52 
--AL A  LV G------G— TV-----------------------  52
---------------------------------------------  52
   LFMEQ- - A— E--QR-SLI----F-I------S-N-- 4 3
MSIQRSEKE-AGQLLDDLY-DMFHLVEEHTQC 3 2
- E----
LDE-LL.,
Mouse- SVGPLQYASRMEPQVCVRASEAQDGPQTFRVIKADAQTPEEVGPSEASLRRR 114
Human- ---------H------- H-----E---K-K-VR-GVHA------ R--G----114
Rat-  N------------------ 114
zebrafish- Q-SA----- E-Q-L-H-ETRNYMIYHFLTGLRRRVHTKQKEVKEGEQETDEV 95
Drosophila- RINLERCNASGAILLARTRFQHGGSQCVSTAQIPTENSA-FNALCRWDSTD 84
Mouse- KGPTKTKELGSAWPQDPLNWFGILVPHSLRQAQASFRDGLQLAADIASLQT 156
Human-  P-PE-SEA-------------------------------------  156
Rat- --------S----------------------------------------------  156
Zebrafish- ....    TDSPTPEHR-K------- QN-K---SA-KE- 131
Drosophila- GVCIERQAVDKSKGFVE--H— SV-P-M N-VNK-K-CIE-V-ESTN--R 136
Mouse- RINWGQSQLRGLQKKLKELDPGPA 18 0
Human- --D R E Q-E--A- 180
Rat-  L-----R----------  180
Drosophila- QLGEA-DSITKLRRSALLS 155
Figure 3.1.4 Comparison o f  ccpl primary structure across species
Alignment was carried out using Mega Align version 5.05 (DNA Star). High 
similarity was found in rat (97.2% homology and 83.3% identity) and human 
sequences (83.3% homology and 78.9% identity). Less similarity was found with 
zebrafish (37.2 % homology and 30.6% identity) and drosophila (31.9% homology 
and 19.5% identity) sequences. The coiled coil regions and the NES are conserved 
in mouse, human, and rat sequences (shadowed) but not in drosophila and zebrafish. 
Gene accession numbers are listed in the Table 3.1.
sequences. The two coil coiled regions, the NES and the leucine-zipper motif 
(CC1/LZ/NES and CC2) were conserved within the mammalian species but absent in 
drosophila and zebrafish sequences.
3.1.4 Primary CNC treatment with FGF2 and heparin.
Ccpl was identified as a downstream gene of FGF2. Therefore, FGF2 has been 
routinely used as stimulatory ligand in the experiment. In order to determine the 
optimal concentration of FGF2 to use in the treatment of CNC, a time and a 
concentration course was performed. E14.5 CNC were cultured and at 1 DIV treated 
them with different concentrations of recombinant FGF2 (1-10 ng/ml) and heparin (1- 
0.001 qg/ml). The cells were observed daily (Fig 3.1.5). When the cells were treated 
only with FGF2 (10 ng/ml) (Fig 3.1.5, A-C) or with a smaller concentration of 
heparin (0.1 pg/ml) (Fig 3.1.5, J-L), no changes were detected in comparison with the 
mock treated cells (Fig 3.1.5, M-O). At 1 DIV, high concentrations of heparin (10 
pg/ml) lead to the formation of neuronal clusters that become bigger at 3 and 5 DIV 
(Fig 3.1.5, D-F). Because any were detected, 10 ng/ml FGF2 and 0.1 ng/ml heparin 
did not cause changes in cell phenotype, Therefore, these concentrations of the 
ligands for cell treatments longer than 24 h. For treatment no longer than 4 h the 
concentration of 50 ng/ml of FGF2 in the presence of 10 ng/ml of heparin was used 
based on the ligand concentration used in the microarray experiments and the 
literature search carried out in the laboratory before the commencement of this 
project.
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Figure 3.1.5 Cortical neuron culture was treated with different 
concentration on FGF2.
Mouse E l4 CNC were treated at 1 DIV using different concentration of 
FGF2 and heparin for 5 days: 10 ng/ml o f FGF2 (A-C); 1 mg/ml o f heparin 
(D-F); 10 ng/ml o f FGF2 and 1 pg/ml o f heparin (G-I); 10 ng/ml of FGF2 
and 0.1 ng/ml of heparin (J-L); mock treated cells (M-O). Cells were 
observed at 1DIV (A, D,G, J, M), 3 DIV (B, E, H, K, N) and 5 DIV (C, F, I, 
L, O) after the treatment.
3.1.5 Ccpl expression level was up-regulated upon FGF2 stimulation.
The microarray data showed that ccpl was up-regulated upon FGF2 stimulation by 
2.3 fold in E14.5 CNC. To assess whether the regulation is a cell specific process, 
Northern blotting was performed using the RNA extracted from different cell types 
(Fig 3.1.6). In the previous microarray experiment, CNC were semm starved for 24 h 
and stimulated for 4 h with 50 ng/ml of FGF2 in the presence of 10 pg/ml of heparin. 
As a control, cells were treated only with heparin. E14.5 CNC were treated as above 
and Northern blotting was performed (Fig 3.1.6, A). The ccpl cDNA probe was 
prepared from the cDNA vector in the NIA mouse 15k cDNA clone set (pSportl- 
H3104E08) that contained a part of the coding sequence and 3’ un-translated region 
(UTR). After hybridisation, ccpl transcript with an expected size of 2.0 kb 
(kilobases) was observed, together with shorter fragments of 0.24 and 0.5 kb. The 2.0 
kb band showed the strongest signal, whereas the 0.24 and 0.5 kb bands showed a 
similar intensity. The bands were further quantified using the Quantity One 4.2.3 
program (Biorad), taking account of the level of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) control hybridisation (Fig 3.1.6, E).
Next, the analysis was performed using total RNA extracted from a 
neuroblastoma line, SK-N-SH cells, under the same condition of FGF2 stimulation. 
The two fragments of 0.24 and 0.5 kb were detected (Fig 3.1.6, B). After 
quantification, the 0.24 kb band showed stronger up-regulation (1.9 fold) in 
comparison with the 0.5 kb band (1.3 fold) (Fig 3.1.6, E). In this experiment, 2.0 kb 
ccpl transcript was below the level of detection. NorthemMax kit (Ambion) kit used 
in Fig 3.1.6, A, may have allowed more efficient hybridisation than in Fig 3.1.6, B.
84
v GAPDH
C SK-N-SH (mRNA) D BC30 (total RNA)
GAPDH
E
kb Cell type 
RNA
Treatment
Panel
E14CNC 
Total RNA 
FGF2 
(A)
SK-N-SH 
Total RNA 
FGF2 
(B)
SK-N-SH 
Poly A -RNA 
FGF2 
(C)
BC30 
Total RNA 
FGF2 
(D)
2 +1.1 +1.9
0.5 +1.4 +1.3 +1.2
0.24 +3.6 +1.9 +1.4 +1.2
Figure 3.1.6 Ccpl expression level was up-regulated upon FGF2 
treatment.
Northern blotting was performed using cells treated with 50 ng/ml of 
FGF2 in the presence o f 10 pg/ml heparin (FGF2) and with heparin alone 
as control (-) for 4 h. (A) Three transcripts of 2.0, 0.5 and 0.24 kb were 
observed in the CNC total RNA. (B) Two transcripts o f 0.5 and 0.24 kb 
were observed in SK-N-SH total RNA. (C) In poly-A RNA, two 
transcripts of 2.0 and 0.24 kb were observed. (D) Two transcripts of 0.5 
and 0.24 kb were observed in BC30 total RNA. (E) By normalizing the 
band intensity based on the hybridisation with GAPDH and 
quantification, the bands showed a regulation upon FGF2 stimulation.
The experiment was carried out using poly-A RNA from SK-N-SH stimulated as 
above. A band of approximately 2.0 kb was indeed detected, together with the shorter 
fragment of 0.24 kb (Fig 3.1.6, C). Upon FGF2 stimulation, the 2.0 kb band was up- 
regulated by 1.9 fold, whereas the 0.24 kb band was up-regulated by 1.4 fold (Fig 
3.1.6, E).
Finally, in total RNA extracted from immortalised oligodendrocyte progenitors 
BC30, the two fragments of 0.24 and 0.5 kb were detected (Fig 3.1.6, D). Both bands 
showed up-regulation by 1.2 fold after FGF2 stimulation (Fig 3.1.6, E).
All together, ccpl showed a modest up-regulation upon FGF2 stimulation in 
accordance with the microarray data. This regulation was observed both in CNC and 
in cell lines. Interestingly, three different transcripts were detected. Since the 
transcript size of ccpl was expected to be 2.0 kb, the smaller fragments of 0.24 and 
0.5 kb may be alternative splice variants. However, RT-PCR amplification using 
primers flanking the entire CDS did not produce any PCR product corresponding to 
this fragments (see ccpl-CDS amplification, Fig 3.1.8).This observation do not imply 
that these bans are not alternative splicing products and more work should be done 
for conclusive results. The 0.5 kb band was not detected in the Northern blot using 
poly-A RNA, indicating that the corresponding alternative splice variant may not 
contain the poly-A signal. Since the smaller bands were detected in all the cell types 
analysed, they are unlikely to be degradation products.
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3.1.6 Ccpl was predominantly expressed in the heart and liver in adult mouse.
In order to analyse ccpl expression in adult tissues, Northern blotting was performed 
using the probe generated above and the £ Poly-A RNA adult mouse Multiple Tissue 
Blot’ (Clontech) (Fig 3.1.7). A 2.0 kb single band was observed in the heart, liver, 
kidney and testis. Lower levels of expression were also observed in brain and lung. 
Expression in the spleen and muscles was under detection level. Hybridisation with 
P-actin was performed to confirm equal sample loading.
3.1.7 Ccpl gene encoded a protein.
In order to test whether ccpl, originally a Riken cDNA 2310061109 clone, encodes a 
protein, transient expression was performed using a vector containing the ccpl cDNA 
in mammalian cells. Ccpl was expressed as a fusion protein with a Myc tag, in order 
to enable a detection using an antibody against Myc. The bacterial clone encoding 
ccpl obtained from the NIA mouse 15k set (pSPORT-H3104E08) contained only a 
part of the coding sequence and the 3’ UTR (nucleotide 453-1697). In order to obtain 
the full length clone, a 858 base pair (bp) long ccpl sequence, including part of the 5’ 
UTR, the coding region (CDS) and a part of the 3’ UTR, was amplified using RNA 
extracted from primary E14.5 CNC as a template (Fig 3.1.8, A). Next, the region of 
the ccpl CDS (562 bp) was amplified using the previous 858 bp fragment as a 
template (Fig 3.1.8, B-C). Ccpl was then cloned into pCRII vector and its sequence 
was confirmed by sequencing. Finally, the 562 bp fragment was cloned into the 
expression vector pcDNA4/Myc-His (Invitrogen), allowing the fusion of ccpl to a 
Myc tag at the C-terminus, resulting in pcDNA4-ccpl/Myc(His).
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Figure 3.1.7 Ccpl expression in adult mouse tissues
A multiple tissue northern blot (Clontech) was hybridised with ccpl 
cDNA probe. A single band corresponding to the 2.0 kb transcript was 
observed. Ccpl was highly expressed in the heart, liver, kidney, and 
testis, less in the brain and lung. Expression in the spleen and muscles 
was under detection level, p-actin hybridisation was used as loading 
control.
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Figure 3.1.8 Construction o f  pcDNA4- ccpl/Myc(His) vector
RT-PCR was carried out to amplify ccpl CDS. (A) Schematic view 
indicating the location o f the primers used is shown. (B) RT-PCR was 
carried out to amplify a fragment containing part o f the 5’ UTR, the CDS 
and part of the 3’ UTR. The product size was 858 bp (C). A fragment of 
562 bp containing the CDS was amplified. (D) The 562 bp fragment was 
inserted into pCRII vector generating the intermediate pCRII-ccpl vector. 
(E) The 562 bp fragment was then re-ligated in the expression vector 
pcDNA4-Myc(His).
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Figure 3.1.9 Ccpl/Myc fusion protein was expressed as 27.6 kDa 
band.
Ccpl was expressed as a fusion protein with the Myc tag in HEK293 
cells and detected with an antibody against Myc (9E10). (A) A single 
28-kDa band was detected in cells transfected with the pcDNA4- 
ccpl/Myc(His). Cells were also transfected with only vector (vector) or 
mock-treated (mock). Immunoblot with p-tubulin was shown as a 
loading control. (B) The protein size was precisely determined by the 
Odyssay infrared imaging system (LI-COR) as 27.6 kDa. (C) Ccpl 
expression vector was transfected for the time indicated. Expression of 
ccpl-Myc was detectable 24 h after the transfection and the level of the 
ccpl-M yc was maintained without any obvious degradation at 108 h. 
12.5% SDS-PAGE.
HEK293 cells were transiently transfected with the pcDNA4-ccpl/Myc(His). 
After 24 h, expressed ccpl fusion protein was analysed by Western blotting using 
antibody against Myc, 9E10 (Fig. 3.1.9, A). The number of amino acids in the fusion 
protein were 209 (ccpl sequence, 180 AA; Myc sequence, 10 AA; His sequence, 6 
AA; extra AA in the expression vector, 13 AA). Using the value of 112 kilo Dalton 
(kDa) as average molecular weight for each amino acid, the protein was expected to 
be 24 kDa. The Western blotting indeed revealed a single protein band of about 27 
kDa (Fig 3.1.9, B).
For precise analysis of the protein size, the Odyssay infrared imaging system 
(LI-COR) was used. The LI-COR program calibrates the molecular weight of a given 
band by identifying the set of standards used in the molecular weight markers. 
Lysates from HEK293 cells transfected by pcDNA4-ccpl/Myc(His) were blotted and 
incubated with primary antibody against Myc (9E10). Ccpl protein was visualised 
using the anti-goat Alexa Fluor secondary antibody. The analysis determined the ccpl 
fusion protein size as 27.6 kDa (Fig 3.1.9, B).
Expression of ccpl fusion protein was further examined by allowing cells to 
express up to 108 h. Expression of ccpl/Myc protein was detectable 24 h after the 
transfection and the level of the ccpl/Myc was maintained without any obvious 
degradation up to 108 h (Fig 3.1.9, C).
3.1.8 Expression of ccpl/His fusion protein as an antigen
In order to produce specific monoclonal and polyclonal antibodies against the ccpl, 
ccpl fusion protein was expressed and purified as an antigen to be injected into mice
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and rabbits. In order to express ccpl protein in a large quantity, the pET system 
(Novagen) was used. Ccpl was cloned in pET28b-His, a vector that allows 
expression of the inserted gene as a His tagged fusion protein under control of the 
strong bacteriophage T7 promoter (pET28b-ccpl/His). Ccpl insert was sequenced to 
confirm that no mutations had occurred during the PCR amplification.
For bacterial expression, pET28b-ccpl/His expression vector was transformed in 
E. coli strain, BL21(DE3)pLysS. Bacterial cells were harvested and lysed. The lysate 
was then separated in to the soluble (s) from the insoluble (i) phases by 
centrifugation. Both the soluble and insoluble phases of each sample were analysed 
by SDS-PAGE gel-comassie stained. As a negative control, the soluble and insoluble 
fraction of proteins from bacterial lysates before the addition of IPTG were analysed 
(Fig 3.1.10, A). First, bacterial cells were incubated with 0.1 mM IPTG for 24 h at 
25°C (Fig 3.1.10, B) and at 37 °C (Fig 3.1.10, C). Ccpl/His protein was detected as a 
23 kDa band in the insoluble fraction in both samples with similar intensity. Then, in 
order to determine the optimal time course for ccpl/His expression, the bacterial cells 
were incubated with 1 mM IPTG at 25°C (Fig 3.1.10, D) and at 37 °C (Fig 3.1.10, E).
At 25°C, ccpl/His protein expression was detectable in the insoluble fraction 
after 6 h of induction (Fig 3.1.10, D). At 37°C, ccp 1/His expression reached 
maximum level after 4 h. However, no expression of pppl/ffis \yas detected after 6 h 
(Fig 3440, E). In order to confirm if tfte expressed 23 kRa bend was indeed the 
pcpl/ffis prptpip; ^Vestem blotting was performed using an .anti-His aptibody on the 
insoluble fractions generated after 4 h pf 1 mM IPTG induction at 37°C. A band of 23 
HPp |p (b? sample, whereas no band was detected in the negative control
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Figure 3.1.10 Characterization o f  ccpl protein expressed in bacteria
Ccpl protein was expressed as a fusion protein with His-tag at the C 
terminus in E. coli strain BL21(DE3)pLysS. The soluble (s) and the 
insoluble (i) fraction of the expressed protein were analysed before 
IPTG induction (A), after induction at 25°C (B) or at 37 °C (C) using 
0.1 mM IPTG for 24 h. Ccpl/His was detected as a 23 kDa band in the 
insoluble fraction. Ccpl/His was induced at 25°C (D) and 37°C (E) 
using 1 mM IPTG from 2 to 6 h. Protein were detected by comassie 
staining. (F) In order to confirm the identity of the band, western 
blotting was carried out using anti-His antibody on the samples 
induced at 37°C. 12.5 % SDS-PAGE gels.
(Fig 3.1.10, F), showing that the protein expressed was indeed ccpl/His protein. As 
the strongest level of ccpl/His protein expression was detected at 4 h of 1 mM IPTG 
induction at 37°C, these conditions were used to produce the ccpl/His protein 
required for antibody generation.
3.1.9 Purification of the ccpl/His fusion protein.
In order to purify the ccpl/His protein suitable for injection to animals, Ni (Nickel)- 
charged beads were firstly used. Since ccpl/His protein was detected in the insoluble 
fraction, the protein was purified following a denaturing protocol using a batch 
method. The protein was washed twice in lysis buffer without addition of urea (Fig 
3.1.11, A; D l, D2) or using 6 M urea (D3) and mixed with Ni-charged beads. Then 
the protein complex was packed into a column and the flow through (FT) was 
collected. The protein lysate in the column was washed with binding solutions (Wl, 
W2) and with washing buffer (W3). Finally, the elution was performed with 
increasing concentration of imidazole (El, 100 mM; E2, 250 mM; E3, 1 M). 
Unexpectedly, after analysis in comassie-stained gel, ccpl/His protein was observed 
in the flow through fraction (FT), indicating that the protein did not bind the beads 
(Fig 3.1.11, A). Ccpl/His protein was also partly eliminated during the solubilisation 
process together with the discard (Fig 3.1.11, A; D3).
As an alternative method, electro-elution was used to purify ccpl/His protein. 
The protein lysate was first separated on a 12.5% SDS-PAGE gel. The band was 
excised from the gel and extracted using a dialysis bag in an electrophoretic chamber. 
The protein solution was finally desalted and concentrated by centrifugation in
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Figure 3.1.11 Purification o f  the bacterially expressed ccpl/His protein
(A) Samples were analysed during the purification of ccpl protein in a 
Nickel-agarose chromatography column. SI: no IPTG induction, 
insoluble fraction; S2: no IPTG induction, soluble fraction; S: insoluble 
and I: soluble fraction after IPTG induction; D l, D2, D3: discards 
obtained from the solubilisation process; FT: flow through; W l, W2, 
W3: washing; El: elution with 100 mM imidazole; E2: elution with 250 
mM imidazole; E3:elution with 1M imidazole. See text for explanation.
(B) Ccpl/His protein was purified using electro-elution. The 
concentration of the protein sample was determined by comparison with 
a series of diluted samples with known concentration. Ccpl 
concentration was determined as 0.6 mg/ml. Proteins were visualised 
using comassie staining.
Centricon tubes. The resulting protein solution contained only the ccpl/His protein, 
as shown in a SDS-PAGE gel (Fig 3.1.11, B). In total, 3 mg of ccpl/His recombinant 
protein were purified at a concentration of 0.6 mg/ml.
3.1.10 Generation of antibodies against ccpl.
Monoclonal and polyclonal antibodies were generated by the Antibody Facility at the 
Beatson Laboratories. The specificity of the anti-rabbit polyclonal ccpl-antisemm 
was tested using different dilutions between 1:500-1:10000. 10 pg of protein 
extracted from HEK293 cells transiently expressing ccpl/Myc fusion protein were 
used for this analysis (Fig 3.1.12, A). A few weak background bands were detected at 
lower dilutions (1:500-2000). Increasing the antisemm dilution to 1:10000, the signal 
at the band at 27.6 kDa corresponding to ccpl/His protein was weaker but more 
specific. Next, the sensitivity of the ccpl-antiserum was tested using known amount 
of ccpl/His protein between 2-20 ng at 1:1000 dilution. The antisemm detected as 
little as 10 ng of ccpl/His protein (Fig 3.1.12, B). Based on these results, 1:10000 
dilution of the antisemm was used in the Western blot experiments when expressed 
ccpl was analysed. Instead, 1:1000 dilution of the antisemm was used when the 
endogenous ccpl was detected.
To facilitate the detection of endogenous ccpl protein, primary MEF were 
treated with FGF2 for 24 h and cell lysates were analysed by Western blotting (Fig 
3.1.13, A). Endogenous ccpl up-regulated upon FGF2 by 2.1 fold. Protein lysates 
extracted from HEK293 and from HEK293 cells transiently expressing ccpl/Myc 
fusion protein were also analysed. Ccpl polyclonal antiserum recognised the
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Figure 3.1.12 Characterization o f  ccpl polyclonal antiserum
Titration of the polyclonal antiserum against endogenous ccpl was 
carried out. (A) Protein lysate extracted from HEK293 cells transiently 
expressing ccpl/Myc fusion protein were analysed using dilutions o f the 
ccpl polyclonal sera. (B) The sensitivity o f the antiserum was tested 
using dilutions of ccpl/His protein. The polyclonal antiserum detected 
as little as 10 ng of ccpl/His protein. 12 % SDS-PAGE gels.
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Figure 3.1.13 Polyclonal and monoclonal antibody.
(A) Western blotting was carried out on MEF cells treated with 50 ng/ml 
of FGF2 and 10 pg/ml of heparin for 24 h. Endogenous ccpl was 
detected at 19 kDa by ccpl-polyclonal antiserum. After normalization 
with p-actin, it was up-regulated by 2.1 fold upon stimulation. (B) 
Transiently expressed ccpl/Myc fusion protein in FIEK293 cells was 
detected at 23 kDa by ccpl-polyclonal antibody. (C) Stably expressed 
ccpl/EGFP fusion protein in MEF cells was detected at 55 kDa by ccpl- 
monoclonal antibody. The samples were analysed in 7.5 % SDS-PAGE 
gels. The ccpl polyclonal antiserum was used at 1:1000 dilution; the 
monoclonal antibody was used undiluted.
ectopically expressed protein at 27.6 kDa as well as a small but strong band at 19 kDa 
(Fig 3.1.13, B). The endogenous ccpl, expected at 19 kDa was not detected in 
HEK293. Therefore, the 19 kDa band observed in the HEK293 transiently expressing 
ccpl/Myc protein may be a cleavage product. Protein lysates extracted from MEF and 
from MEF cells stably expressing ccpl/EGFP fusion protein (see Chapter 3.3.7) were 
analysed using ccpl-monoclonal antibody. The antibody recognised the ectopically 
expressed protein at 55 kDa (Fig 3.1.13, C). The endogenous ccpl, expected at 19 
kDa was not detected.
3.1.11 Ccpl polyclonal antisenim was not suitable for immunocytochemistry.
In order to test whether the generated antisemm recognised ccpl at the cell level, 
immunocytochemistry was performed. MEF were stained using increasing dilutions 
of the polyclonal ccpl-antiserum (Fig 3.1.14, A-C). The pre-immune sera showed a 
similar pattern to that observed in the cells stained with ccpl antisemm (Fig 3.1.14, 
D-F). Ccpl-polyclonal antisemm did not show specificity, since the pre-immune sera 
obtained from the rabbit before the immunization gave a similar result. Furthermore, 
the ccpl antigen used to inject the rabbits was used to inhibit the specific antiserum- 
antigen interaction. The purified ccpl protein was added at the concentration of 0.5, 
1, and 5 mg/ml to the ccpl antisemm diluted at 1:1000 (Fig 3.1.13, G-E). Up to 1 
mg/ml of inhibitory peptide did not inhibit ccpl-antiserum stain. These data indicate 
that ccpl-polyclonal antisemm is not specific and it is not suitable for 
immunocytochemistry.
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Figure 3.1.14 Ccpl polyclonal antiserum did not show specificity in 
im m unocytoch em is try experim en ts.
In order to test whether the polyclonal ccpl-antiserum recognises ccpl in 
the cells, immunocytochemistry was performed using MEF. (A-C)Cells 
were stained using increasing dilution o f ccpl polyclonal antiserum. (D- 
E) Cells were treated with increasing dilution o f pre-immune sera, which 
showed similar staining pattern to the ccpl antiserum. (G-I) Ccpl 
antigen, used to arise the antiserum, was used as an inhibitory peptide for 
ccpl antiserum diluted at 1:1000. Scale bar: 25 mm.
Finally, anti-ccpl monoclonal antibody was characterised by 
immunocytochemistry. MEF cells were stained using un-diluted antibody. However, 
no fluorescent signal was detected in the cell (data not shown). Ccpl monoclonal 
antibody was therefore not suitable for immunocytochemistry experiments.
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3.2 Ccpl expression during brain development
The FGF family plays an important role during the development of the CNS (89,148, 
149). Among the family members, FGF2 is known to be a mitogenic factor in specific 
neural cell types and to promote differentiation and survival of neurons in culture 
(151-153, 286). Neuronal abnormalities were observed in FGF2 knock-out mice in 
the cerebral cortex, hippocampal commissure, and spinal cord (106). In particular, 
FGF2 knock-out mice presented abnormal formation of the cortex layer and showed a 
general decrease in neuronal cell number (155). The fact that FGF2 knock-out mice 
present such a dramatic brain phenotype suggests that FGF2 plays a key role in 
regulating corticogenesis (155).
As described in Chapter 3.1, ccpl was originally identified as a gene 
downstream of FGF2 in CNC derived from the cortices at E14.5. This chapter firstly 
describes overall expression of ccpl in different regions of the embryonic and adult 
brain using Northern Blotting and RT-PCR. Secondly, ccpl expression patterns in the 
developing forebrain was examined by in situ hybridisation. Ccpl showed a unique 
pattern of expression with regional variation which was altered during the embryonic 
development. The pattern reflected some of the aspects of radial and tangential 
migration (16).
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3.2.1 Ccpl transcript was detected in all regions of the embryonic brain.
In order to identify the regions of ccpl expression in the embryonic brain, RT-PCR 
was performed using total RNA extracted from embryonic telencephalic vesicles, 
striatum, diencephalon, mesencephalon, romboencephalon and spinal cord (Fig 
3.2.1). As it has been shown in Chapter 3.1 by Northern blotting, ccpl transcript was 
highly expressed in heart in adult mouse tissues. Therefore, the expression of ccpl in 
embryonic heart was also analysed in comparison to the brain regions. GAPDH was 
used as a control for the starting amount of total RNA used in the experiment. Ccpl 
transcript was detected throughout the embryonic brain regions.
3.2.2 Expression of ccpl in the adult brain
To investigate whether ccpl is expressed in various regions of the adult brain, 
Northern blotting was performed using a poly-A RNA blot (Clontech) derived from 
different regions of the human brain, including cerebellum, cerebral cortex, medulla, 
spinal cord, occipital lobe, frontal lobe, temporal lobe and putamen (Fig 3.2.2, A). 
Although weak, the band corresponding to the 2.0 kb transcript was detected 
throughout the brain regions. After stripping the membrane, p-actin hybridisation 
was carried out as a loading control, which showed a similar amount of RNA loaded 
in the samples.
Ccpl expression was also analysed by RT-PCR. A 12-weeks old CD1 mouse 
was sacrificed and the following regions of the brain were dissected out: piriform 
cortex, frontal cortex, cerebellum, thalamus, medulla, spinal cord and olfactory bulb. 
Ccpl was expressed in all parts of the brain, however, its expression was not detected
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Figure 3.2.1 Ccpl transcript was detected in all regions o f  the 
embryonic brain.
In order to determine which region o f the embryonic brain expresses 
ccpl, RT-PCR was performed using RNA extracted from E l6.5 mouse 
embryo brains. Ccpl was detected in all areas examined including the 
spinal cord. RNA extracted from adult mouse heart and lung was 
included for comparison. Amplification o f GAPDH was used as a 
control.
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Figure 3.2.2 Ccpl is expressed in human and mouse adult brain.
(A) Multiple Tissue Northern blot containing adult human brain mRNAs 
showed a single band corresponding to the ccpl 2.0-kb transcript. 
Hybridization o f the same blot was performed with p-actin to confirm 
equal sample loading. (B) RT-PCR showed ccpl expression in all the brain 
regions analysed, except the cerebellum. GAPDH amplification was used 
as control.
in cerebellum (Fig 3.2.2, B). This observation was in contrast to that in the adult 
human cerebellum (Fig 3.2.2, A).
3.2.3 Expression pattern of ccpl in the embryonic brain
In order to examine the spatial expression pattern of ccpl in mouse embryonic 
forebrain during development, in situ hybridisations with DIG-labelled probes were 
performed (Fig 3.2.3). The expression of ccpl was detected strongly at E13.5 in a 
ventro-lateral area of striatum and lateral cortex (Fig 3.2.3, A). At E15.5, some of the 
ccpl-positive cells appeared to shift toward the CP, a region that originates in the 
upper part of the cortex around E14.5 stage. At this stage, ccpl expression was 
strongly observed in the superficial layer of dorsal cortex, whereas in the ventral 
cortex there was a decrease in its intensity (Fig 3.2.3, B). This shift in expression 
extended further in a dorsal manner at E16.5 (Fig 3.2.3, C).
3.2.4 Ccpl may follow the radial migration.
During embryonic cortex development, neuronal progenitors originate in the 
proliferative region, the VZ (14, 15). Once the cells exit the cell cycle, they migrate 
radially towards the pial surface, forming six layers of neurons in a inside-out 
sequence (Chapter 1.1.2) (14,15). Ccpl expression was further analysed in the dorsal 
cerebral cortex at different stages of embryonic development. At E14.5, ccpl was 
expressed in the VZ (Fig 3.2.4, A). Some of the cells in the CP also expressed ccpl. 
At later stages, ccpl expression become stronger in the CP and few positive cells
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Figure 3.2.3. Expression pattern o f  ccpl in the developing mouse brain
The expression pattern o f ccpl in the developing embryonic forebrain 
was examined by in situ hybridization. (A) Ccpl showed strong 
expression at the lateral and ventral forebrain (white arrows) at E l3.5.
(B) The expression gradually shifted toward dorsal cortex in E l5.5. (C) 
Further dorsal expression was observed within the superficial area of the 
cortex at E l6.5 (black arrows in B and C). Str; striatum, H; 
hippocampus. Scale bar: 800 /vm.
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Figure 3.2.4 Expression o f  ccpl in the dorsal cortex
(A) Ccpl transcript was detected in the VZ at E l4.5. (B) The expression 
shifted to CP splitting the preplate to MZ and SP at E l5.5. (C) Stronger 
and specific staining shifted inward within the CP at E l6.5. Serial 
coronal sections o f E l5.5 cortex were probed with reelin (D), ccpl (E) 
and Tbrl (F). Reelin was detected by immunohistochemistry and ccpl 
and Tbrl by in situ hybridization. (G) Ccpl defined a population of 
cortical progenitors bom after reelin and Tbrl-positive cells. MZ, 
marginal zone; CP, cortical plate; SP, subplate, SVZ, subventricular 
zone; VZ, ventricular zone. Scale bar: 200 pm .
remained in the VZ. At E15.5, ccpl expression was localised both in the VZ and CP 
(Fig 3.2.4, B). At E16.5, the majority of the expression was in the deeper CP (Fig 
3.2.4, C). The hybridisation with the sense probe did not show any significant 
staining (data not shown).
The ccpl expression pattern in the dorsal cortex suggests that ccpl-positive cells 
generated in the VZ and then migrate to the pial surface. To determine in which layer 
of the cortex ccpl-positive cells locate, ccpl expression was compared to those of 
layer markers. Layer markers, reelin and Tbrl were used in this study. Reelin is a 
protein produced by cells that originate in the VZ at E10.5-E11.5. This group of cells 
are called Cajal-Retzius (CR) cells (24) and they are the first group of migrating cells 
to leave the proliferative zone and migrate to the MZ, where they finally reside (287). 
Tbrl is a transcription factor expressed by the second group of cells that leave the 
VZ, which migrate to the surface and finally locate in the inner layer of the cortex, 
layer VI (31). Consecutive coronal sections from CD1 mice at E15.5 were used to 
analyse the expression of markers in the cortex. The comparison of reelin and Tbrl 
expression to ccpl showed that ccpl was expressed at a lower level than reelin and at 
higher level than Tbrl-positive population of cells in the CP (Fig 3.2.4, D-F).
These data suggest that ccpl defines a population of cortical progenitors bom 
around E13-E14 in the VZ after CR cells and Tbrl-positive cells.
3.2.5 Ccpl may follow tangential migration.
During the brain development, a class of cells that originate in the basal ganglia 
migrate tangentially to the developing cortex (32). As described previously, ccpl
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Figure 3.2.5 Ccpl expression in the embryonic brain was similar to 
those o f  GABAergic neurons.
Serial coronal sections deriving from E l3.5 (A-D) and E l5.5 (E-H) 
CD1 mice cortex were used to detect the expression of ccpl by in situ 
hybridization (A, E), calbindin (B, F), Dlx2 (C, G) and GAD65/67 (D, 
H) by immunohistochemistry. At E l3.5, Dlx2 and GAD65/67 were 
expressed strongly in LGE and MGE, whereas weak expression of ccpl 
was detected in LGE (red arrows in A, C, D). At E l5.5, tangentially 
migrating cells were marked by Dlx2 and GAD65/67 (red arrows in G, 
H). Similar staining was observed in ccpl (red arrow in E). Furthermore, 
calbindin was expressed in the striatum and lateral cortex, where ccpl 
expression was also detected at both E l3.5 and E l5.5 (black arrows in A, 
B, E, F). Str; striatum, LGE; lateral ganglionic eminence, MGE, medial 
ganglionic eminence. Scale bar: 200 mm in A-D, 800 mm in E -H.
expression during the development appeared to shift from the ventral to the dorsal 
telencephalon (Fig 3.2.3). Cells that migrate tangentially are known to be GABAergic 
intemeurons (34). To see whether ccpl-expressing cells follow the tangential 
migration, the expression of ccpl was compared with known markers of tangentially 
migrating neurons, calbindin, Dlx2 and GAD65/67 (Fig 3.2.5). At E13.5, ccpl and 
calbindin showed a similar pattern of expression (Fig 3.2.5, A, B). Both were present 
in the ventro-lateral cortex and in the peri-striatum region. At E15.5, ccpl and 
calbindin were still present in the ventro-lateral cortex (Fig 3.2.5, E, F). In contrast, 
Dlx2 and GAD65/67 positive cells were strongly detected in the progenitor zones of 
the LGE and MGE at E13.5 (Fig 3.2.5, C, D). Some ccpl-positive cells were present 
in the LGE at E13.5 (Fig 3.2.5, A). At E15.5, Dlx2 and GAD65/67 positive cells 
migrated to the dorsal cortex and were present both in the CP, in the MZ and SVZ 
(Fig 3.2.5, G, H). In the MGE and LGE, some cells were still positive for Dlx2 and 
GAD65/67, but not for ccpl. In summary, a particular group of ccpl-positive cells 
present at the LGE at E13.5 may migrate from the basal ganglia to the dorsal cortex, 
similar to Dlx2, GAD65/67.
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3.3 Cellular localisation of the ccpl protein
Ccpl was shown to contain domain structures indicative of the localisation of ccpl in 
the cell, including NES domains (Chapter 3.1.1). In this part of the study, cellular 
localisation of ccpl was investigated by immunocytochemistry both in cell lines and 
in primary CNC. Firstly, localisation was studied by transiently expressing ccpl as 
Myc tag-fusion protein. When transiently expressed, ccpl fusion protein localised in 
a vesicle-like structure identified as lysosomes. In contrast, when stably expressed, 
the ccpl fusion protein localised to the nucleus and to the cytoplasm in punctate 
spots. Cellular localisation of the endogenous ccpl protein is still unclear. The N- 
terminus of ccpl sequence presented two putative NES domains. Location of 
ccpl/EGFP protein was investigated upon FGF2 stimulation. Ccpl was 
predominantly detected in the cytoplasm and to a lesser extent in the nucleus.
3.3.1 Ccpl was localised to cytoplasmic vesicles when transiently expressed as a 
Myc-tagged fusion protein.
Since ccpl antibody was not initially available, cellular localisation of ccpl protein 
was first investigated in the expressed protein fused with a tag that could be detected 
by the tag-specific antibody. First, ccpl/Myc fusion protein was transiently expressed 
in human neuroblastoma, SK-N-SH (Fig 3.3.1). Ccpl/Myc fusion protein was 
visualised using anti-Myc antibody. Ccpl/Myc was localised to vesicle-like structures 
present in the cytosol and near the plasma membrane. Ccpl did not appear to localise
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Figure 3.3.1 Transiently expressed ccpl was localises in vesicle-like 
structures.
To localise ccpl in the cell, ccpl/Myc fusion protein was expressed in 
SK-N-SH cells and visualized using antibody against Myc (9E10) 
(green). Filamentous actin was visualized with Texas Red-cojugated 
phalloidin (red). (A) Ccpl was observed in the vicinity of the plasma 
membrane, as well as in cytosol. (B) Upon magnification, ccpl localised 
to the surface of vesicle-like structures (arrow). (C) The cells were 
observed under confocal microscopy by scanning 14 serial sections 
through of the image and ccpl was observed throughout the plasma 
membrane. Scale bar: 20 pm in A; 1.3 pm in B; 25 pm in C.
inside the nucleus. Upon magnification, ccpl/Myc was localised to the surface of the 
vesicles. In order to better characterize ccpl-positive vesicles, confocal microscopy 
was used. Based on the scanning 14 serial sections of 0.6 pm, three-dimensional 
image of the cell were build up and the presence of ccpl/Myc in the cytoplasm was 
more clearly observed.
To determine whether ccpl/Myc localisation in vesicle-like structures was 
specific phenomena to SK-N-SH cells, HEK293 and primary MEF were transfected 
by ccpl/Myc construct and its localisation was examined (Fig 3.3.2, A, B). In 
addition, neuronal cells, including immortalised oligodendrocyte progenitors (OPC) 
BC30 cell line (Fig 3.3.2, C) and primary E14 CNC (Fig 3.3.2, D) were examined. In 
HEK293 and in MEF, ccpl/Myc protein was observed in vesicle-like structures in the 
vicinity of the plasma membrane and cytosol. In BC30 and CNC, ccpl-positive 
vesicles were present in the cytosol, as well as in the cellular processes.
As a control, cells were transfected with vectors without insert. These cells did 
not show any positivity upon detection with Myc antibody (data not shown). Since 
the expression of Myc-fusion tag may cause artificial localisation, the fusion protein 
MEK/Myc and Mayven/Myc were expressed in HEK293 and SK-N-SH, respectively, 
and then localisation was examined (Fig 3.3.2, E, F). MEK is known to be expressed 
in endosomes (289) and Mayven is known to be expressed in the extremities of the 
cell processes (290). As expected, MEK/Myc fusion protein was localised to 
endosome compartments (Fig 3.3.2, E). Mayven/Myc fusion protein was localised to 
the extremities of the cell body, but not to vesicles structures (Fig 3.3.2, F).
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Figure 3.3.2 Transiently expressed ccpl/Myc fusion protein was 
localised to cytosolic vesicles in various cell types.
To examine ccpl cellular localisation, ccpl/Myc fusion protein was 
transiently expressed in cell lines HEK293 (A), MEF (B), BC30 (C), and 
primary CNC derived from E l6.5 brain (D) and detected using antibody 
against Myc. Ccpl/Myc was observed in the cell cytoplasm in a 
vesicular form (arrowheads). In BC30 and in CNC, ccpl was also present 
in the processes (arrowheads). As a control for the specific staining of 
the Myc tag, MEK/Myc (E) and Mayven/Myc (F) fusion proteins were 
examined in the cells (arrows). Scale bar: 25 pm.
3.3.2 Ccpl protein transiently expressed with fluorescent protein-tags was also 
localised to cytoplasm and showed vesicular structure.
Transient overexpression of fusion-tagged proteins can results in artifactual 
localization within the cell. Furthermore, the position of the tag at the N- or C- 
terminus, may also affect the localisation of a protein in the cell. In order to address 
this issue, ccpl was fused with fluorescent tags either at the N- and C-terminus and 
the localisation of the transiently expressed protein was analysed. As a tag, EGFP and 
Discosoma sp. Red fluorescent proteins were placed at both the N and C-terminus of 
ccpl. Localisation was analysed in SK-N-SH cells and primary CNC derived from 
E15.5 embryos. The ccpl/Red-N, ccpl/Red-C, ccpl/EGFP-N and ccpl/EGFP-C 
proteins were expressed in the cells (Fig 3.3.3). As negative controls, the fluorescent 
proteins EGFP and Red alone were expressed.
The cells expressing ccpl/EGFP were stained with anti-GFP antibody. In 
contrast, ccpl/Red-C and -N fluorescence was observed under the microscope 
without the immunocytochemistry. Ccpl/EGFP-C and -N and ccpl/Red-C and -N 
were localised to the surface of vesicle-like structures in SK-N-SH (Fig 3.3.3, A-D), 
similar to those transiently expressed ccpl/Myc protein. Ccpl-positive vesicles were 
dispersed in the cytoplasm but did not localise to the nucleus. In CNC, ccpl vesicles 
were detected both in the cytoplasm and cellular processes (Fig 3.3.3,1-L). Both in 
SK-N-SH and CNC cells, no difference was detected in the expression of ccpl with 
tags positioned at the N- or the C-terminus. The cells expressing only the fluorescent 
proteins EGFP and Red showed a signal throughout the cell body.
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Figure 3.3.3 Fluorescently-tagged ccpl-fusion proteins localised to 
cytosolic vesicles.
Ccpl was expressed in SK-N-SH cells (A-D) and in CNC (I-L) with 
fluorescent tags ccpl/Red-N (A, I), ccpl/Red-C (B, J) ccpl/EGFP-N (C, 
K) and ccpl/GFP-C (D. L). As a negative control, the fluorescent tags 
were expressed alone: DsRed (E, M, F, N), EGFP (G, O, H, P). Both in 
SK-N-SH and CNC, ccpl was localised to vesicle-like structures in the 
cytoplasm. (I-L) Ccpl was also present in the processes of the CNC 
(arrow). Scale bar: 25 pm in A-D, I-L; 20 pm in E-H, M-P.
3.3.3 Chloraquine treatment indicated that ccpl was localised to lysosomes.
Chloraquine is a lyso-somotropic weak base used for the treatment of malaria and 
rheumatologic disorders. Chloraquine is a known inhibitor of endosomal and 
lysosomal functions by mechanisms thought to involve alkalisation of endo- 
lysosomes (291, 292). In order to see whether the vesiscles-like structures observed in 
cells transiently expressing ccpl were lysosomes or endosomes, the transient 
ccpl/Myc expressing SK-N-SK were treated by adding 25-500 pM of chloraquine. 
Using in 25 pM of chloraquine, ccpl-vesicles remained intact. Using 100 pM of 
chloraquine some of the vesicles were disrupted. Using 500 pM of chloraquine, ccpl- 
positive structures were disrupted. To verify the inhibitory activity of chloraquine on 
endo-lysosomes compartments, SK-N-SH cells were treated with the same 
concentrations of chloraquine as above and stained with transferrin receptor (TfR) 
antibody, a marker for recycling endosomes (Fig 3.3.4, B, E, H) (293). As expected, 
the endosomes positive for TfR were disrupted upon treatment with 500 pM of 
chloraquine, similarly to the ccpl-positive structures. Therefore, chloraquine 
treatments indicated that expressed ccpl/Myc localised to endosomes or lysosomes.
33,4  Expressed ccpl did not localise in endosomes or autophagy vesicles.
Endosomes are small membrane-bound vesicles formed by the invagination of the
cell membrane (197). The endosome populations involved in recycling of vesicles to
the plasma membrane have been classified in two categories, the early and the
recycling endosomes (197). All internalized molecules are transported to early
endosomes, also called sorting endosomes (294). Localisation ccpl/Red protein was
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Figure 3.3.4 Ccpl localisation to vesicle-like structures was disrupted 
by chloraquine treatment.
Chloraquine is an inhibitor of lysosomal and endosomal function. (A-G) 
SK-N-SH expressing ccpl/M yc were treated with increasing 
concentration of chloraquine. The cells were stained with antibodies 
against Myc (A, D, G) and Transferrin receptor (TfR), a marker for 
recycling endosomes (B, E, H). Upon treatment with chloraquine, 
structure positive with ccpl and TfR-positive endosomes were disrupted, 
indicating that expressed ccpl localised to endosome/lysosome structures 
(G, H). Scale bar: 25 pm.
compared to that of early endosomes antigen 1 (EEA1), a marker for early endosomes 
(295) (Fig. 3.3.5, A, B). Ccpl/Red and EEA1 did not co-localise (Fig 3.3.5, C).
One of the known markers for recycling endosomes is TfR (293). This receptor 
escapes degradation by a process mediated by recycling endosomes (296). To address 
whether ccpl/Myc protein was localised to recycling endosomes, co-localisation 
study between ccpl/Myc and TfR was carried out (Fig 3.3.5, D-F). Ccpl-positive 
vesicles were not positive for TfR, indicating that ccpl-positive vesicles were not 
recycling endosomes.
The endoplasmic reticulum (ER) is an extensive network of membranes that 
extends from the cell membrane through the cytoplasm to the nuclear membrane 
(197). Using a specific ‘ER stain’ (Sub-cellular structure localization kit, Chemicon), 
ccpl/Red localisation to the ER was investigated (Fig 3.3.5, G, H) (297). Ccpl/Red 
did not localise to the ER.
Finally, ccpl/Red localisation in autophagy vesicles was investigated. 
Authophagy vesicles are double membrane structures that constitute one of the 
degradative cell pathways (298). To visualise autophagy vesicles, auto-fluorescent 
compound Monodansyl-Cadaverin (MDC) was used (279) (Fig. 3.3.5, J, IQ. 
Ccpl/Red did not localise to autophagy vesicles (Fig 3.3.5, L).
3.3.5 Transiently expressed ocpl localised to lysosomes.
Next, localisation of the ccpl/Myc protein in lysosomes was investigated. Lysosomes 
are membranous vesicles characterised by low pH content and by their hydrolytic 
activity (197). Specific markers for low pH vesicles were used, including Lysotracker
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Figure 3.3.5 Ccpl did not localise in endosomes or autophagy 
vesicles.
To determine the identity of ccpl-positive vesicles, SK-N-SH cells 
transiently expressing ccpl/Red-N (A, G, J) and ccpl/Myc (D) were 
stained with specific markers for endosomes and cellular compartments. 
Anti-EE A 1 (B) and anti-TfR (E) antibodies were used. The
endoplasmatic reticulum (ER) was visualised with a specific stain 
(Chemicon) (H). Autophagic vesicles were identified with 
monodansilcadaverin (MDC) (K). Ccpl did not co-localise with any of 
those markers tested. Scale bar 25 pm.
Figure 3.3.6 Transiently expressed ccpl/Myc localised to lysosomes.
In order to determine whether expressed ccpl/Myc localised to 
lysosomes, double immunostaining was performed using specific 
markers. Ccpl/Myc fusion protein was expressed in U20S (A-F) and 
SK-N-SH cells (G-I) and visualised with anti-Myc antibody. The 
lysosomes were visualised with Lysotracker (B) and Lamp2 antibody 
(E, H). In U20S cells, ccpl co-localised with the Lysotraker, but little 
with the lysosomes marked by Lamp2 (C, F). Ccpl co-localised with 
the lysosomes marked by Lamp2 in SK-N-SH cells (arrows) (I). Scale 
bar 25 pm.
and antibody against Tysosome-associated membrane protein type 2’ (Lamp2). 
Lysotracker is a fluorescent acidotophic probe that selectively accumulates in cellular 
compartments with low internal pH (299). Lamp2 is a protein that specifically 
localised to the lysosomal membrane (300). Since both Lysotraker and Lamp2 
antibody were specific for human tissue, ccpl/Myc was transiently expressed in 
human osteosarcoma U20S (Fig 3.3.6, A-D) and human neuroblastoma SK-N SH 
cells (Fig 3.3.6, G). In the U20S cells, ccpl/Myc vesicles co-localised with the 
Lysotraker-positive structures. However, co-localisation with Lamp2 was observed 
only in few cases (Fig 3.3.6, F). In the SK-N SH cells, some vesicles positive for 
ccpl/Myc were also positive for Lamp2 (Fig 3.3.6, G-I). Ccpl co-localisation with 
Lysotraker and with Lamp2 to a lesser extent indicates that transiently expressed 
ccpl, localised to a population of lysosome vesicles.
3.3.6 Ccpl positive vesicles did not co-localise with cytoskeletal components.
Cellular vesicles involved the endocytic traffic are often associated with cytoskeletal 
components (197). To determine whether ccpl-vesicles aligned with the cytoskeletal 
components, ccpl/Myc expressing SK-N-SH cells were stained with specific markers 
for the cytoskeletal components (Fig 3.3.7, A, D, G). First, alignment between 
ccpl/Myc vesicles and vinculin was analysed. Vinculin is a cytoskeletal protein 
associated with the focal contacts and is one of several interacting proteins involved 
in anchoring F-actin to the membrane (301). Anti-vinculin antibody was used and 
vinculin was visualised at the cell periphery (Fig 3.3.7, B). Ccpl/Myc vesicles were 
expressed in the cytoplasm, showing no co-localisation with vinculin (Fig 3.3.7, C).
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Figure 3.3.7 Ccpl did not align with the cytoskeletal components.
To examine whether ccpl vesicle-like structures associated with 
cytoskeletal components, double immunostaining was carried out. 
Ccpl/Myc was expressed in SK-N-SH cells and visualized using anti- 
Myc antibody (A, D, G), anti-vinculin (B) and P-tubulin antibodies (E). 
Texas red-conjugated phalloidin was used to visualize actin filaments 
(H). Ccpl did not align with those structures. Scale bar: 25 pm.
Next, alignment with a-tubulin as well as actin was analysed (Fig 3.3.7, D-F). Texas 
red-phalloidin (Fig 3.3.7, E) was used to visualise filamentous actin. Both tubulin and 
actin filaments did not show co-localisation with ccpl (Fig 3.3.7, F, I). In conclusion, 
ccpl-positive vesicles did not show any association with the cytoskeletal components 
tested.
3.3.7 Generation of cell lines stably expressing ccpl by retrovirus system.
In order to study the localisation and the function of ccpl in vitro, cells stably 
expressing ccpl were established by retrovirus approach. Ccpl was expressed as a 
fusion protein with EGFP tag positioned at the N- and C-tenninus using the retroviral 
construct pLPC (Fig 3.3.8) (280). pLPC-ccpl/EGFP and pLPC-EGFP were first 
transfected in ecotrophic phoenix packaging-cells, in order to produce virus particles. 
After 24 h, the virus-containing conditioned media of the phoenix packaging-cells 
was used to infect the MEF cells. Following the infection, ccpl/EGFP expression was 
checked by immunocytochemistry (Fig 3.3.8, A, B). Cells that incorporated ectopic 
ccpl gene were then selected in 2.5 pg/ml of puromycin for 15 days. 6 clones derived 
from a single cell expressing ccpl/EGFP-N were obtained. By 
immunocytochemistry, the clones 1-6 showed different level of ccpl/EGFP 
expression. Microscopic analysis showed that clone 1 and 5 presented high 
expression. Clone 2 and 6 showed low expression and clone 3 and 4 showed medium 
levels of expression (data not shown).
In order to examine the level of expression of ccpl/EGFP-N and ccpl/EGFP-C 
fusion proteins, Western blotting was performed (Fig 3.3.8, C). 15 pg of protein for
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each sample were analysed and the membrane was blotted using anti-GFP antibody. 
A strong band of 30 kDa corresponding to the EGFP-control was detected. Bands 
representing ccpl/EGFP-N and ccpl/EGFP-C were observed at the expected 
molecular weight, 55 kDa. Ccpl/EGFP-N stably expressed in MEF cells was also 
analysed by Western blotting using anti-ccpl polyclonal antiserum (Fig 3.3.8, D). 
The MEF cells stably expressing ccp/EGFP-N showed a band of 55 kDa, 
corresponding to ccpl/EGFP (Fig 3.3.8, D). The same membrane was then blotted 
using anti-GFP and a band at the same size was observed. Following the same 
procedures, SK-N-SH cells stable expressing ccpl/EGFP were generated and the 
level of the expression was analysed using ccpl polyclonal and GFP antibodies. 
Using both antibodies, a band of 55 kDa was observed (Fig. 3.3.8, E).
In order to compare the level of ccpl expression between a transient and a stable 
system, 10 p,g of protein lysates extracted from HEK293 cells transiently expressing 
ccpl/Myc, SK-N-SH, and MEF stably expressing ccpl/EGFP fusion protein were 
compared in a 4-12% gradient SDS-PAGE gel. Ccpl polyclonal antiserum 
recognised expressed ccpl/Myc at 27.6 kDa in HEK293 (Fig 3.3.8, F). In addition, 
ccpl/EGFP protein was observed at 55 kDa in MEF cells. The presence of the 55 kDa 
band corresponding to ccpl/EGFP protein was not obvious from this gel in SK-N-SH 
cells. Therefore the blot using anti-GFP antibody was performed. The level of ccpl in 
the transient system was much higher than in the stable system. In the MEF, a band 
was observed at 19 kDa, which may represent endogenous ccpl. This band was not 
obvious in the human SK-N-SH cells, probably due to the low level of ccpl 
expression or due to a specificity of the antiserum for the mouse ccpl protein.
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Figure 3.3.8 Stable expression o f  ccpl in M EF by retrovirus approach.
Cell lines stably expressing EGFP, ccpl/EGFP-N and ccpl/EGFP-C 
fusion proteins were generated. (A, B) MEF expressing ccpl were 
visualised with an anti-GFP antibody. (C) The level of the ccpl 
expression was determined by Western blotting using anti-GFP antibody. 
EGFP expression was detected at 30 kDa and ccpl/GFP-N and -C  were 
detected at 55 kDa. (D) Ccpl stable expression was analysed and MEF 
cells using ccpl polyclonal and GFP antibodies. (E) Ccpl stable 
expression was analysed in SK-N-SH cells. (F) Ccpl expression was 
compared in HEK293 cells transiently expressing ccpl/Myc, in SK-N-SH 
and in MEF stably expressing ccpl/EGFP fusion protein using ccpl 
polyclonal and GFP antibodies. C, D, E: 7.5% SDS-PAGE gel. F: 4-12% 
SDS PAGE gradient gel. Scale bar in A, B: 25 pm.
3.3.8 Stably expressed ccpl was localised to the cytoplasm and to the nucleus.
Ccpl was localised to lysosomes when transiently expressed in the cells (Fig 3.3.6). 
To determine whether ccpl fusion protein shows a similar cellular localisation when 
stably expressed in the cells, immunocytochemistry was carried out using MEF stably 
expressing ccpl/EGFP-N using anti-GFP antibody. The control MEF cells expressing 
EGFP alone showed diffuse fluorescence throughout the cell (Fig 3.3.9, A). In a 
population within a single clone expressing ccpl/EGFP-N, different localisation of 
the ccpl protein was observed. In some cells, ccpl/EGFP-N localised throughout the 
cytoplasm in punctate spots (Fig 3.3.9, B), whereas other cells showed ccpl/EGFP-N 
accumulated in the nucleus (Fig 3.3.9, C). A very few cells showed staining of ccpl 
in aggregates (Fig 3.3.9, D).
Cells transiently expressing ccpl showed localisation of ccpl in a population of 
lysosomes (chapter 3.3.5). The punctate spots observed in cells stable expressing 
ccpl were much smaller than the structures observed in the transient expressing cells. 
In order to determine whether the punctate spots detected in the cells stable 
expressing ccpl/EGFP-N were part of the lysosomes, double immunocytochemistry 
was carried out using Lysotracker (Fig 3.3.9, E-G) and antibody against EEA1 (Fig 
3.3.9, H-J). The ccpl-positive spots did not co-localise either with Lysotraker- and 
EEAl-positive structures, indicating a discrepancy between ccpl localisation 
observed in the transient and in the stable cell lines. It is possible that, when 
transiently expressed, the level of ccpl fusion protein was high and it caused 
accumulation in lysosomes leading to degradation. In the stable cell lines, the level of 
ccpl fusion protein was much lower (Fig 3.3.8, F).
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Figure 3.3.9 Ccpl/EGFP-N stably expressed in MEF was localised
mainly to the cytoplasm.
MEF stably expressing ccpl/EGFP-N fusion protein were generated 
using a retroviral approach. Cells stably expressing EGFP did not show 
any major specific staining (A). Ccpl stably expressed in MEF 
localised to the cytoplasm in punctate spots (B), or in the nucleus (C), 
or in aggregates (D). Double-immunocytochemistry was performed 
between ccpl (E, FI) and Lysotraker (F) or EEA1 antibody (I) to assess 
whether the punctate spots were lysosomes or endosomes, respectively. 
Scale bar: 25 um.
3.3.9 Putative nuclear exporting signal (NES) domains might affect ccpl cellular 
localization.
Two putative NES domains were identified in the N-terminus of the sequence 
(Chapter 3.1.4). As described previously, the NES is a short sequence that determines 
nuclear transport of the protein through the nuclear complex from the nucleus to the 
cytoplasm (257, 302). The NES is composed of a leucine-rich region and the accepted 
consensus sequence (with some variation) is LX2 -3 LX2-3 LXL (261). The mouse ccpl 
sequence contains two consensus sequences at residues 6-17 and 18-26, (Fig 3.3.10, 
A). The second NES (position 18-26) is similar to the NES of well-known proteins, 
including MEK (269), pl20 catenin (303) and Trim27 (304) (Fig 3.3.10, B). Since 
ccpl contains a NES domain similar to MEK, which is also known to localise to 
cytoplasmatic spots (269), co-localisation between ccpl and MEK was carried out 
(Fig 3.3.10, C-F). Although the two proteins showed a very similar punctate spots, 
they did not overlap upon close inspection.
In order to test the functionality of NES in ccpl and to determine whether the 
NES domains regulate ccpl localisation between the nucleus and the cytoplasm, sub- 
cellular localisation of ccpl/EGFP-N was examined by immunofluorescence in MEF 
stably expressing ccpl. Ccpl/EGFP-N was predominantly observed to the cytoplasm 
and partly in the nucleus (Fig 3.3.9). In order to determine if ccpl localisation would 
have been affected by a specific stimuli, such as the addition of a growt factor, the 
cells were treated with 50 ng/ml FGF2 in the presence of 10 pg/ml heparin for 1-24 h 
(Fig 3.3.10, G-I). As a control, MEF with stable expression of EGFP were also 
treated and analysed. Three different conditions of ccpl localisation were observed,
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Figure 3.3.10 Two putative nuclear exporting signals (NES) are 
present in ccpl amino acid sequence.
(A) The mouse ccpl sequence contained the two consensus at the 6-17 
and 18-26, respectively. (B) The second NES in ccpl (position 18-26) 
presented some homology to NES of well known proteins, as highlighted 
in the boxes. (C-E) Immunocytochemistry was performed using anti- 
MEK antibody in order to analyse co-localisation with ccpl. Ccpl was 
detected using anti-GFP antibody. (G-I) Ccpl/EGFP-N expressing MEF 
were treated with 50 ng/ml FGF2 and 10 pg/ml of heparin. Ccpl was 
observed in the nucleus (n), both in the nucleus and the cytoplasm (n=c) 
or in the cytoplasm (c). (L) The number of cells presenting ccpl in 
different compartments were counter-stained and reported as percentage.
in the nucleus (n), in the cytoplasm (c) and in both nucleus and cytoplasm (n=c). The 
total number of cells that shown ccpl/EGFP-N in the three different localisation were 
counted and quantified (Fig 3.3.10, L). In the mock-treated cells, ccpl was mainly 
present in the cytoplasm (86%), however a small percentage of cells showed nuclear 
staining (about 1.3%). At 1 and 4 h of FGF2 treatment, 12.5 and 18.2% of the cells, 
respectively, showed ccpl/EGFP-N both in the cytoplasm and the nucleus (n=c). At 
24 h of treatment, no more staining was present in the nucleus and a larger proportion 
of cells (26.1%) presented ccpl both in the cytoplasm and the nucleus (n=c). These 
results showed that FGF2 treatment may induce movement of ccpl between the 
nucleus and the cytoplasm, however further studies are required for conclusive 
results.
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3.4 The function of ccpl i n  v i t r o
In this chapter, the function of ccpl was investigated in vitro by modifying its 
expression levels in cells by overexpression and by RNA interference (RNAi). 
Assays were performed to investigate whether ccpl expression influenced cell 
proliferation, cell death and cell migration. The results showed that ccpl increased 
cell proliferation. Furthermore, MAPK signalling, one of the major pathways 
activated by growth factor signalling and known to promote cell proliferation (202, 
305), was investigated as a potential modulator of ccpl-induced proliferation.
3.4.1 Cellular ccpl overexpression caused morphological changes.
In order to investigate the function of ccpl in vitro, cell lines stably expressing ccpl 
were established by retrovirus approach, as described in chapter 3.3.7. The cells 
stably overexpressing ccpl/EGFP-N fusion protein were used in all the functional 
studies presented in this chapter. Ccpl/EGFP-N protein will be referred as ccpl 
protein.
MEF cells present a flat shape typical of fibroblasts (Fig 3.4.1). When ccpl was 
overexpressed in MEF, a change in cell morphology was observed (Fig 3.4.1, B). 
Cells expressing ccpl appeared smaller and had a spindle-like phenotype. 
Furthermore, phenotype became more prominent in cell expressing ccpl upon 
stimulation with 50 ng/ml FGF2 in the presence of 10 pg/ml heparin for 24 h. FGF2 
treatment enhances changes in cell shape of MEF expressing ccpl (Fig 3.4.1, D).
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Figure 3.4.1 Stable expression o f  ccpl in M EF caused morphological 
changes.
MEF stably expressing ccpl were generated using a retroviral approach. 
(A) Normal MEF presented a typical fibroblast flat shape. (C) Upon FGF2 
stimulation for 24 h, MEF presented a mild spindle shape. (B) MEF 
expressing ccpl showed a change in cell morphology. Cells appeared 
smaller and spindle-like. (D) In the MEF stably expressing ccpl, the 
spindle shape become more apparent upon FGF2 stimulation. (F) Serum 
starvation reversed the shape changes induced by ccpl expresson.
Interestingly, serum starvation only partially reverse the shape changes of MEF 
expressing ccpl (Fig 3.4.1, F). Change in the cell shape in MEF stably expressing 
ccpl may indicate ccpl role in enhancing cell proliferation.
3.4.2 No significant change in wound healing closure was observed in MEF 
stably expressing ccpl.
To assess whether ccpl has a role in cell migration, wound assay was performed in 
MEF expressing ccpl. After the wound was made in the confluent cells, the width of 
the closure of the wound was measured over the time (Fig 3.4.2, A). Migration 
experiment was performed using single clones of MEF stably expressing ccpl, 
previously derived as described in Chapter 3.3.7. By Western blotting analysis, levels 
of the ccpl/EGFP fusion protein was analysed in 3 of the 6 single clone/cells using 
anti-GFP antibody (Fig 3.4.2, B). Clone 1 showed ccpl band at the expected size of 
55 kDa, whereas clone 2 and 3 showed in addition a smaller band of about 37 kDa, 
which may be a cleavage product. Upon assaying the wound closure in the ccpl 
clones, no difference was observed in clones expressing ccpl in comparison with the 
EGFP expressing controls (Fig 3.4.2, C), suggesting that ccpl is unlikely to regulate 
cell migration in MEF.
3.43  Ccpl stable expression induced an increase in cell number.
In order to determine whether ccpl plays a role in cell proliferation, growth of cells 
were analysed in culture. Control MEF and MEF stably expressing ccpl were
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Figure 3.4.2 Wound healing closure was not induced by M EF stably 
expressing ccpl.
To investigate whether ccpl influenced cell migration, wound assay was 
carried out. (A) Monolayer o f control MEF, MEF expressing EGFP and 
ccpl was scratched and photographed at 0, 4, 6, 8 and 24 h. 
Representative photos after 8 h are shown. (B) The clones stably 
expressing ccpl/EGFP were used. The level o f ccpl expression was 
determined by western blotting in clone 1 (cl), clone 2 (c2) and clone 3 
(c3). (C) Measurements were made (two in each treatment) and 
compared to the measurement at time 0. No significant difference in 
migration activity was detected between the controls and the ccpl 
positive cells.
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Figure 3.4.3 Ccpl expression caused an increase in cell number.
(A) Control MEF and MEF expressing ccpl were plated at the same 
density in the presence o f serum and cell number was counted after 
trypsinisation. Ccpl caused an increase the proliferation rate in cell 
number. (B) In the absence of serum, three-fold increase in cell 
number was observed in MEF stably expressing ccpl in comparison to 
control MEF at 3 days o f culture.
initially plated at the same density and cultured for up to 5 days. Cell number was 
counted after trypsinisation at each time point (Fig 3.4.3, A). MEF stably expressing 
ccpl showed 123% increase in cell number in one day in culture. The difference 
between the two groups increased over days. After 5 days in culture, the cells 
expressing ccpl grew 4-fold more than control MEF, indicating that expression of 
ccpl promote cell proliferation. Next, cell proliferation was investigated in the 
absence of serum. Control MEF were cultured showed a mild increase in cell number 
up to 4 days (Fig 3.4.3, B). In contrast, MEF stably expressing ccpl showed a three­
fold increase in cell number at 3 days in culture. Ccpl expression increased total cell 
number in both the presence and absence of serum.
3.4.4 No significant change in apoptosis was observed in MEF stably over­
expressing ccpl.
In order to determine whether apoptosis is involved in the increase in cell number 
upon over expression of ccpl, TUNEL assay was performed in MEF stably 
expressing ccpl (Fig 3.4.4). Cells were plated out at the same density and cultured for 
24 h before TUNEL assay was performed. Both lines showed apoptotic cells in 7% of 
population and there was no change in number of apoptotic cells between the control 
MEF and cells expressing ccpl. (Fig 3.4.4, E). Apoptosis mediated by ccpl has been 
investigated only in MEF so far. The involvement of ccpl in cell death in neuronal 
cell types is not excluded.
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Figure 3.4.4 Apoptosis was not induced in M EF stably expressing ccpl.
In order to determine if  ccpl influenced cell apoptosis, TUNEL assay 
was performed. (A-D) Representative photos o f control cells and MEF 
expressing ccpl are shown. (B, D) The cells were counter-stained with 
DAPI. (E) Apoptotic cells were represented as a percentage of total cells 
present in a given area o f cover-slips (n=5). Control and ccpl expressing 
MEF did not show any difference in the number o f apoptotic cells.
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Figure 3.4.5 Ccpl induced cell proliferation in stably expressing system.
BrdU assay was performed using MEF and SK-N-SH cells stably 
expressing ccpl. (A-C) MEF were stained with BrdU antibody. (D-F) 
Cells were counter-stained with DAPI. Proliferation was calculated as 
the percentage o f BrdU-positive cells present in a given area o f cover 
slips. (G) MEF stably expressing ccpl showed a 45% increase in 
proliferation in comparison to the controls. (H) SK-N-SH stably 
expressing ccpl showed a two-fold increase in proliferation in 
comparison to the controls. * The difference was statistically significant 
between the samples.
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3.4.5 Ccpl promoted BrdU incorporation in MEF and SK-N-SH cells.
In order to determine whether the cell number increase observed above was due an 
increase in cells in the S phase, BrdU assay was performed in MEF and SK-N-SH 
cells stably expressing ccpl (Fig 3.4.5). Cells were cultured in 10% serum for 24 h, 
incubated in 10 pM BrdU for 1 h and stained with anti-BrdU antibody (Fig 3.4.5, A- 
C). The presence of the cell was visualised by nuclear stain with DAPI (Fig 3.4.5, D- 
F). MEF expressing ccpl showed an increase in the number of cells in the S phase by 
45% compared to that in control MEF and to MEF expressing EGFP (Fig 3.4.5, G). 
Similar results were obtained in SK-N-SH cells expressing ccpl, which showed an 
increase in cell proliferation by two-fold compared to the control and to the SK-N-SH 
stably expressing EGFP (Fig 3.4.5, H).
3.4.6 BrdU incorporation was inhibited when ccpl expression was knocked 
down by RNAi in SK-N-SH cells.
RNAi approach was used to address the ccpl function in cell proliferation. RNAi was 
used to suppress ccpl expression by transfecting small interfering RNAs (siRNAs). 
As a negative control, a silencer siRNA designed to share no significant similarity to 
any mouse, rat or human gene sequences, was used. At 24 h post-transfection of 
siRNA molecules, ccpl expression was analysed by RT-PCR. Ccpl expression was 
abolished in cells transfected with the siRNAl, while silencer showed no effect in the 
level of ccpl transcripts (Fig 3.4.6, A).
BrdU assays were then performed in cells lacking ccpl (Fig 3.4.6, B). As a 
control, BrdU assay was performed using mock-treated cells and cells transfected
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Figure 3.4.6 Cell proliferation was inhibited when ccpl expression was 
knocked down in SK-N-SH cells.
(A) Ccpl expression was knock down in SK-N-SH cells using specific 
ccpl-siRNA (siRNAl). Ccpl expression was assessed by RT-PCR. 
GAPDH amplification was shown as control. (B) BrdU assay showed 
that cell proliferation in cells knock down with ccpl decreased to 82.3% 
of the mock-treated cells. Cells transfected with silencer siRNA did not 
show significant reduction in cell proliferation.
with silencer siRNA. In the absence of ccpl expression, cells showed a decrease in 
BrdU incorporation by 82.3% compared to the mock-treated cells. The data were 
obtained by an experiment carried out on 6 different samples that showed similar 
results. This experiment has only been performed once. For conclusive evidence, 
three independent siRNA molecules should have been used and BrdU assay should 
have been performed three times, but due a technical problem related to the 
transfection of SK-N-SH cells, these experiments could not be carried out.
3.4.7 Ccpl rescued MEK inhibition by U0126.
The MAPK pathway is one of the major pathways downstream of growth factor 
signalling involved in cell proliferation (202). In order to identify a signalling 
mechanism of ccpl-induced cell proliferation, MAPK signalling was investigated in 
MEF expressing ccpl. MEK is one of the key proteins of the MAPK signalling 
pathway (306) and the MEK inhibitor, U0126, was used in the BrdU assays.
First, the optimal concentration of U0126 was determined in the culture system 
used (Fig 3.4.7, A). MEF were plated out at the same density and treated with varying 
concentrations of U0126. As a control, the cells were not treated or incubated with a 
corresponding amount of Dimethyl Sulfoxide (DMSO), the solvent in which U0126 
was dissolved. After 24 h, BrdU assays were performed. Treatment with 10 pM 
U0126 resulted in a 10.4% reduction in cell proliferation in comparison to the 
untreated cells. 20 pM U0126 caused a 45.3% decrease in proliferation in comparison 
to the untreated cells. DMSO alone did not show any effect at this concentration. 50 
pM U0126 caused a 63.4% reduction in cell proliferation, but the cells treated with
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Figure 3.4.7 Cell proliferation promoted by ccpl was reduced by 
addition o f  MEK inhibitor.
To investigate whether ccpl-induced proliferation was mediated by 
MAPK pathway, MEK inhibitor U0126 was used. (A) To identify the 
concentration o f inhibitor, MEF were treated with different 
concentrations o f U0126 in the presence of serum for 24 h and BrdU 
assay was performed. The concentration o f 20 pM was chosen. (B) Cells 
expressing ccpl were treated with 20 pM of U0126 and BrdU assay was 
performed. (C) Control MEF and MEF expressing ccpl were treated as 
above and Western blotting was performed to detect the level o f p- 
ERK1/2. 7.5% SDS-PAGE gel was used.
DMSO also showed reduced proliferation (34.9%). In consideration of the toxicity of 
DMSO volume used when 50 pM of U0126 was added to the culture, the 
concentration of U0126 at 20 pM (lesser volume of DMSO) was chosen for the 
following experiments.
Control MEF and MEF expressing ccpl were cultured overnight in the presence 
of serum in the presence and absence of 20 pM U0126. In the absence of U0126, a 
20% increase in BrdU incorporation was detected in the MEF stably expressing ccpl 
compared to the control MEF (Fig 3.4.7, B). This value was somewhat lower than the 
data observed in figure 3.4.3, probably due the fact that, in this experiment, the cells 
were plated for two days before BrdU assay was performed. In the presence of 
U0126, both group of cells showed a decrease in cell proliferation. Control MEF 
showed a 49% decrease in BrdU incorporation, whereas ccpl expressing MEF 
showed a decrease of only 18.8%. This result indicates that ccpl rescued MEK 
inhibition by U0126.
To examine whether U0126 inhibited MAPK activation, Western blotting was 
performed using antibody against phosphorylated ERK, one of the key protein that 
mediate the effect of MAPK signalling (202). The lysates were prepared from control 
MEF and MEF expressing ccpl treated with 20 pM of U0126 for 24 h (Fig 3.4.7, C). 
U0126 blocked the phosphorylation of ERK in control MEF and in the MEF 
expressing ccpl.
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3.4.8 Effects of growth factor stimulation on ccpl-induced cell proliferation.
In order to determine whether addition of growth factors further increases cell 
proliferation in cells overexpressing ccpl, Control MEF and MEF expressing ccpl 
were starved overnight in order to allow all the cells to exit from the cell cycle. Cells 
were treated with FGF2 or serum (Fig 3.4.8, A). In order to measure the total number 
of proliferating cells from the same moment in which the cells were treated, BrdU 
was added to the culture together with the treatment and in corporation was allowed 
for 24 h. With not treatment, MEF expressing ccpl showed increase in BrdU 
incorporation in comparison to control MEF. Similar results but more drastic were 
observed in the cell treated with FGF2 or semm. Furthermore, upon stimulation with 
serum, more cells in S phase were observed in comparison to the FGF2 treated cells. 
Control MEF showed 28.5% and 26.8% of cells in S phase when treated with FGF2 
and serum, respectively. MEF expressing ccpl showed 57.4% and 83.1% of BrdU 
positive cells in FGF2 or serum, respectively.
Next, in order to determine whether MAPK signalling has a role in ccpl 
induced cell proliferation upon FGF2 addition, the cells were serum starved and 
treated with 20 pM U0126 in the presence or not of 50 ng/ml FGF2 and 10 pg/ml 
heparin or 10% SERUM. BrdU incorporation was inhibited in control MEF but not in 
MEF expressing ccpl. Similar trend was observed when FGF2 or serum where added 
together with U0126 (Fig 3.4.8, A). In control MEF the number of cells in S phase is 
similar to the samples in which only U0126 was added. On the contrary, MEF 
expressing ccpl showed an increase in BrdU positive cells in the presence of FGF2 
and even more in the presence of serum.
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Figure 3.4.8 Effects o f  growth factor stimulation on ccpl-induced cell 
proliferation.
MEF expressing ccpl and control MEF were cultured in absence o f serum 
for 24 h and treated with FGF2 and heparin, serum, or U0126 for 24 h. (A) 
BrdU assay was performed. BrdU was incorporated for 24 h. (B) Western 
blotting was carried out to analyse activation o f o f ERK1/2. Blotting with 
ERK 1/2 antibody was carried out to indicate the loading.
Western blotting was carried out to analyse phosphorylation of ERK, (Fig 3.4.8,
B). Control MEF and MEF expressing ccpl showed a basal level of p-ERK Addition 
of U0126 alone blocked ERK phosphorylation in both type of cells. When U0126 
plus FGF2 or serum was added together, the level of p-ERK was still high. It is likely 
that after 24 h U0126 efficiency is decreased in the presence of strong mitogens as 
FGF2 or serum.
3.4.9 Levels of ERK phosphorylation in ccpl expressing cells in the presence and 
absence of FGF2 stimulation.
Despite an increase in cell proliferation in cells expressing ccpl (Fig 3.4.2), a 
decrease in ERK phosphorylation was observed when cultured in serum over time 
(steady state) (Fig 3.4.9, A), which was also observed in the previous data (Fig 3.4.7,
C). Densitometry analysis showed a 60% reduction in phosphorylation of ERK in 
cells expressing ccpl.
In order to determine whether ERK phosphorylation can be induced upon FGF2 
stimulation in these cells, levels of p-ERK were examined upon FGF2 stimulation 
over time in the absence of semm. Cells were starved overnight and treated with 50 
ng/ml FGF2 in the presence of 10 pg/ml heparin for a short time period up to 15 min 
(Fig 3.4.9, B). By Western blotting using anti p-ERK antibody, control MEF showed 
a gradual activation of ERK A similar pattern was observed in the cells expressing 
ccpl. However, in these cells the activation of ERK was stronger after 10 min, 
indicating that ccpl increased the FGF2-induced phosphorylation of ERK The 
regulation of ERK phosphorylation by ccpl was then examined upon FGF2
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Figure 3.4.9 Regulation o f  ERK 1/2 phosphorylation in M EF expressing 
ccpl upon FGF2 stimulation
(A) MEF expressing ccpl showed a decrease in p-ERK 1/2 by 60%. (B) 
Cells were cultured in absence o f serum and treated with FGF2. Control 
MEF showed activation o f ERK 1/2, whereas a stronger signal was shown 
by the ccpl expressing cells. (C) Experiment was carried out for longer 
time frame. (D) Cells were starved and treated with 10% FBS. Analysis of 
ERK 1/2 was performed to confirm sample loading in all the blots. 
Quantification o f each panel by densitometry is shown in the graphs.
stimulation over a prolonged period up to 24 h (Fig 3.4.9, C). ERK phosphorylation 
increased after 1 h of FGF2 stimulation in the control MEF, reaching a peak at 2 h 
and decreased at 24 h. Similar increase in the p-ERK level was observed in MEF 
expressing ccpl at 1 h of stimulation and thereafter it remained at the constant level 
up to 24 h. Next, ERK phosphorylation was examined upon stimulation by the serum 
for up to 15 min. ERK was highly activated at 5 min in control MEF. Similar 
activation was also observed in MEF stably expressing ccpl, but phosphorylation was 
stronger at 5 min (Fig 3.4.9, C).
In summary, the data showed that ccpl overexpression caused a decrease in 
ERK phosphorylation in cells in the steady growing phase. However, p-ERK level 
can be increased by FGF2 stimulation in MEF expressing ccpl in comparison to the 
control MEF. Of note, phosphorylation of ERK was not decreased in cells expressing 
ccpl at time 0 after serum starvation. This may indicate the presence of a feedback 
mechanism that inhibits ERK phosphorylation in cells expressing ccpl maintained in 
the presence of serum for a long period.
3.4.10 Sprouty, a negative regulator for MAPK pathway, was up-regulated in 
ccpl-positive MEF.
Sprouty is a protein known to be a negative regulator for MAPK signalling (Chapter
1.3.3) (213, 307). In order to determine the cause of the decrease in p-ERK in MEF 
expressing ccpl in a steady growing phase, experiments were carried out to analyse 
the expression of Sprouty by Western blotting using a pan-Sprouty antibody (Fig 
3.4.10, A). MEF expressing ccpl were cultured in the absence of serum overnight and
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3.4.10 Sprouty was up-regulated in M EF stably expressing ccpl.
In order to investigate the cause of the decrease o f p-ERK in the MEF 
expressing ccpl, the level o f the expression of Sprouty was analysed by 
Western blotting. (A) MEF expressing ccpl were cultured in absence o f 
serum ON and treated with 50 ng/ml FGF2 in the presence o f 10 pg/ml 
heparin. (B) Quantification o f Sprouty levels by densitometry is shown 
in the graph. In the MEF expressing ccpl, the level o f Sprouty was 
higher than in the control MEF. 7.5% SDS-PAGE gel was used and 
analysis of ERK1/2 was performed to confirm sample loading.
treated with 50 ng/ml FGF2 in the presence of 10 pg/ml heparin for up to 24 h. In the 
control MEF, the level of Sprouty was low at time 0 and gradually increased upon 
FGF2 stimulation over the time. In contrast, in the MEF expressing ccpl, the level of 
Sprouty was 100 times higher than in the control MEF at time 0 (Fig 3.4.10, B). After 
24 h, the level of Sprouty was higher than in the control MEF by 2 fold. This 
preliminary result indicated that ccpl expression increased the level of Sprouty 
protein. This effect was amplified further by FGF2 stimulation. Expression of ccpl in 
MEF may induce Sprouty, which in turn, in the prolonged presence of growth factors, 
participates in negative-feedback control of ERK signalling.
CHAPTER 4 
CONCLUSIONS and DISCUSSION
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4.1 Conclusions
FGFs play important and multiple roles in the brain, from patterning to terminal 
differentiation of cortical cells (89). As FGFs exert their effect mainly through 
regulating their downstream genes, identifying such genes downstream of FGF2 
would enhance understanding of FGF2 function during development. Relatively 
small numbers of such genes are currently known. In this context, genes downstream 
of FGF2 were screened in CNC by microarray approach. In this study, a RIKEN 
clone named ‘coiled coil protein V  (ccpl) was identified and characterised.
The overall findings of this thesis are summarised as follows:
• Ccpl was identified as a novel gene downstream of FGF2.
• Ccpl gene consists of 5 exons and it encodes a novel protein of 180 amino 
acids (MW: 19 kDa).
• Mouse ccpl has homologues in human and rat. Genes with 30-40% 
similarity were also found in zebrafish and drosophila.
• Ccpl is located on mouse chromosome 1,1B and its human homolog on 
chromosome 2q21.2.
• Ccpl contains a number of putative domains, including two coiled coil 
regions, several potential phosphorylation sites, a leucine zipper, a 
myristoylation site, and two NES domains.
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• Ccpl was up-regulated by 2.3 fold upon FGF2 stimulation using microarray 
analysis.
• Ccpl was up-regulated by FGF2 both at transcriptional and protein level.
• Ccpl was expressed in adult mouse brain, kidney, testis, heart and skeletal 
muscle at both protein and mRNA levels.
• In the cortex, ccpl was expressed in two progenitor origins in the forebrain, 
one in the dorsal VZ and the other in the basal ganglia.
• Studies using in situ RNA hybridization has shown that ccpl was expressed 
in the developing brain in a specific temporal and spatial pattern that reflected 
some aspects of radial and tangential migration of an early-born population of 
cortical cells.
• In the dorsal cortex, ccpl was localised between reelin and Tbrl-positive 
layers, indicating that it may be expressed in the cortical progenitors bom after 
CR and Tbrl-positive populations.
• In the basal ganglia, ccpl was localised in differentiating progenitors, 
similar to calbindin, a marker of a population of GABAergic intemeurons. In 
the superficial area of lateral cortex, ccpl expression was similar to Dlx2 and 
GAD65/67.
• In cell culture, expressed ccpl/EGFP protein localised to the cytoplasm in a 
punctate pattern and to the nucleus.
• Growth curve showed that ccpl increased cell number in MEF in the 
presence and absence of semm.
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• Overexpression studies in MEF and SK-N-SH cells showed that ccpl 
increased number of cells in S phase, effect that is enhanced in the presence of 
serum or FGF2.
• Knockdown of ccpl in SK-N-SH reduced number of cells in S phase.
• Cell proliferation was not suppressed in MEF expressing ccpl when cells
were stimulated with FGF2 in the absence of MAPK signalling. Ccpl 
expression in the cells rescued MEK inhibition by U0126.
• A decrease in ERK phosphorylation was observed in MEF stably expressing 
ccpl when cultured in serum over time. Over a short time of stimulation with 
FGF2, expressed ccpl enhanced MAPK activation in the cells. Levels of 
Sprouty were higher in MEF expressing ccpl and this effect was enhanced after 
FGF2 stimulation. The mechanism of decreased p-ERK in MEF expressing 
ccpl is currently unknown.
• Ccpl did not influence apoptosis and migration in vitro in MEF.
This study provides a better understanding of ccpl gene function in vitro and gives
solid bases for further cell biology and functional studies.
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4.2 Discussion
4.2.1 Ccpl function in relation to its cellular localisation and domains in the 
amino add sequence.
With a long-term aim to understand FGF signalling and how it influences the brain 
development, the function of ccpl, a novel gene downstream of FGF2 was 
investigated. The function of ccpl has not been reported so far. In addition, ccpl 
protein does not present any similarity to known proteins. The studies carried out on 
ccpl cellular localisation, together with the presence of specific domains within the 
amino acid sequence, may suggest a potential role for ccpl protein (Chapter 3.1 and
3.3).
4.2.1.1 Coiled coil regions in ccpl
Protein motif searches predicted two coiled coil regions in ccpl (Fig 3.1.1). Several 
coiled coil proteins with diverse functions are known, including skeletal proteins such 
as keratin and vimentin, motor proteins such as myosin, kinesins, and dyneins and 
proteins important for vesicular transport, such as synaptobrevin, syntaxin and 
SNAP-25 (197, 229, 230, 242). The main function of these proteins is to organize the 
cytoplasm by moving different organelles and macromolecular complexes along 
microtubules, microfilaments and intermediate filaments by recognizing their 
respective cargoes through coiled coil domains (197). Ccpl may be involved in
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organelle movement and organization of the cytoplasm by interacting with 
cytoskeletal or motor proteins through its coiled coil domains. In mature neurons, 
signalling endosomes play an important role in retrograde transport of neurotrophic 
signals from nerve terminals to cell bodies (308). The evidence of retrograde axonal 
transport of FGF2 in the specific brain regions and in spinal autonomic neurons has 
been reported (309, 310), however its mechanism is so far unclear. Moreover, a 
specific expression of ccpl in the developing brain that partially reflects tangential 
and radial migration of early-bom cortical progenitors was observed. A protein 
complex that consists of Lisl, DCX, NudE, and NUDEL proteins has been proposed 
to play an essential role in the radial migration of early-bom neurons involving 
nuclear translocation and dynamic regulation of microtubules (311). Lisl and 
doublecortin (DCX) genes are identified as genes responsible for neuronal migration 
defects in human genetic disorder, Lissencephally (312). NudE and NUDEL are 
coiled coil proteins that are shown to interact with the cytoskeletal motor protein, 
dynein, which also contains the coiled coil domain. Ccpl may be associated with 
multiple cellular proteins and may play a role in cortical neuronal migration during 
brain development.
4.2.1.2 The leucine zipper domain in ccpl
Within the first coiled coil domain of ccpl, a leucine zipper motif, indicative of DNA 
binding, has been predicted (Fig 3.1.1) (197). Leucine zipper domains often occur 
together with DNA-binding domains in regulatory proteins, such as eukaryotic 
transcription factors (247). Ccpl may be one of these regulatory proteins.
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Ccpl/EGFP fusion protein was localised to the nucleus in some cases (Fig 3.3.9). In 
addition, in vitro experiments showed that ccpl promoted cell proliferation (Fig 
3.4.2-3.4.3). Cell proliferation may be mediated by a direct ccpl-activation of target 
genes implicated in DNA replication in the nucleus. Several transcription factors are 
important components of cell proliferation control, e.g. E2F, a transcription factor 
that plays an important role in progression into S phase (313).
4.2.1.3 NES in ccpl
Two domains identified at the N-terminal region of ccpl sequence showed significant 
similarity to NES domains (Fig 3.1.1). The presence of NES domains is known to be 
fundamental for the role of the protein (284). For example, Smadl, a mediator of 
transforming factor (3 (TGF-p), is know to contain a NES and its shuttling from the 
nucleus to the cytoplasm is shown to be essential for its transcriptional activation 
(271). Another protein, whose NES is known to be essential for its function, is Tob, a 
member of the Tob/BTG family that is known to be an anti-proliferative protein 
(314). It has been recently demonstrated that its cellular localisation caused by the 
NES, is essential for its anti-proliferative activity (315).
The NES residue at the amino acid position 18-26 in ccpl shows high homology 
with the validated NES present in MEK sequence (Fig 3.3.10) (316). MEK is mainly 
localised to the cytoplasm because of its NES (316). Although not co-localized, MEK 
cytoplasmatic localisation was similar to that of ccpl (Fig. 3.3.10). Due to its small 
size of 19 kDa, ccpl may shuttles from the cytoplasm to the nucleus by passive 
diffusion and relocates to the cytoplasm by activation of its NES, similarly to MEK
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(316). Functionality of NES in ccpl remains unclear. Site-directed mutagenesis of 
amino acids in the NES domains is one of the approaches that would determine 
whether ccpl NES domains are functional. Furthermore, the use of the fungicide 
Leptomycin B (LMB), a direct inhibitor of the export receptor CMR1 (Chapter 1.3), 
would assist the analysis.
Ccpl localisation upon FGF2 treatment was also addressed in this study (Fig 
3.3.10). After 24 h of treatment, nuclear or cytoplasmatic segregation of ccpl was 
less obvious and the protein was observed to be diffused throughout the cell body. 
Therefore, FGF2 may regulate location of ccpl in the cells. However, more 
experiments should be performed for conclusive results.
4.2.1.4 FGF signalling and ccpl in vesicle compartments
This study revealed that transiently expressed ccpl protein was localised to 
endo/lysosomal compartment of the cell. Endosomal system regulates the turnover of 
cellular membrane components by two major pathways; one leading to degradation in 
lysosomes and another recycling back to the plasma membrane (197). Recently, 
attenuation of FGF signalling was reported by down-regulation of the FGF receptor 
(FGFR) protein mediated by the ubiquitin ligase, Cbl (331). Ubiquitylation has been 
traditionally regarded as a mechanism of protein degradation by proteasomes, 
however the essential role of ubiquitylation regulating endocytic transport has 
recently been demonstrated (332). Furthermore, it was suggested that lysosomal 
targeting and subsequent protein degradation of receptor tyrosine kinases (RTKs) is 
controlled, at least partially, by sustained ubiquitylation of RTKs and Cbl binding to
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RTKs (333). Ccpl may be involved in the FGFR protein turnover, thereby providing 
a mechanism of negative feedback for FGF stimulation.
4.2.1.5 Phosphorylation and myristovlation sites in ccpl
Ccpl sequence also contained putative phosphorylation sites by protein kinase C and 
casein kinase II (Fig 3.1.1). These potential sites have not been investigated for actual 
phosphorylation. Their activation and regulation may influence ccpl-function and 
cellular localisation. A potential N-myristoylation site was also present, but its 
activity has not been investigated (Fig 3.1.1).
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4.2.2 Ccpl induces cell proliferation in vitro.
The data presented in this thesis have indicated that expression of ccpl promotes cell 
proliferation in vitro (Chapter 3.4). FGF2 modulates cell proliferation both in vitro 
and in vivo (150, 155, 157). Being a gene downstream of FGF2, ccpl may regulate 
cell proliferation in some of the FGF2-responsive populations. However, the 
mechanism by which ccpl regulates cell proliferation is unknown.
4.2.2.1 Reorganisation of the cellular cvtoskeleton
Spindle-like cell morphology became apparent in both MEF and SK-N-SH cells 
stably expressing ccpl (Fig 3.4.1). This effect was observed in the absence of FGF2 
and was enhanced upon treatment with FGF2. This may be due the higher expression 
of endogenous ccpl induced by FGF2. Interestingly, serum starvation partially 
reversed the shape changes induced by ccpl expression, indicating that ccpl effect in 
cell shape is mediated by mitogens stimulation.
Ccpl promoted cell proliferation and the change in the cell morphology may be 
required for this proliferative effect. Proteins such as Discs large (Dig), Scribble 
(Scrib) and Lethal giant larvae (Lgl) are known to be involved in cell polarity and cell 
proliferation in epithelial cells (317). The molecular mechanisms by which Dig, Scrib 
and Lgl proteins regulate cell proliferation is still not known, but it is has been 
hypothesised that the epithelial polarisation is required for this process (317). Change 
in cell shape is generally mediated by dynamic reorganization of the actin 
cytoskeleton (318, 319). Rho family of small GTPases in signal transduction
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pathways is a major determinant of cell morphology and polarity and the assembly 
and disassembly of filamentous actin structures provides a driving force for dynamic 
processes (320). Ccpl may play a role in the reorganization of the cytoskeleton, 
possibly interacting with skeletal proteins through its coiled coil regions.
4.2.2.2 Regulation of the cell cycle
Growth curve in the presence and absence of serum showed that the proliferating rate 
of MEF expressing ccpl was higher compared to that of the control cells (Fig 3.4.2). 
Furthermore, incorporation of S phase marker, BrdU, in MEF and SK-N-SH 
expressing ccpl indicated that ccpl enhances Gi-S transition (Fig 3.4.3). Finally, 
silencing of ccpl expression by RNAi dramatically reduced SK-N-SH cell 
proliferation, providing further evidence that ccpl acts as a mitogen (Fig 3.4.4). 
Mitogens generally increase cell proliferation by shortening the Gi phase of the cell 
cycle (197). FGF2 was shown to promote proliferation of cortical progenitor cells via 
a change in cell cycle kinetics simultaneously decreasing Gi duration and increasing 
the proportion of proliferative divisions (321). In another study, FGF2 did not alter 
cell cycle parameters, but was shown to prolong capacity of cells to continue 
proliferating (322). How ccpl influences the cell cycle progression is still unclear. 
Ccpl may influence the Gi-S phase transition by up-regulating the transcription of 
cyclins, including Cyclin A, Cyclin D1 and Cyclin E. Alternatively, ccpl may 
promote the degradation of cell cycle inhibitors by up-regulating transcription of 
ubiquitin ligases.
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4.2.2.3 Signalling involved in the proliferative effect of ccpl
From this study, it appeared that ccpl may respond to the stimulation of several 
mitogens other than FGF2 and that its up-regulation may coordinately activate 
distinct cellular pathways that lead to cell proliferation. Two different conditions 
were investigated, culture (a) in the presence of serum or (b) serum-starved and 
consequentially treated with FGF2. Both in the absence or presence of semm, MEF 
expressing ccpl showed a higher number of proliferating cells in comparison to the 
control, suggesting a pro-proliferative effect of ccpl (Fig 3.4.7 and 3.4.8). 
Furthermore, the addition of FGF2 or semm increased this effect supporting the idea 
that ccpl acts as mitogen.
Finally, the involvement of MAPK signalling in ccpl-induced proliferation was 
investigated using the MEK inhibitor, U0126. In the constant presence of semm, 
U0126 only partially blocked cell proliferation in MEF expressing ccpl. This result 
suggests that ccpl rescued MEK inhibition by U0126. It is likely that signalling 
pathways other than MAPK may be involved in ccpl-induced proliferation when the 
cells are cultured in media rich in mitogens (Fig 3.4.7).
Similarly, in cells serum-starved and subsequently treated with FGF2 or semm 
and U0126, cell proliferation decreased in control MEF but not in MEF expressing 
ccpl, suggesting that once again ccpl rescued MEK inhibition by U0126. MEK 
inhibition did not affect ccpl induced cell proliferation, suggesting that ccpl may be 
downstream of MAPK It is still not excluded that ccpl induced cell proliferation is 
mediated by unknown pathway (Fig. 4.1) not affected by MEK inhibition. 
Interestingly, the western blotting analysis of the protein lysated after the treatment
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Figure 4.1 Hypothesis o f  mechanism o f  ccpl-induced cell 
proliferation.
Schematic diagram showing how FGF or other mitogens (named 
X) pathways could interact with ccpl to form a signalling network. 
(A) Ccpl may function as mediator of the signalling from the 
FGFRs and the MAPK, possibly associated with cellular protein 
complexes through its coiled coil domain. (B) MAPK is known to 
induce cell proliferation. (C) Nevertheless, ccpl maybe activated 
through a different pathway, so far unknown, independently from 
MAPK.
with U0126 revealed that in the presence of mitogens, such as FGF2 and serum, 
phosphorylation of ERK is not inhibited, indicating that U0126 activity maybe 
decreased over 24 h when the strong mitogens are added to the culture.
In conclusion, binding of the extracellular FGF ligands to FGFRs leads to 
dimerization of the receptors and initiates the intermolecular auto-phosphorylation of 
tyrosines. The MAPK cascade is one of the best known for its key role in mediating 
the transduction of signals from FGFRs. Ccpl may function as mediator of the 
signalling from the FGFRs to the MAPK, possibly associated with cellular protein 
complexes through its coiled coil domain. Alternatively, ccpl may be one of the gene 
transcriptionally regulated by MAPK upon stimulation with FGF2. Nevertheless, ccpl 
maybe activated through a different pathway, so far unknown, independently from 
MAPK. Other major signalling pathways downstream of FGF are PI3K and 
PLCgamma-PKC (179). BrdU incorporation in the presence of pathway specific 
inhibitors, such as wortmanin and LY294002 for PI3K, and Bisindolylmaleimide I for 
PKC pathways, could help to clarify ccpl pathway.
The signalling pathway may be differently regulated depending whether (a) the 
cells are maintained in serum and therefore the cell cycle is continuously activated or 
(b) the cells are serum starved (arrest of the cell cycle) and then stimulated with 
mitogens (re-enter the cell cycle). How ccpl is involved within the pathway of FGF2- 
MAPK signalling pathway is still unknown.
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4.2.2.4 Regulation of MAPK signalling
The involvement of MAPK in ccpl-dependent cell proliferation was further 
investigated by Western blotting. Short-time stimulation with FGF2 or semm 
increased phosphorylation of ERK in MEF expressing ccpl in comparison to the 
control (Fig 3.4.9). This effect was not observed when the cells were treated with 
FGF2 over a longer period of time, probably due a maximal expression of ccpl both 
in control MEF and in MEF expressing ccpl.
It was shown that p-ERK was low in ccpl-overexpressing cells cultured in the 
presence of serum over the time (Fig 3.4.9). In cells maintained in media containing 
mitogens for a long period, ccpl expression may reach the maximal level and start a 
mechanism that lead to inhibition of phosphorylation of ERK Sprouty is a negative 
regulator of MAPK signalling generally activated by growth factors such as FGFs 
(213, 214). Sprouty inhibits MAPK pathway exerting its function downstream of the 
tyrosine kinase receptor and upstream of ERK (213). It has been shown that in mouse 
fibroblasts, Sprouty interferes with growth factor-induced ERK activation at the level 
of RAS (307). Indeed, preliminary experiments showed that, upon FGF2 stimulation, 
cells expressing ccpl showed a higher level of Sprouty in comparison with the 
control (Fig 3.4.10). In contrast, an inhibitory effect on cell proliferation and on 
phosphorylation of ERK was not observed, even if the level of Sprouty was high in 
ccpl-expressing cells under these conditions (Fig 3.4.9, C). A decrease in 
phosphorylation of ERK was detected in cells expressing ccpl when cultured in 
serum for a long period (Fig 3.4.9, A). Level of Sprouty in this condition has to be
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determined. The ability of Sprouty to regulate ERK activation is regulated by both its 
level of expression and phosphorylation (213). This aspect remains to be addressed.
4.2.3 Ccpl in the brain
This study showed that ccpl was specifically expressed in multiple tissues including 
adult and embryonic brain (Fig 3.2.5). Experiments using in situ RNA hybridization 
showed that ccpl was expressed in the developing brain in a specific pattern that 
reflected some aspects of tangential and radial migration of an early-born population 
of cortical cells, implying specific function of ccpl during brain development 
(Chapter 3.2). Whether ccpl is also expressed by a different class of brain cells, such 
as oligodendrocytes or astrocytes, remains to be investigated.
4.2.3.1 Effect of ccpl in progenitor proliferation
In order to gain insight into the physiological role of ccpl in the brain, its expression 
pattern was examined. Ccpl was expressed by early-born neurons in the developing 
brain in a specific temporal and spatial pattern (Fig 3.2.1). Ccpl was expressed in two 
progenitor origins in the forebrain, one in the dorsal ventricular zone (VZ) and the 
other in the basal ganglia. In the dorsal cortex, ccpl was detected in the VZ at early 
embryonic day. In mice, cortical progenitors in the VZ are known to undergo 11 cell 
cycles between E l l  and E16 during neurogenesis and the timing of cell cycle exit is 
closely correlated to their destination in the cortical layers (13). Ccpl expression was 
analysed using layer markers, reelin that labels Cajal-Retzius (CR) neurons (323) and 
Tbrl, expressed in one of the most early-born neurons (29) (Fig 3.2.4). Ccpl 
localised between reelin and Tbrl-positive layers, indicating that ccpl may be 
expressed in the cortical progenitors that are bom after CR and Tbrl-positive
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populations and migrate radially to the superficial cortex. At early stages, ccpl 
expression was also detected in the progenitor zone of the LGE. At the same stage, 
additional expression was also detected in the differentiating progenitors in a ventro­
lateral area of the striatum, similar to calbindin, a marker of a population of 
GABAergic intemeurons (324). In the superficial area of lateral cortex, ccpl 
expression was similar to Dlx2 and GAD65/67, markers for differentiating 
intemeurons tangentially migrating toward the dorsal cortex (43, 51). The pattern of 
ccpl expression, therefore, reflected some of the aspects of the tangential migration 
that occurs at the early stages of brain development (32, 325).
Lack of FGF2 caused a reduction in the total number of mature neurons and 
glia, suggesting a fundamental role of FGF2 in neuronal cell proliferation (155). 
Since ccpl was expressed in a subpopulation of progenitors, ccpl may regulate cell 
proliferation and neurogenesis in some of the FGF2-responsive progenitor 
populations.
It has been shown that there is a strong correlation between precise cell cycle 
regulation and determination of neuronal identity (326). Cell cycle regulator proteins 
such as Retinoblastoma (Rb) are known to be involved in the regulation of neuronal 
migration and specification of GABAergic intemeurons (327). The mechanism by 
which Rb influences neuronal migration is not fully understood. There may be a 
correlation between the role of ccpl on the cell cycle and its high and specific 
expression during the brain development, as in case of Rb protein. The mechanism of 
ccpl regulation of cell proliferation and its consequence in neurogenesis are still 
unknown.
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4.23.2 Function of ccpl in post-mitotic cells
Experiments showed that some of the ccpl-positive neurons were located in a 
differentiated region of the cortex. The role of ccpl in post-mitotic cells is still 
unknown. Ccpl expressing cells may not migrate during the development but may be 
temporally and regionally switched in different regions of the cortex. Ccpl may 
regulate factors that control the trajection of tangentially migrating neurons. So far, 
many guidance molecules have been identified, including the Slit and the Ephrin 
families (328). Slitl/2 are temporally and regionally expressed and they have a 
repulsive role, whereas the ephrin family are permissive factors (40, 329, 330). As 
Slit and ephrin proteins, ccpl may be a guidance factor for migrating neurons. In 
contrast, in vitro experiments using MEF have shown that overexpression of ccpl did 
not affect cell migration and motility (Fig 3.4.10). However, ccpl may promote cell 
migration in different cell types, such as neuronal cells. Furthermore, ccpl induced 
cell proliferation in vitro and it is not excluded that this process may mask any 
potential activity of ccpl in closing the wound and therefore in cell migration. 
Performing the same experiment using an inhibitor of cell proliferation, such as 
nacodazole, an inducer of G2/M-phase block, could help to clarify whether ccpl has a 
role in cell migration in vitro.
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4.3 Future research direction
A long-term aim of this project would be to provide better understanding of 
potentially novel regulation of cell proliferation by ccpl in vitro and during brain 
development. Future work would include (a) identification of ccpl binding partners; 
(b) identification of how ccpl regulate cell cycle phases; (c) identification of the in 
vivo function of ccpl using conditional knockout approach; (d) investigation of ccpl- 
function in regulating cortical progenitors proliferation using the mice generated; (e) 
identification of potential roles of ccpl in pathogenesis.
(al Identification of ccpl binding partners
A way to approach ccpl function in the cell would be to identify its binding partners. 
Ccpl has two coiled coil regions, which is often found in the protein-protein 
interaction. By identifying the binding partner of ccpl with known function, it may be 
to clarify ccpl function. This may be achieved by using 2-hybrid screen, co- 
immunoprecipitation or proteomic analysis.
(b) Identification of how ccpl regulates cell cycle phases.
To understand how ccpl regulates cell proliferation, the regulation of the cell cycle 
progression by ccpl in vitro would be addressed. BrdU incorporation assays have 
shown the increase of cells in the S phase in ccpl stable cell lines, indicating that Gi- 
S transition is involved. Further to this observation, fluorescence activated cell sorting
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(FACS) analysis of cell lines stably expressing ccpl would precisely measure the cell 
population in each cell cycle phase. Cell cycle phase would be analysed both upon 
culturing cells in the presence and absence of serum. In addition, RNAi could be used 
to examine the effect of reduced ccpl protein in cell cycle progression. Mitogens 
increase cell proliferation by up-regulating the transcription of G1 cyclins, hence 
increasing the Gl-cyclin dependent kinases (Cdk) activity, or that of ubiqiutin ligases, 
promoting the degradation of cell cycle inhibitors (194). If Gi-S phase is identified as 
the target of ccpl regulation in the above study, the regulation of Cyclin A, Cyclin 
Dl, cyclin E, and p21cip/wafl, and p27kipl would be further examine by Western blot. 
Signalling pathways involved in the increase of cell proliferation by ccpl would be 
also studied. The major signalling pathways downstream of FGF include MAPK, 
PI3K and PLCgamma-PKC (179). MEK inhibitor, U0126, only partially inhibited the 
ccpl-induced BrdU incorporation, indicating that ccpl may be associated with 
mechanism other than MAPK signalling pathway. BrdU incorporation in the presence 
of pathway specific inhibitors would be examined, such as wortmanin and LY294002 
for PI3K, and Bisindolylmaleimide I for PKC pathways.
(c) Identification of the in vivo function of ccpl using conditional knockout approach 
In order to characterise physiological functions of ccpl during development in vivo, it 
would be important to generate a mouse model in which the ccpl gene is deleted. As 
ccpl was expressed in multiple tissues, a conditional approach is essential to allow 
tissue-specific and cell-specific deletion. The in vivo model will allow determination 
of the function of ccpl during brain development and the function of the ccpl-
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positive subpopulation of progenitors and neurons. This issue can be only addressed 
in the in vivo model system. Drosophila and zebrafish systems would not be suitable, 
as the homology of putative ccpl homologues is low.
(d) Investigation of ccpl-function in regulating cortical progenitors proliferation 
using the mice generated.
After generation of the ccpl null mice is available, it would be possible to analyse 
how ccpl regulate proliferation of the cortical progenitors in vivo. The mitotic rates 
of progenitor cells would be tested as well as its effect in neurogenesis by in vivo 
pulse labelling with BrdU. Furthermore, FACS and immunohistochemistry could also 
address the cell population in each cell cycle phase. Originally identified downstream 
of FGF2, ccpl deletion may lead to a phenotype similar to that of FGF2 knockout 
mice. A reduction of glutamatergic pyramidal neurons and parvalbumin-positive 
intemeurons was observed in the dorsal cortex (103). It was also reported that some 
of the cortical neurons failed to target the layer II and III (103). Ccpl expression was 
observed in a subpopulation of calbindin-positive neurons. Immunohistochemistry 
would be performed to quantify the numbers of specific neuronal cells in the ccpl- 
null mice in comparison to control littermates in adult brains. Antibodies against 
Glutamate receptor 1 (GluRl) and NeuN (glutamatergic projection neuron), calbindin 
and parvalbumin (GABAergic intemeurons) would be used.
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(e) Identification of potential roles of ccpl in pathogenesis
The last major question that should be investigated is whether ccpl has roles in 
pathogenesis. Ccpl showed to be highly expressed in the brain and in the heart. The 
mouse ccpl is localised in the chromosome 1,1B and its human counterpart in the 
chromosome 2q21.2 (chapter 3.1). Diseases such as cerebral palsy or the coronary 
heart disease may be linked to genetic predisposition. A genetic form of spastic 
cerebral palsy maps to 2q21-q31 (OMIM%603513). Cerebral palsy is a common 
paediatric disorder with 1 in 250-1000 births. It affects the posture and movement 
caused by the abnormalities in the brain. Another genetic disease that maps in a close 
location to ccpl is the coronary heart disease (CHD), located to 2q21-q22 
(OMIM%608316). Coronary heart disease (CHD) is one of the most common leading 
causes of death in the western world. CHD is caused by several factors, including 
genetic and environmental. Since ccpl chromosome location is close to spastic 
cerebral palsy and of the CHD and since ccpl is expressed both in brain and heart, it 
maybe related to the mutation that lead to these genetic diseases. Genome linkage 
mapping using DNA from patients and sequencing of ccpl would be performed to 
identify possible mutation that may be responsible for the occurrence of spastic 
cerebral palsy or CHD. In case of identification of mutations in ccpl DNA-sequence, 
site directed mutagenesis would be carried out on ccpl sequence to generate a mouse 
model. This approach would allow significant advances in understanding the 
progression and severity of the diseases. In addition, a mouse model would be an 
important tool for functional analysis of the brain or heart in culture, as human tissue 
samples are difficult to obtain.
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